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Abstract 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a global health 
challenge and is one of the leading causes of death worldwide. New biomarkers that 
support rapid and accurate TB diagnosis, and are able to recognise early treatment 
failure as well as cure are urgently needed. MicroRNAs (miRNAs) are small non-
coding RNAs that have recently come into prominence as promising diagnostic and 
prognostic biomarkers. They have been isolated from a number of tissues and body 
fluids and have been extensively studied and reviewed in both health and disease. 
This thesis explores the application of miRNAs as biomarkers in pulmonary 
tuberculosis and explores their expression in macrophages, the key innate immune 
cell involved in host defense against the bacterium.   
 
As with messenger RNA (mRNA), measuring miRNA expression requires a 
consistently expressed and stable miRNA to act as a reference in order to control for 
non-biological variation. The suitability of 12 miRNAs, used in published studies to 
normalise miRNA expression, was examined in 24 TB patients, 12 patients with 
latent TB infection (LTBI) and controls sampled from Sydney, Australia and 
Yinchuan, China. Using geNorm and Normfinder software to analyse the data 
plasma-derived miR-93 was identified as a suitable reference miRNA and was used 
to normalise the large cohort study that examined the expression of miRNAs in 
patients from north-west China with pulmonary TB.  
 
Using real-time quantitative reverse transcriptase polymerase chain reaction (qRT-
PCR) panels we investigated the expression of 175 miRNAs in a test set of 20 TB 
patients and their age and sex-matched healthy controls. These arrays identified 87 
 xi 
miRNAs that were differentially regulated between the two groups, including 18 that 
were up-regulated and 69 that were down-regulated. From this group, ten miRNAs 
were selected for targeted validation in a larger cohort of 100 patients with newly 
diagnosed pulmonary TB sampled before the commencement of antibiotic therapy 
and then at one, two and six months following treatment commencement. These 
miRNAs were chosen based on a mean fold change ≥ 1.5, a p-value < 0.01 and/or 
miRNAs previously reported in the literature to be regulated in the setting of TB, 
other infections or known to be important in macrophage function. miRNA 
expression levels were compared to those in 100 healthy controls. miRNA 
expression levels from plasma samples were analysed for their ability to detect and 
differentiate active pulmonary tuberculosis from healthy subjects and for their 
capacity to predict response to therapy. This is, to our knowledge, the largest miRNA 
profiling study in tuberculosis to date and also represents the first longitudinal study 
that examined miRNA expression over a time course. 
  
From the ten miRNAs selected for the validation study, five were differentially 
regulated in newly diagnosed pulmonary TB subjects. miR-29a and -99b-5p were up-
regulated in the setting of tuberculosis infection whilst miR-21-5p, -146a-5p and -
652-3p were down-regulated. Following the TB patients over the course of 
treatment, this study observed that for most miRNAs there was a reduction in the 
mean difference between the TB and healthy subjects as treatment progressed. miR-
99b which was significantly elevated in TB patients before the commencement of 
therapy returned to levels not dissimilar from healthy subjects following one month 
of therapy, whilst the levels of miR-29a-5p, which were also up-regulated in TB 
subjects, took far longer to return to healthy control levels with significant variation 
 xii 
noted up until treatment completion at six months. miR-146a-5p, which was 
significantly down-regulated in the TB subjects, fell further in the TB patients over 
the course of their therapy and miR-26a-5p which was not significantly regulated 
prior to the commencement of therapy became significantly down-regulated and 
remained so throughout the course of TB therapy.  
 
The Chinese cohort consisted of two distinct ethnic populations, the Han and the Hui 
Chinese. Traditionally, these groups differ, not only ancestrally, with Hui being one 
of China’s Islamic minorities, but also socioeconomically, with the Han generally 
residing in the more affluent city areas and the Hui living and working in the poorer 
farming regions of the area. Sub-group analyses noted significant variation in a 
number of plasma miRNAs, most notably, miR-146a-5p, -29a-5p and -221-3p that 
appeared to be secondary to ethnic or geographical differences. Other factors such as 
co-morbid illness or socio-economic status may have also influenced these 
observations.  
 
Quite significant variation in miRNA expression was also noted between the sub-
group that completed TB treatment successfully compared to those who did not. The 
overall trend was that those miRNAs that were down-regulated in the plasma of the 
patients with TB disease were more significantly down-regulated in those that 
inevitably failed therapy. This was particularly notable for miR-146a-5p, -26a-5p, -
133a and -652-3p. These findings suggest that miRNA may be able to act as an early 
biomarker to predict treatment failure. 
 
 xiii 
Given that plasma miRNA expression levels were clearly modulated by M. 
tuberculosis infection the capacity of M. tuberculosis to modulate miRNA 
expression in human macrophages was examined. Monocyte-derived macrophages 
were isolated from freshly collected human buffy coats from six healthy donors. 
Based on current literature together with the miRNAs that we found to be regulated 
in the plasma of TB subjects, seven miRNAs were chosen and examined in human 
macrophages with and without M. tuberculosis infection. The expression of miRNA 
in M. tuberculosis infected macrophages largely mirrored the findings from the 
plasma with a few exceptions. miR-146a and -21 which were significantly down-
regulated in the plasma of TB subjects, were up-regulated in M. tuberculosis infected 
macrophages. So too, the expression of miR-221 which was significantly down-
regulated in M. tuberculosis infected macrophages, was not differentially expressed 
in the plasma of the TB subjects compared to their matched healthy controls. The 
varying miRNA expression in different tissues is suggestive of likely varying 
miRNA targets and functional roles. Accompanying in vitro M. tuberculosis 
infection of human macrophages was a heightened secretion of pro-inflammatory 
cytokines. 
 
Based on the findings from this work, miRNAs demonstrate great promise in their 
role as a potential biomarker for TB diagnostics and as early marker of treatment 
failure. Further work is needed to better understand the function of miRNAs in the 
biology of TB, and to better explore external factors that may alter their expression 
including ethnicity.  
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 1 
1! INTRODUCTION 
1.1! Tuberculosis: an overview 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. 
Although substantial progress has been made in the treatment, management and 
prevention of TB, it remains a global public health problem and is still one of the 
most important infectious diseases worldwide (World Health Organization, 2013). 
Although the rates of TB in most Western countries which are inherently more 
wealthy, including Australia, are decreasing, migration and easy travel have allowed 
TB to re-emerge. In 2009, the UK reported a 75% increase in reported TB cases over 
the preceding 20 years (Abubakar et al., 2011). 
 
In 2013 the World Health Organisation (WHO) reported nine million new cases of 
TB and approximately 1.5 million deaths attributable to the disease (World Health 
Organization, 2014). Approximately 13% (1.1 million) of the nine million people 
who develop TB each year are human immunodeficiency virus (HIV) co-infected 
(World Health Organization, 2014). The majority, about 60%, of the world’s cases 
are found in China, India and Russian Federation (World Health Organization, 
2014). The highest incidence rates are in sub-Saharan Africa (Figure 1.1) and are 
attributable to the high prevalence of HIV in that region (Figure 1.2). 
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Figure 1-1. Estimated TB incidence (2013). Data from WHO report (World Health 
Organization, 2014). 
 
 
 
 
Figure 1-2. Estimated HIV prevalence in new and relapsed tuberculosis cases 
(2013). Data from a WHO report (World Health Organization, 2014). 
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Typically TB affects the lungs (pulmonary) but it can also affect other organs (extra-
pulmonary). TB is spread through the air by droplet infection from a person with 
pulmonary disease expelling the bacteria, usually by coughing. Approximately one 
third of the world’s population is latently infected with M. tuberculosis (World 
Health Organization, 2014). About 10% of those infected will go on to develop 
disease at some stage during their lives, with most reactivation occurring within two 
years of infection (Tiemersma et al., 2011). The rate of progression is substantially 
increased in those co-infected with HIV (Tiemersma et al., 2011). Reactivation is 
also influenced by other factors such as M. tuberculosis strain type, genetic 
background, degree of immunosuppression, geographical location, concurrent 
medical illnesses such as diabetes or renal impairment, and other risk factors (World 
Health Organization, 2010a). 
 
TB, although a curable disease, remains a major health problem. Without proper 
treatment mortality rates are high. The WHO estimates that in 2009 almost ten 
million children were orphaned as a result of parental deaths caused by the disease 
(Skogen et al., 2011). There has been a marked increase in the number of multi-drug 
resistant, extensively drug resistant and totally drug resistant TB strains and in such 
cases treatment is prolonged and often requires more intensive intravenous therapy 
(World Health Organization, 2010b). Compliance with therapy for drug-resistant 
disease is made more difficult as many of the drugs used have unpleasant side-effects 
and are often poorly tolerated. Hospitalisation of patients who cannot be treated with 
conventional drugs in the community ties up resources and exposes otherwise 
healthy patients and staff to nosocomial cross-infection of resistant organisms. There 
is also a huge economic cost associated with treating drug resistant TB due to the 
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prolonged and often more expensive antibiotic therapy required and significant lost 
workplace productivity. 
 
The usual treatment consists of multi-drug chemotherapy given for a period of at 
least six months. Efforts to control the disease are hampered by difficulties in 
diagnosis, prevention, treatment and the emergence of drug resistance. 
 
1.2! An historical perspective  
M. tuberculosis is the causative agent of TB in humans and is a member of the 
Mycobacterium tuberculosis complex. The M. tuberculosis complex strains include 
seven species and subspecies – M. tuberculosis, Mycobacterium africanum, 
Mycobacterium canettii, Mycobacterium pinnipedii, Mycobacterium microti, 
Mycobacterium caprae and Mycobacterium bovis. It is a family of very closely 
related mycobacteria, with each species being adapted to cause tuberculosis disease 
in a specific host species or group (Smith et al., 2006). It is possible, however, for 
inter-species transmission to occur. 
 
Robert Koch was the first to identify M. tuberculosis as the causative agent of TB in 
1882 (Daniel, 2006). It was originally thought that cattle were the source of TB 
disease and that M. tuberculosis evolved from M. bovis, a zoonotic infection 
predominantly affecting cattle and other livestock (Michel et al., 2010). However, 
recent findings indicate that M. tuberculosis first emerged in humans and was then 
transmitted to animals (Wirth et al., 2008). 
 
 5 
There is evidence to suggest that the common ancestor of the M. tuberculosis 
complex emerged about 70,000 years ago in East Africa (Comas et al., 2013). 
Approximately 10,000 – 20,000 years later two independent groups evolved, one 
resulting in M. tuberculosis lineage in humans and the other diversifying into other 
M. tuberculosis complex species including M. bovis (Michel et al., 2010). Using 
sensitive polymerase chain reaction (PCR)-based deoxyribose nucleic acid (DNA) 
techniques, M. tuberculosis DNA was able to be identified from a human male who 
lived approximately 2,200 years ago and was suffering Pott’s disease (Taylor et al., 
2005).  
 
TB became a major problem in the Western world when the industrial revolution 
created crowded living condition that favoured the spread of the bacillus. Termed 
“the white plague”, TB arose in the seventeenth century, peaking in the nineteenth 
century when TB was the most common cause of death in Europeans (Dubos, 1987). 
As Europeans migrated to more distant lands TB became endemic worldwide, firstly 
in the Americas and later in North and sub-Saharan Africa. It was not until the 
emergence of HIV infection in the late twentieth century that TB reached epidemic 
proportion in the African continent (Good et al., 1993).  
 
1.3! Immunopathology of tuberculosis 
M. tuberculosis is an obligate intracellular pathogen and although it can infect 
several different animal species, humans are the principal host. It is an aerobic, acid 
fast, non-encapsulated, non-motile, non-spore forming bacillus. It grows best in 
tissues with high oxygen content such as the lungs. The cell wall is lipid rich and is 
relatively impermeable to basic dyes unless combined with alcohol. It is neither 
 6 
Gram positive nor Gram negative but it is described as acid fast. M. tuberculosis has 
a very slow replication rate of 15-20 hours. This very slow doubling rate and its 
ability to persist in the latent state means that duration of therapy for both treatment 
and prevention is long (Lawn and Zumla, 2011). 
 
TB is transmitted via inhalation of aerosolised M. tuberculosis from patients with 
active TB disease (Lawn and Zumla, 2011). Although pulmonary TB is by far the 
most common presentation, the disease can also affect other sites (extra-pulmonary) 
(Tiemersma et al., 2011; Lawn and Zumla, 2011). Upon inhalation of bacilli, most of 
these particles settle in the upper respiratory epithelium and are expelled by the 
mucocilliary escalator. Only a few droplets reach the respiratory bronchioles and 
alveoli in the peripheral lung tissue.  
 
Innate immunity plays a critical role in host defences against M. tuberculosis with 
the first step being the recognition of the bacteria by the innate immune system. 
Phagocytic cells, in particular alveolar macrophages, play a key role in the initiation 
and orchestration of the adaptive T-cell response to infection. They do this by 
presenting mycobacterial antigens on their cell surface and also by secretion of co-
stimulatory signals and cytokines (Van Crevel et al., 2002). 
 
Mycobacteria that arrive in the lung parenchyma are phagocytosed by alveolar 
macrophages and are either killed or survive (Behar et al., 2011). Mycobacteria that 
are able to evade destruction, multiply leading to the activation of the macrophage 
with release of several cytokines. When this occurs, monocytes and other 
inflammatory cells are recruited to the lung. The monocytes differentiate into 
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macrophages, which ingest but may not destroy the Mycobacterium. Two-to-three 
weeks after initial infection, T-cell immunity develops with antigen-specific T 
lymphocytes proliferating and activating macrophages to kill the intracellular 
mycobacteria. This inhibits bacterial growth and can aid development of latency.  
 
One of the hallmarks of the immune response to M. tuberculosis infection is the 
formation of the granuloma. The granuloma is made up of aggregates of infected 
macrophages together with other innate and adaptive immune cells. The granuloma 
effectively contains the Mycobacterium, which facilitates the persistence of latent TB 
infection. It also provides a local milieu where inflammatory cells can communicate 
with each other, either directly or via the production of cytokines and chemokines. 
During active disease, the integrity of the granuloma is compromised, releasing the 
bacteria resulting in dissemination of the bacteria and clinical symptoms of TB 
disease (Ehlers et al., 2013).  
 
Toll-like receptors (TLR) are one of the primary receptors in the macrophage that 
recognise M. tuberculosis. Following this recognition, their signals activate nuclear 
factor-kappaB (NF-κB) that then induces pro-inflammatory cytokine release.  
Cytokines released by several immune cells including macrophages play an integral 
role in both the innate and adaptive response to TB, either directly or by means of 
stimulating other immune cells and thereby facilitating a coordinated response 
against the invading pathogen. Of critical importance in TB are tumour necrosis 
factor (TNF) and interferon-γ (IFN-γ). 
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TNF has a central role in controlling the growth of M. tuberculosis and is important 
in the establishment of the latent state of the infection (Stenger, 2005). TNF deficient 
mice have much higher mycobacterial loads and succumb more quickly to M. 
tuberculosis infection (Flynn et al., 1995). Anti-TNF therapies have provided 
effective treatment for several debilitating diseases such as inflammatory bowel 
disease and other autoimmune pathologies (Seymour et al., 2001; Peyrin-Biroulet, 
2010). Associated with their use is an increased risk of reactivation from LTBI to 
active TB disease (Harris et al., 2010). Interestingly, reactivation of TB associated 
with TNF-blockers, not uncommonly follows an unusual course with extra-
pulmonary and disseminated disease far more common among patients using these 
therapies (Keane et al., 2001). Interestingly, the pattern of disease is not dissimilar to 
TB encountered in other immune deficiency settings such as HIV (Keane et al., 
2001). The general consensus is that TNF inhibitors disrupt the integrity of the 
granuloma, which normally contains latent bacilli (Harris et al., 2010). The increased 
risk of TB reactivation associated with these therapies highlights the important roles 
of TNF in maintaining the bacterium in the latent state. 
 
IFN-γ is a crucial cytokine in adaptive immunity to infection. T-cell mediated 
immune responses to M. tuberculosis are critical to the host’s control of the disease. 
The ability of CD4+ T cells to produce IFN-γ is crucial to contain the intracellular 
bacteria and afford protection against the disease (Ottenhoff et al., 2005). Type 1 T 
helper (TH1) cells and the IFN-γ that they produce are critical to protection against 
the disease. This is evident by the vastly increased risk of developing disease in 
individuals who have deficiency in IFN-γ or interleukin (IL)-12, which acts to 
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promote TH1 cell differentiation, and the association between the depletion of CD4+ 
T cells in HIV infected persons and their increased risk of TB (Lawn et al., 2009). 
 
There are several other important cytokines in M. tuberculosis infection, including 
the pro-inflammatory IL-1β, IL-6, IL-12 and IL-18 and anti-inflammatory cytokines 
IL-10 and TGFβ. Furthermore there are number of key chemokine and chemokine 
receptors which have been found important in the setting of TB such as IL-8 (CXCL-
8), MIP-1α (CCL-3) and IP-10 (CXCL10). IL-8 (CXCL8) is a potent neutrophil, 
monocyte and T-cell attractant that is secreted by macrophages following infection 
with M. tuberculosis (Monin et al., 2014).  
 
The role of macrophages and the cytokines that they secrete in M. tuberculosis 
infection will be explored during Chapter Five. 
1.4! Current diagnostics 
Two approaches can be taken in order to reduce the burden of TB. The first approach 
is to diagnose active TB rapidly and institute prompt and effective treatment to those 
with the disease. This will reduce transmission and thus reduce the number of 
persons who will develop active TB later on. However, as presented below, there is 
often a significant delay in diagnosis of active disease that results in on-going disease 
transmission. The second approach is to diagnose and then treat persons with latent 
TB infection (LTBI) to prevent the later development of disease.  
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1.4.1! LTBI diagnostics 
LTBI is a sub-clinical infection with M. tuberculosis without clinical, bacteriological 
or radiological evidence of disease. Diagnosing LTBI is important for overall control 
of the disease. Offering anti-tuberculosis chemoprophylaxis to those with LTBI 
substantially reduces their risk of developing active disease. The most currently used 
regime is isoniazid for nine-months which has an estimated efficacy of 90% 
(Society, 2000). 
 
The most widely used test to diagnose TB is the tuberculin skin test (TST), also 
commonly referred to as the mantoux test (Huebner et al., 1993). This test involves 
the intra-dermal injection of purified protein derivative (PPD), which results in 
injection site induration that peaks at 48-72 hours. The PPD comprises of numerous 
antigens that are found in M. tuberculosis and other non-tuberculosis mycobacteria 
including from immunisation with the vaccine strain M. bovis bacilli Calmette-
Guérin (BCG). The major short fall of the TST is therefore its lack of specificity, 
especially in BCG-vaccinated persons, and its low sensitivity in the setting of 
immune-compromise (HIV or other immune suppression). Immune-compromised 
patients are at the greatest risk of developing TB, but the poor sensitivity limits its 
utilization in this subgroup (Pesanti, 1994). The absence of a gold standard to 
diagnose TB, makes it difficult to establish its exact sensitivity and specificity. 
 
Recently commercially available immune-based blood tests were developed that 
measure IFN-γ release in response to stimulation of sensitized T-cells by specific M. 
tuberculosis antigens, specifically early secreted antigenic target of 6 kDa (ESAT-6) 
and culture filtrate protein-10 (CFP-10) (X. Q. Liu et al., 2004). The two available 
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tests are the QuantiFERON®-TB Gold test (Cellestis Ltd., Victoria, Australia) and T-
SPOT-TB assay (Oxford Immunotec Ltd., Arbingdon, United Kingdom). These tests 
have the advantage of greater specificity, as results are not influenced by previous 
BCG vaccination. Their use in immunocompromised and children however have not 
been verified and further studies are needed to determine their utility (Mazurek et al., 
2010).  
1.4.2! Active TB diagnostics 
There has been substantial progress in global TB control, however these gains are 
threatened by the global spread of drug resistant TB. Early diagnosis and treatment 
are both essential for effective TB management and control. Delays in diagnosis and 
hence treatment negatively affect both the individual and the community. Most 
transmission of infection occurs between the onset of cough and the initiation of 
treatment (Storla et al., 2008). A meta-analysis by Storla et al. found that the 
diagnostic delay, as defined by the onset of clinical symptoms to the notification of 
disease, to be in the range of 60-90 days (mean ± standard deviation: 72 days ± 28 
days) with the longest delays (>120 days) in some endemic countries (Storla et al., 
2008). Factors associated with a delay in diagnosis including HIV co-infection, 
extra-pulmonary TB, sputum smear negative TB, healthcare seeking behaviour of 
patients, low access to healthcare and poor health care infrastructure and facilities. 
 
The lifetime risk of developing active disease after being infected is about 10% 
(Lawn and Zumla, 2011). The actual risk is influenced by a number of factors 
including geographical location, M. tuberculosis strain type, genetic background, 
immunocompetency and other risk factors. Most immune-competent people infected 
with M. tuberculosis either eliminate the bacterium or contain the bacterium in a 
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latent state. LTBI is a state where equilibrium is established between host and 
pathogen. The host’s immune response maintains M. tuberculosis in a quiescent 
phase thus preventing active replication and surrounding tissue damage. During this 
time M. tuberculosis bacilli are present within the host but there are no signs or 
symptoms of disease activity and no possibility of disease spread.  
 
Reactivation can occur at any time in an infected person’s life, though it is greatest 
within the first two years of infection (Lawn and Zumla, 2011). Risk factors for the 
development of active disease include a waning immune system, either due to 
diseases such as HIV, chronic kidney disease, malnutrition and diabetes or the use of 
immune modulating therapy including corticosteroids, TNF inhibitors and other 
immunosuppressive agents. Genetic factors also contribute to increased risk. 
 
There are complex interactions between M. tuberculosis and both environmental and 
host genetic factors which play a critical role in TB development. Host genetic 
factors explain, at least in part, why some people are more or less susceptible to 
infection. Recent studies, including twin studies, genome-wide linkage studies and 
recently published genome-wide association studies demonstrate that host genetics 
strongly influence susceptibility to TB. As an example, the TLR2 variant, R753Q, 
appears to influence the progression of LTBI to active TB disease in children (Dalgic 
et al., 2011). Another single nucleotide polymorphism (SNP) of TLR2 (597T-C) was 
found to be strongly associated with TB meningitis and miliary TB in Vietnam 
(Thuong et al., 2007). Purinoceptor (P2X)7 is responsible for mediating adenosine 
triphosphate (ATP)-induced killing of Mycobacterium and a polymorphism in the 
 13 
P2X7 receptor (1513 A-C) has been associated with increased susceptibility to extra-
pulmonary TB (Fernando et al., 2007). 
 
Diagnosis of TB can be difficult. Sputum smear microscopy remains one of the most 
common ways to diagnose pulmonary TB, especially in resource-poor settings. 
Accuracy of this test varies and is reported to be 20-80% using fluorescence 
microscopy methods (Steingart et al., 2007). It is often insensitive in children (as 
they are often unable to give a good sample) and the immunocompromised who are 
more likely to be sputum smear negative (Steingart et al., 2007; McNerney et al., 
2012). It also is unsuitable for use in extra-pulmonary TB as there is no disease 
within the lung parenchyma. 
 
Ultimately, however, definitive TB diagnosis is reliant on the isolation and later 
culture of M. tuberculosis from the sputum or other tissue of infected patients 
coupled with radiological and clinical findings. Corbett et al. examined the rates of 
sputum smear and culture positivity in a population of HIV infected and uninfected 
individuals in Zimbabwe with active pulmonary TB. Of the 31 cases in non-HIV 
infected individuals, 14 (45%) were both sputum and culture positive and nine (29%) 
were culture positive meaning that 26% (eight cases) were both smear and culture 
negative. In the HIV population the smear and culture rates were even lower (Corbett 
et al., 2010). This low rate of sputum and/or culture positivity delays diagnosis and 
hence treatment and impedes the discovery of potential drug resistant strains. This 
increases the rate of person-person transmission and treatment failure. 
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Extra-pulmonary disease often requires invasive investigations and in some instances 
several diagnostic procedures in order for a diagnosis to be made (Solovic et al., 
2013). For example, those with TB meningitis often require cerebral spinal fluid 
analysis. Such invasive investigations require a skilled practitioner and are not 
feasible to be performed in resource-poor settings. Given that extra-pulmonary TB 
accounts for about 30% of all TB, this represents a large pool of TB that is hard to 
diagnose and effectively treat (Lawn and Zumla, 2011). 
 
In recent times there have been several new diagnostic tests that have become 
available. The most significant of these being the recently developed GeneXpert® 
(Xpert). Xpert is a fully automated platform that performs real-time (RT) PCR to 
amplify M. tuberculosis nucleic acid. With a turnover time of two hours, it is able to 
detect the M. tuberculosis complex whilst simultaneously detecting the most 
common mutation responsible for rifampicin resistance (a reliable proxy for multi-
drug resistant (MDR)-TB [as defined by resistance to both first-line agents, isoniazid 
and rifampicin]) (Piatek et al., 2013). The sensitivity of Xpert is superior to sputum 
smear microscopy with a case detection rate of 73% in Xpert compared with 28% 
using smear microscopy (McNerney et al., 2012). Xpert has no role to play in 
monitoring response to treatment as it is purely a diagnostic tool. 
 
The implementation of Xpert in a clinical setting presents many hurdles and it is not 
a panacea. Although performing Xpert is relatively simple and involves minimal 
specimen preparation and manipulation, major challenges particularly related to cost 
and infrastructure exist that inhibit its rollout, particularly in resource-poor settings 
where it is most needed. To successfully implement Xpert into standard diagnostic 
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practice, operational requirements would include uninterrupted power supply, 
ambient temperature no higher than 30°C, adequate biosafety to handle potentially 
infectious material, adequate storage for test kits at temperatures no higher than 
28°C, waste disposal system for cartridges, secure location to protect equipment 
from theft, trained laboratory and clinical staff and yearly calibration of the machine 
(Piatek et al., 2013). Additional programmatic requirements would also be required. 
Such a comprehensive list of requirements would not be feasible in many areas 
where TB is endemic, as the systems to support such technology would not be in 
place (Piatek et al., 2013). 
 
Of other concern relating to Xpert, a number of false-positive cases of rifampicin 
resistance have been detected and as such it cannot be reliably used as a definitive 
point-of-care (POC) test (Boehme et al., 2010). The unforeseen negative implications 
of a falsely positive test could be the unwarranted initiation of MDR-TB therapy, 
which is highly intensive with considerably more potential serious side effects for the 
patient coupled with the unnecessary cost of implementing the MDR-treatment 
regime. These issues are currently being investigated so that a resolution can be 
identified and implemented (Piatek et al., 2013). 
 
1.4.3! More rapid and accurate diagnostics needed 
The WHO estimates that in the African Region 40% of active TB cases are detected. 
This means that over half of all active cases remain undetected and continue to 
transmit infection (World Health Organization, 2010b). These figures are often 
worse in HIV-TB co-infected subgroups. In addition it is estimated that only 7% of 
the estimated 500,000 MDR cases each year are being identified. This translates to 
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people receiving ineffective treatment thereby further amplifying drug resistance and 
the on-going transmission of multi-drug resistant strains to close contacts (World 
Health Organization, 2010a). 
 
1.4.4! Ideal criteria for diagnostic test 
Failure to halt the spread of TB is in part due to the inability to detect active cases in 
the early phase of disease. TB diagnostics lack an accurate and rapid POC test. The 
current gold standard diagnostic tests for TB are primarily laboratory based. It is not 
uncommon for numerous tests to be carried out over a prolonged period before a 
diagnosis is made. 
 
The ideal test would be simple, cheap and robust and would be a POC, on the spot, 
accurate diagnostic test of active disease for both pulmonary and extra-pulmonary 
disease. Ideally it would be able to detect resistance profiles to all first line agents so 
as to avoid inappropriate antibiotic use. It should also be able to distinguish active 
disease from LTBI. In addition, there needs to be a better test than the surrogate 
marker of sputum culture conversion to monitor response to treatment. 
 
1.5! Biomarkers in tuberculosis 
A biomarker is defined as a characteristic that can be objectively measured and 
assessed as an indicator of normal processes, pathological processes or 
pharmacological responses following therapeutic intervention (McNerney et al., 
2012). They can either be host or pathogen specific. A biomarker may provide 
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information about the pathological processes including the current health status and 
the long-term prognosis of the disease state.  
 
An effective and reliable biomarker in tuberculosis is most important in three key 
areas:  
(1)! to predict durable (non-relapsing) treatment success in patients with active 
disease, 
(2)! to determine reactivation risk in those with latent disease and in those 
without active TB, and 
(3)! to indicate protection from the disease by new vaccines (Wallis et al., 2010). 
 
1.5.1! Biomarkers predicting non-relapsing cure 
The current marker used to predict response to treatment and likelihood of cure is 
sputum culture status following two months of treatment. Wallis et al. found that 
sputum culture conversion at two months was reliable to determine the effect of new 
treatment on relapse rates (Wallis et al., 2010). This supports the role of two-month 
sputum culture conversion as a viable endpoint, which therefore has the potential to 
fast track new drug development, which is particularly important in drug-resistant 
disease. Sputum culture conversion however has not been shown to be a good 
prognosticator for the individual. Although a positive sputum culture at two months 
was an independent predictor of relapse for an individual (hazard ration 2.8, 95% CI 
1.7-4.7), both its positive predictive value (18%) and sensitivity (50%) were low 
(Benator et al., 2002). This may be explained by a small sub-population of drug-
resistant bacteria that are not readily detected in sputum by culture at the time of 
assessment.  
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In pulmonary TB, obtaining suitable sputum specimens is sometime problematic. 
Many patients have difficulty in producing a sputum suitable for examination, this is 
particularly the case in the paediatric population. Accompanying this, is the need to 
have competent technical staff to examine the sputum in a well set-up laboratory. 
This may not be possible, especially in developing countries or non-urban settings. 
Compounding these shortfalls, sputum culture takes time and the results of the 
culture are often not available for several weeks. During this time there is the real 
risk of amplifying drug resistance in cases where treatment is not effective and 
therefore continues to propagate the on-going spread of potentially drug-resistant 
TB.  
 
In cases of extra-pulmonary disease, monitoring response to treatment and predicting 
relapse is even more difficult. This is due to the fact that two-month culture is not 
performed on extra-pulmonary cases because the procedures are often invasive, 
difficult and typically low yielding. In extra-pulmonary disease and culture negative 
cases, clinical judgement and possibly radiological assessment are often the only 
tools available to monitor treatment response. 
 
Studies have been undertaken during the implementation of new drug regimes that 
examine M. tuberculosis colony counts on agar at varying time points, in addition 
other studies have measured the time to culture conversion as a means of monitoring 
therapy (Dorman et al., 2009; Kolibab et al., 2014). However, these studies are still 
in their infancy and further evaluation of their effectiveness needs to be assessed. A 
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limitation of these potentially new biomarkers is the need for positive culture to 
exclude extra-pulmonary  and paucibacillary disease.  
 
1.5.2! Determining risk of reactivation 
The principle strategy with regards to TB management aims to reduce the incidence 
of infection with M. tuberculosis. This is achieved through three main interventions: 
the first being to treat active cases of TB promptly, the second is vaccination with 
BCG before acquisition of infection with the aim of reducing the risk of progression 
from sub-clinical latent infection to active disease should infection occur and lastly 
to treat sub-clinical, latent M. tuberculosis with preventative chemotherapy.  
 
The diagnosis of LTBI is made based on either a positive TST (usually greater than 
15 mm) or a positive IFN-γ release assay (IGRA) coupled with no clinical evidence 
of active disease and normal chest radiography. Treating LTBI is very effective and 
reduces the risk of reactivation by 90% (Menzies et al., 2011). However, not all that 
are infected will go on to develop active disease. In fact, the lifetime risk is thought 
to be around 10%(Society, 2000). Prophylactic treatment is prolonged (up to nine 
months) and there are many serious side effects from the medications, most notably 
hepatitis that can become fulminant. Therefore careful selection of patients to offer 
chemoprophylaxis to is important. 
 
There are certain risk factors that are known to increase a persons risk of reactivation 
including immunosuppression especially HIV, those receiving immunosuppressive 
agents, especially TNF inhibitors, chronic kidney disease, diabetes, silicosis, poverty 
and malnutrition and residing in a high TB burden country (Lopez et al., 2006). 
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Although these are known risk factors that increase the risk of reactivation, there still 
are a large population with no identifiable risk factors that develop active disease 
(Lönnroth et al., 2009). These patients would benefit from chemoprophylactic 
therapy. Recently there have been a number of studies that have tried to determine 
the risk of reactivation by means of measuring TB-specific antigens and IFN-γ. 
 
Recently, studies have examined IFN-γ levels and their correlation with progression 
from latent to active disease. There is a suggestion that increasing concentrations of 
IFN-γ may be associated with the development of active TB (Diel et al., 2008; 
Aichelburg et al., 2009; Diel et al., 2011). Other measures of TB-specific antigens 
such as ESAT-6 and CFP-10 have also been investigated as prognosticators for 
active TB development, though at this stage studies have been limited to animals and 
further work needs to occur in human studies (Weldingh et al., 2008). Both ESAT-6 
and CFP-10 are specific M. tuberculosis complex antigens that are used as part of the 
IGRA. IGRA detects the level of IFN- γ that is released in response to these antigens. 
Being better able to predict those most likely to develop active disease following 
infection would allow a more tailored approach to chemopreventative therapy and 
would limit the need to use such treatment in patients who if left untreated would 
never develop active disease.  
 
1.5.3! Biomarkers to predict drug and vaccine efficacy 
Currently there are no known biomarkers that can predict the efficacy of a TB 
vaccine candidate. This means that vaccine studies involve lengthy and costly trials. 
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Our understanding of M. tuberculosis and its interaction with the human host is 
incomplete. These knowledge gaps hinder the development of biomarkers that can 
distinguish active from latent disease and predict those that will progress from latent 
to active TB. These knowledge gaps also impede new drug and vaccine 
development. Small non-coding ribonucleic acids (RNA) termed microRNAs 
(miRNAs) have recently been identified as a potential biomarker for other human 
diseases such as malignancy (Chen et al., 2012) and this research project aims to 
study miRNAs in the setting of M. tuberculosis infection with the aim of developing 
a suitable biomarker.  
 
1.6! MicroRNAs  
MicroRNAs (miRNA) are short, 19-24 nucleotides in length, non-coding RNAs that 
play an important role in post-transcriptional regulation of gene expression through 
targeting messenger RNA (mRNA). It is estimated that more than 60% of mRNAs 
are targeted by at least one miRNA (Mause et al., 2010). miRNAs are therefore key 
regulators of cellular processes. It has been suggested that miRNAs play a role in 
nearly all aspects of cell physiology, including cell proliferation, differentiation and 
apoptosis (Tomankova et al., 2010). Circulating miRNAs exist in a highly stable 
cell-free form and recent literature has demonstrated their varying expression in 
diseased states such as malignancy, schizophrenia, diabetes, heart failure and sepsis 
(He et al., 2004; Oak et al., 2011; Mastronardi et al., 2012). Circulating miRNAs 
have potential as a diagnostic, prognostic and predictive markers. The lung has been 
shown to have a very specific miRNA profile across mammalian species (Williams 
et al., 2007).  
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Biomarker discovery, not only for TB, but also for other inflammatory and infectious 
disease has featured prominently in the literature. There is emerging evidence that 
miRNAs play a crucial role in pathogen-host interactions. Circulating miRNAs have 
been shown to be consistently expressed and are stable in blood and tissue (Chen et 
al., 2008; Kroh et al., 2010; Turchinovich et al., 2011). miRNAs have been found to 
be useful prognosticators in the setting of malignancy and their use in clinical 
medicine as a biomarker, particularly in malignancy, is increasing (Ng et al., 2009; 
Yamamoto et al., 2012; Y. Lu et al., 2012; Yuxia et al., 2012). At the 
commencement of this body of work, little was known about the role of miRNAs in 
TB. However, knowledge in this area is increasing and there has been an exponential 
rise in miRNA-related research over the last decade. 
 
1.6.1! Discovery of miRNAs 
In 1993 the first miRNA precursor, lin-4, was discovered. lin-4 was shown to 
regulate worm (Caenorhabditis elegans) development (R. C. Lee et al., 1993). The 
lin-4 miRNA was found to be necessary for development beyond an early larval 
stage; interestingly, examination at that time of its sequence revealed a 22-nucleotide 
RNA sequence with no open reading frame. This was found to interact with the three 
prime untranslated region (3’-UTR) of its negatively regulated protein, lin-14, 
thereby inhibiting protein synthesis (T. H. Lee et al., 2011). It was not until several 
years later, with the discovery of let-7, that miRNAs were found to be highly 
conserved across mammalian species (Pasquinelli et al., 2000). It is now understood 
that humans express >2000 miRNAs (as listed in microRNA database, 
www.mirbase.org) that can regulate the translation of mRNA and can silence genes 
at the DNA level (Friedman et al., 2009).  
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1.6.2! miRNA biogenesis 
The canonical biogenesis pathway for most animal miRNAs is summarised in Figure 
1.3. miRNAs are derived from precursor transcripts known as primary miRNA (pri-
miRNA) that originate in the nucleus as single long transcripts up to 1000 
nucleotides in length. They are processed by Drosha, an RNase III enzyme and 
DiGeorge Syndrome critical region 8 (DGCR8), an RNA binding protein, into a pre-
cursor hairpin structure, 70-100 nt long, known as “pre-miRNA”.  
 
Next, pre-miRNA is then transported to the cytoplasm via Exportin 5 where it 
undergoes further processing by Dicer into mature miRNA and a miRNA strand, 
which is later degraded. The mature miRNA is incorporated into the RNA-induced 
silencing complex (RISC). Once incorporated into the RISC, the mature miRNA will 
guide the RISC to the target mRNA. For those with known characterized gene 
targets, miRNAs have been found to regulate gene expression through translational 
repression and mRNA degradation (He et al., 2004). 
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Figure 1-3. miRNA biogenesis pathway. Illustration of miRNA biogenesis pathway 
showing the primary precursor molecules (pri-miRNA) which are processed by 
Drosha to 70 nt long precursor hairpins (pre-miRNA) and exported to the cytoplasm 
by Exportin 5. Dicer then cleaves the pre-miRNA hairpins to generate 20 bp long 
miRNA duplexes, one strand of which gets incorporated into RNA induced silencing 
complex (RISC) to bind to target mRNAs, leading to gene silencing. Figure adapted 
from van Rooij (van Rooij, 2011). 
 
1.6.3! Mechanisms of miRNA action 
Following its synthesis and incorporation into the RISC complex, the mature miRNA 
interacts with its target mRNA. miRNAs target mRNA through the second to seventh 
bases of the mature miRNA sequence known as the miRNA seed (Lewis et al., 
2005). This miRNA seed has complementarity to target sites in the 3’-UTR of 
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mRNA transcripts (Lewis et al., 2005). The binding of miRNA to mRNA via this 
mechanism allows miRNAs to regulate hundreds of genes, as the miRNA is capable 
of binding to any mRNA with sufficient seed region complementarity (Lim et al., 
2005). 
 
In humans the most common method of miRNA:mRNA interaction is first through 
translational repression followed by deadenylation and decay of the mRNA, leading 
to mRNA degradation and a decrease in protein expression (Friedman et al., 2008; 
Meijer et al., 2013). Translational repression is where a decrease in protein product is 
found that is greater than the observed decrease in mRNA, therefore the mRNA is 
not being transcribed. This occurs initially through miRNAs binding to mRNAs in a 
complex with Argonaute (AGO) proteins 1-4, forming the initial translational 
repression at the 3’-UTR. This complex then recruits one of the trinucleotide repeat-
containing proteins and binds to a secondary structure in the 5’-UTR causing 
deadenylation. In other methods of miRNA control, mRNAs are formed with the 
addition of a 3’poly(A) tail which increases the stability of the mRNA structure, thus 
limiting degradation. miRNAs can cause degradation of this poly(A) tail 
(deadenylation), and therefore destabilising of the mRNA (Djuranovic et al., 2012; 
Meijer et al., 2013). 
 
1.6.4! miRNA nomenclature 
miRNAs are named in three parts as illustrated in Figure 1.4. The initial 
classification relates to the species they are observed in, with “hsa” referring to 
human miRNAs, and “rno” referring to rat miRNA and “mmu” referring to mouse 
miRNA. They are then named as such with a prefix, miR, followed by a number. The 
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number relates to the miRNA’s time of discovery and is sequential; meaning more 
recently discovered miRNAs receive a higher number. miRNAs with a similar 
structure are distinguished by a lower case letter following the number. For example, 
miR-146a and miR-146b are very similar in sequence. Some miRNAs are transcribed 
from two different genetic loci and are named by a dash and a second number. For 
example, miR-250-1 and miR-250-2. Finally, miRNAs originating from the same 
pre-miR, but originating from the 3’ or 5’ end are denoted with -3p or -5p suffix.  
 
There are a few exceptions that exist for miRNAs that were described before the 
advent of the naming system, such as lin-4 and let-7 from model C. elegans. 
 
 
Figure 1-4. Nomenclature of miRNAs. 
 
1.6.5! MicroRNA as a biomarker 
An ideal biomarkers needs to fulfil a number of criteria. It should be accessible 
through reasonably non-invasive measures and specific to the disease of interest; it 
should be a reliable means to detect disease before clinical symptoms appear; it 
should be sensitive to changes in pathology, either disease progression or therapeutic 
response; and it should be easily translatable from the bench to the patient. In terms 
of TB,  a good biomarker would be able to detect those that are most likely to 
      hsa-miR-146a-3p 
  
  
Species information                         3’origin 
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progress from latent TB to active TB. It would also be able to detect non-response to 
therapy earlier than the current standard 2-month sputum culture and would be able 
to detect drug resistance in those with active disease. Finally, it should be able to be 
used as a marker of vaccine or new drug efficacy. It is likely that no single biomarker 
on its own would be able to fulfil these criteria and that a combination of biomarkers 
will need to be used in conjunction. 
 
Most of the current biomarkers are blood based and measure levels of specific 
proteins, for example, troponin, for ischaemic cardiovascular problems, 
carcinoembryonic antigen for colorectal malignancy and prostate-specific antigen for 
prostate pathology (Duffy, 2001; Rao et al., 2008). The development of protein-
based biomarkers is sometimes problematic in part due to the relatively low 
abundance of many proteins of interest in blood (Drucker et al., 2013). Furthermore, 
often biomarkers with high sensitivities have low specificity, meaning that over 
diagnosis is often made (Drucker et al., 2013). Those that are more specific inversely 
have low sensitivities.  
 
miRNAs have many requisite features of a good biomarker. They are stable in 
various body fluids, the expression of some miRNAs are specific to tissues and the 
level of miRNAs can be easily assessed by various methods including PCR. The 
changes in miRNA expression in plasma, serum, saliva and urine have been 
associated with different diseases. Serum miRNAs have been shown to be modulated 
in cases of interstitial fibrosis in smokers, expression of let-7 and miR-181b have 
been associated with chemoresponse in colon cancer, and expression of a number of 
miRNAs in urinary sediment was found to predict both the presence and severity of 
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IgA nephropathy (Nakajima et al., 2006; G. Wang et al., 2010; Y. Huang et al., 
2012). 
 
1.6.6! Circulating miRNAs 
It wasn’t until 2008 that miRNAs were discovered to be present in the blood, where 
they were detected in platelets, plasma, erythrocytes and nucleated red blood cells 
(Mitchell et al., 2008; Xi Chen et al., 2008). Interestingly plasma-based miRNAs are 
remarkably stable and this is in contrast to synthetic miRNAs added to samples, 
which degrade quickly. This is thought to be due to the effects of RNase activity in 
the plasma (Mitchell et al., 2008; Xi Chen et al., 2008). This stability of endogenous 
miRNAs suggests that plasma miRNAs are protected. Recently it has become 
apparent that miRNAs achieve this through two mechanisms; miRNAs can be 
packaged within small microvesicles (exosomes, microvesicles or apoptotic bodies) 
(Valadi et al., 2007; Zernecke et al., 2009) or alternatively be associated with 
lipoprotein complexes or RNA-binding proteins  such as Ago2 (Vickers et al., 2011). 
 
1.6.6.1! miRNAs packaged in microvesicles 
One of the ways that plasma-derived miRNAs are protected from degradation is to 
be packaged into protein or lipid vesicles. Exosomes (50-100 nm) originate from the 
endosome and are released into the extracellular environment when multivesicular 
bodies fuse with the plasma membrane.  
 
Exosomes can transfer molecules, such as miRNAs, from one cell to another via 
membrane-vesicle trafficking (Raposo et al., 2013). Valadi et al. discovered that 
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mast cell-derived exosomes carry approximately 121 different miRNAs (Valadi et 
al., 2007). Mesenchymal stem cells have also been shown to secrete miRNA 
exosomes, however these miRNAs were secreted as pre-miRNA and not in their 
mature form (Chen et al., 2010).  
 
Microparticles are larger than exosomes at 0.1-1 µm that are released from cells 
through outward budding and fission of the plasma membrane. Once shed, 
microparticles can travel large distances which enables packaged miRNA to act at 
distant sites (Muralidharan-Chari et al., 2010). Diehl and colleagues examined 
miRNA in microparticles from human platelets in the setting of coronary artery 
disease. They observed that platelet microparticles contained numerous miRNAs and 
that these microparticles acted as transport vehicles for a large number of miRNAs 
(Diehl et al., 2012). 
 
Apoptotic bodies are the largest microparticle measuring 0.5-2 µm and are shed from 
cells during apoptosis. It has recently been reported that endothelial cell-derived 
apoptotic bodies are formed during atherosclerosis and these were found to contain 
miR-126. Furthermore, incubation of these apoptotic bodies with human umbilical 
vein cells resulted in the transfer of miR-126 into recipient cells and production of 
anti-inflammatory chemokines (Zernecke et al., 2009). 
 
1.6.6.2! miRNAs bound to protein complexes 
It is thought that up to 90% of plasma miRNA exist in non-membrane-bound form 
(Arroyo et al., 2011). A large proportion of non-vesicular miRNAs have been shown 
to be bound to Ago2. Ago2 is thought to be the key intracellular effector protein of 
 30 
the miRNA-mediated RISC (Hutvagner et al., 2008). It remains unclear however as 
to how the miRNA complex is exported by the cell, it has been hypothesised that 
Ago2-miRNA complexes are released following apoptosis of the cell and that the 
Ago2-miRNA complex remains intact in the extracellular environment due to its 
high binding affinity (Arroyo et al., 2011). A recent study by Laffont et al., 
interestingly has found that Ago-miRNA-223 complexes were carried in platelet-
derived microparticles where they modulate gene expression both locally and at 
distant sites (Laffont et al., 2013). 
 
1.6.6.3! miRNAs associated with lipoproteins 
High-density lipoprotein (HDL) was classically known for its ability to transport 
excess cellular cholesterol to the liver for excretion. However, it has recently become 
apparent that HDLs can transport and deliver miRNAs to target cells. The exact 
mechanism, by which they do this remains unknown. Vickers et al. found that 
injecting HDL into mice retrieved distinct miRNA profiles from both normal and 
atherogenic murine-models (Vickers et al., 2011). Vickers and colleagues also 
collected HLD from patients with hypercholesterolaemia and from patients with 
normal cholesterol levels and used these to treat cultured hepatocytes. HDL-miRNA 
from patients with hypercholesterolaemia induced different gene expression than that 
observed from HDL-treated hepatocytes from healthy controls. These data provide 
evidence that HDL can both transport miRNA to target cells and alter gene 
expression. 
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1.7! miRNA expression profiling 
With the recent advances in miRNA research there needs to be reproducible and 
reliable miRNA quantification measures. There is currently little consensus 
regarding the best methodology to use for miRNA quantification. However, 
quantitative real time PCR (qPCR) is considered to be the gold standard for the 
accurate quantification of miRNA expression. There are several commercially 
available kits which employ distinct approaches to prime the miRNA for reverse 
transcription and then amplify the cDNA. The methods employed in this body of 
work are discussed below in Section 1.7.4. 
 
Generally, cells from blood, tissue, urine or even saliva are isolated and RNA 
extracted and quantitated and the amount of each miRNA measured. The miRNA 
measured is then normalised with the aim of minimising data bias caused by external 
factors such as technical variation, the method used to purify the RNA, the amount of 
sample processed, and the quality of the sample (Peltier et al., 2008). Data is 
analysed in light of the available clinical or pathological information, appropriate 
statistics techniques are applied and the outcomes examined.  
 
1.7.1! Sample considerations 
Sample preparation and RNA extraction methods can have a substantial impact on 
the quantification of miRNA expression. This is especially pertinent for samples that 
are prone to miRNA degradation (W.-X. Wang et al., 2008; Ibberson et al., 2009; 
Podolska et al., 2011). Wang and colleagues performed RNA isolation on a single 
brain sample using eight different isolation methods with miRNA expression 
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measured on microarray and cross-referenced to Northern blots. Markedly different 
results were seen between samples obtained using different RNA isolation 
techniques and also between microarray and Northern blot results (W.-X. Wang et 
al., 2008). 
 
It is possible to extract miRNA from a wide variety of specimens, including sputum, 
whole blood, plasma, serum, cell lines, formalin-fixed tissues and other bodily fluids 
(Accerbi et al., 2010; Weber et al., 2010). miRNA extraction is similar to RNA 
extraction, however the protocols are sometimes modified to capture, and sometimes 
enhance, small RNA isolation (Accerbi et al., 2010).  
 
Tissues and cell lines generally deliver the greatest yield of miRNA. miRNAs were 
shown to be stable and remained intact when samples were formalin-fixed with 
comparable levels of miRNA isolated from both fresh and formalin-fixed samples 
(Doleshal et al., 2008). This is quite advantageous in the clinical setting, as often the 
only tissue sample available is formalin-fixed. 
 
When assessing blood-based miRNA expression, rigorous quality control of 
plasma/serum samples needs to occur to limit factors that can erroneously alter 
miRNA expression. Extra consideration needs to be given in relation to the possible 
effects of endogenous RNase activity present in the blood, as well as the presence 
and effect of red blood cells, especially if haemolysed (Mitchell et al., 2008). 
Kirschner et al. measured miRNA from haemolysed and non-haemolysed plasma 
from the same donor collected at the same time (Kirschner et al., 2011). From the six 
donor plasma samples, miRNA was measured by microarray and later verified by 
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real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). 
Significant variation in miRNA expression was noted between the haemolysed and 
non-haemolysed samples from the same donor. Another consideration is the time 
taken to process the blood sample after collection, centrifugation techniques and 
storage. Cheng et al. measured miRNA expression in plasma from healthy 
individuals subjecting the same donor’s plasma to different centrifugation speeds. 
miRNA expression was then determined using qRT-PCR (Cheng et al., 2013). The 
authors observed quite marked variation in miRNA expression, sometimes more than 
one thousand infold differences in which were due solely to the methods of 
processing. This marked discrepancy was thought to be due to platelet 
contamination. Importantly, the authors also noted, that a second centrifugation, 
largely eliminated this contamination.  
 
Measuring miRNAs present in biofluids such as plasma and serum shows great 
promise as a minimally invasive biomarker, however accurate quantification of 
miRNA expression requires rigorous quality control to limit technical variation 
which can easily affect miRNA levels resulting in biases that do not actually reflect 
the biological state of the sample.  
 
1.7.2! Quantification and quality assessment of miRNA. 
In order to maintain consistency in yield and reproducibility of results, it is important 
that extracted RNA is both quantitatively and qualitatively assessed. As many of the 
profiling methods use total RNA, specific methods to measure miRNA levels are 
unnecessary. However it is standard practice to measure total RNA and RNA 
integrity using instruments such as the Bioanalyzer 2100 (Agilent Technologies, 
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Santa Clara, CA) and Nanodrop Spectophotometer (Thermo Scientific, Wilmington 
DE). In some instances, especially when dealing with plasma samples, a synthetic 
spike-in can be used (such as miRNAs from  C. elegans) The spike-in is added to the 
samples before RNA extraction. The spike-in is then measured in the purified RNA 
and acts as an endogenous normaliser to control for such factors as variation in RNA 
extraction and/or inhibitors of reverse transcription or PCR (Kroh et al., 2010). 
 
There are numerous methodologies employed to quantitatively measure miRNA 
including northern blotting with radiolabelled probes (Válóczi et al., 2004), 
quantitative PCR-based amplification of precursor or mature miRNAs (Caifu Chen et 
al., 2005), cloning (Lau et al., 2001), serial analysis of gene expression (SAGE) (J. 
Lu et al., 2005; Jay et al., 2007), bead-based profiling methods (J. Lu et al., 2005; Jay 
et al., 2007), single molecule detection (Neely et al., 2006), oligonucleotide 
microarrays, (Barad et al., 2004; Cummins et al., 2006) and digital multiplex (G. K. 
Geiss et al., 2008; Kulkarni, 2011) also immunohistochemistry. The merits and 
limitations of each method are listed in Table 1.1. 
 
Despite the many ways to quantify miRNA, there are three methods that are 
commonly used to measure miRNA expression: qRT-PCR; microarrays; and high-
throughput sequencing. Each of these techniques has different strengths and 
weaknesses and they are often used at different stages of the same study with arrays 
or high-throughput technologies used in the discovery stage, and qRT-PCR utilised 
to validate findings.  
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Table 1-1. Methods of profiling miRNA. 
Method' Merit' Limitation' Reference'
Northern'blot' ' Highly'specific;'
gold'standard.'
Low'throughput;'
low'sensitivity.'
(Válóczi'et'al.,'2004)'
qRT6PCR' ' Rapid'detection;'
low'cost;'
superior'detection'
of'low'abundant'
miRNAs.'
ClosedIended*.' (Caifu'Chen'et'al.,'
2005)'
Cloning' ' Discovery'of'new'
miRNAs.'
Time'consuming;'
expensive.'
(Lau'et'al.,'2001;'
Cummins'et'al.,'
2006)'
SAGE' ' Discovery'of'new'
miRNAs;'
Expensive.' (J.'Lu'et'al.,'2005;'
Jay'et'al.,'2007)'
' ' High'throughput.' ' '
Bead6based' ' High'speed;'low'
cost;'superior'
hybridization.'
ClosedIended*.' (J.'Lu'et'al.,'2005;'
Jay'et'al.,'2007)'
Single' molecule'
detection'
' Rapid'detection.' ClosedIended*;'
expensive.'
(Neely'et'al.,'2006)'
Microarrays' ' Low'cost;'
High'throughput.'
ClosedIended*,'
lower'specificity.'
(Barad'et'al.,'2004;'
Cummins'et'al.,'
2006;'F.'Sato'et'al.,'
2009)'
Digital'multiplex' ' Robust,'high'
throughput'
Expensive,'time'
consuming.'
(G.'K.'Geiss'et'al.,'
2008;'Kulkarni,'
2011)'
qRT-PCR, quantitative real-time PCR; SAGE, serial analysis of gene expression. 
*Closed-ended methods assay a predetermined set of miRNAs  
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1.7.3! Microarray measurement of miRNA 
With the advent of genomics and the technology to generate large quantities of 
genomic data, there has been an exponential rise in the study of gene structure and 
function and consequently vastly improved understanding of gene regulation. The 
profiling of miRNAs is a relatively new field and special factors need to be 
considered, such as their small size, low abundance and tissue-state specificities.   
 
There are a number of different microarray platforms that have been used to profile 
miRNAs. These methods differ in RNA labelling and probe design strategies. 
miRNA microarrays, in contrast to standard mRNA arrays, must take into account 
the differences between mature miRNA and miRNA precursors. Moreover, 
microarrays need to be able to differentiate between miRNAs that differ by as little 
as a single nucleotide (Shingara et al., 2005). In addition to this, miRNAs often have 
different melting temperatures for annealing reactions. All of these issues are specific 
to miRNA and present challenges to both sample labelling and probe development. 
 
1.7.3.1! Probe design 
The ideal probe should have both high affinity and high specificity that complement 
the sense and antisense stands of the miRNA. They also need to deal with varying 
melting temperatures of each miRNA, which vary between 45°C and 74°C (van 
Rooij, 2011). Endogenous and exogenous (spike-in controls) positive and negative 
control probes are also required. These help to normalise and provide reference 
points for quality control and facilitate quantitative comparison of different 
microarray platforms.  
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1.7.3.2! Application of miRNA arrays 
miRNA microarrays allow the detection and quantification of several hundred 
miRNAs in the same sample at once thus requiring only small quantities of RNA. 
This is particularly important in the clinical setting when using blood-based 
biomarkers where typically the RNA yield is low. One of the major drawbacks of 
this technology is the inability to compare data from different array platforms. Other 
limitations include lower specificity and lower dynamic range compared to qRT-
PCR or sequencing (F. Sato et al., 2009). The technology is also closed-ended 
meaning there are no avenues to discover new miRNAs. 
 
1.7.4! Quantitative real-time PCR 
qRT-PCR is the method of choice for the accurate quantification of miRNA 
expression. There are several quantitative platforms currently available but 
essentially they all rely on the conversion of RNA to cDNA and subsequent 
quantification by comparison to a standard gene or sample (in this case healthy/non-
infected controls). Each platform employs a distinct approach to prime the miRNA 
for reverse transcription and then to amplify the cDNA. For this research project we 
utilised three different platforms: TaqMan miRNA Assay (Life Technology, 
Victoria, Australia); SYBR Green (GenCopoeia, Rockville, MD); and miRCURY 
LNATM Universal RT miRNA PCR Assay (Exiqon, Vedbaek, Denmark). 
 
The TaqMan assay uses a miRNA-specific stem-loop reverse transcription primer to 
generate cDNA for subsequent qPCR amplification (Redshaw et al., 2013). There are 
advantages of utilising this technology. Firstly it is able to discriminate between 
similar miRNAs, thus increasing its specificity. Secondly it prevents the 
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hybridization of its RT primer to miRNA precursors as well as genomic DNA, again 
increasing its specificity. Finally, the stem-loop extends the 3’ end of the miRNA by 
RT. This results in a longer RT product which is more amenable to qRT-PCR, 
resulting in greater sensitivity (Fu et al., 2011). 
 
The SYBR Green-based method uses tagged and anchored olig-dT primers for 
reverse transcription of polyadenylated small RNAs into mature RNAs, followed by 
SYBR Green-based detection of reversed transcribed miRNA (Z. Zhu et al., 2013). 
The All-In-One qPCR reduces experimental time by providing a universal reaction 
that can be used with almost all primers and most real-time PCR instruments. 
However, this platform is less specific than the TaqMan assay. 
 
The miRCURY LNATM Universal RT (Exiqon) involves poly(A) tailing of mature 
miRNAs. This is followed by the use of a poly(T) reverse transcription primer 
containing a 3’ anchor and 5’ universal tag leading to the generation of cDNA. The 
cDNA is then amplified by SYBR Green qPCR using miRNA-specific forward and 
reverse primers containing locked nucleic acids (LNAs) (Redshaw et al., 2013). 
LNAs are a class of nucleic acid analogues in which the ribose ring is fixed or locked 
by a methylene bridge connecting the 2’-oxygen and the 4’-carbon atom (Figure 1.5). 
The use of miRNA-specific forward and reverse primers offers an advantage in terms 
of the increased specificity of amplification (Vester et al., 2004). 
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Figure 1-5. The Structure of LNA™. The ribose ring is connected by a methylene 
bridge (orange) between the 2’-O and 4’-C atoms thus “locking” the ribose ring in 
the ideal confirmation for Watson-Crick binding. When incorporated into a DNA or 
RNA oligonucleotide LNA™ makes the pairing with a complimentary nucleotide 
strand more rapid and increases the stability of the resulting duplex. Figure courtesy 
of Exiqon (http://www.exiqon.com/lna-technology). 
 
1.7.5! High throughput measurement 
Next generation sequencing (NGS) is a popular, widely adopted approach for 
profiling miRNAs. It is highly sensitive and has the ability to combine multiple 
biological samples in one sequencing reaction, which means that it is becoming more 
cost-effective. It has the advantage of being able to identify novel miRNAs as it is 
not reliant on previously known sequences (Vigneault et al., 2012). Studies utilising 
NGS have shown it to be highly sensitive, reproducible and quantitative (Burgos et 
al., 2013; Murakami et al., 2014; Müller et al., 2014). It also has the advantage of 
being able to very accurately distinguish between miRNAs of similar sequence.  
 
 
1.8! miRNAs in other inflammatory lung conditions 
At the commencement of this research project, little was known or understood about 
the role miRNAs play in M. tuberculosis infection. Many reports at that time 
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described altered expression of miRNAs in cancer samples compared with normal 
tissue including sarcomas (Kang et al., 2011), prostate cancer (Farooqi et al., 2012), 
breast cancer, colon cancer (Boni et al., 2011) and other diseases such as diabetes 
(Foley et al., 2012) and heart disease (Feng et al., 2011). 
 
Interaction between M. tuberculosis and the host results in infection and the 
subsequent host inflammatory response. Chronic obstructive pulmonary disease 
(COPD) and asthma, although not infectious diseases, both evoke an acute and 
subsequent chronic inflammatory response. Both diseases affect the lungs and at the 
start of this research project, there were a number of studies examining the roles of 
miRNAs in these diseases. Listed in Table 1.2 are the miRNAs that have been found 
to be regulated in asthma and COPD. These findings supported the notion that 
miRNAs had an important role to play in the pathogenesis of both conditions.  
 
Given the increasing amount of interest in miRNA research coupled with numerous 
studies highlighting their important roles in disease states such as malignancy and 
lung pathologies, we set out to discover the miRNAs that are modulated in M. 
tuberculosis infection. 
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Table 1-2. List of miRNAs associated with other inflammatory lung conditions. 
miRNA& Tissue/Cell&Type& Function& Species& Condition&& Reference&
miR9221& Serum& Pro)inflammatory& Human& Asthma& (Qin&et&al.,&2012)&
miR9221& &948593p& Serum& Pro)inflammatory& Human& Asthma& (F.&Liu&et&al.,&2012)&
miR9126& Cells& Airway&modelling&& Murine& Asthma& (Collison&et&al.,&2011)&
miR9192& Peripheral&blood& Airway&remodelling&& Human& Asthma&& (Yamamoto&et&al.,&2012)&
miR9146a& BAL& Allergic&inflammation& Murine& Asthma&& (Garbacki&et&al.,&2011)&
mir9126& Respiratory&epithelium& Anti)inflammatory& Murine& Asthma& (Mattes&et&al.,&2009)&
miR91& Respiratory&endothelium& Anti)inflammatory& Murine& Asthma& (Takyar&et&al.,&2013)&
miR9487b& &9181& Respiratory&epithelium& Pro)inflammatory& Human& Asthma& (Coulter,&2008)&
let97& Primary&cultured&T&cells& Regulation&of&IL)13& Murine& Asthma& (Ansari&et&al.,&2003)&
miR9146a& Sputum& Airway&inflammation&and&tissue&remodelling& Human& COPD& (T.&Sato&et&al.,&2010)&
miR9199a95p& Respiratory&epithelium& HIF)1α&leading&to&prolongation&of&lifespan&of&neutrophil& Human& COPD& (L.&Zhang&et&al.,&2008)&
miR9452& Human&alveolar&macrophages& Increasing&levels&MMP)12&which&degrades&elastin& Human& COPD& (Baffa&et&al.,&2009)&
BAL, bronchoalveolar lavage; IL-13, interleukin-13; HIF-1α – hypoxia-induced factor; MMP, matrix metalloproteinase; COPD, chronic obstructive pulmonary disease.
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1.9! miRNAs in tuberculosis 
Upon their discovery, miRNA research predominately focussed on their expression 
in malignant disease. It wasn’t until very recently that the role of miRNA in other 
pathology became of interest. A seminal paper by Guo et al. published in 2010, was 
the first work that studied the possible targets of human miRNAs to M. tuberculosis 
mRNA (Guo et al., 2010). Utilising miRanda software 26 genes were identified as 
possible targets for miRNA from host lungs and macrophages (Ueda et al., 2010).  
The published works relating to M, tuberculosis miRNA research that occurred either 
prior or during my candidature is presented below. A summary of these findings is 
presented in Table 1.3. 
 
1.9.1! Cell-based studies  
In 2011, Lui and colleagues published the first study profiling miRNA expression in 
peripheral blood mononuclear cell (PBMC)s from active TB patients and their 
matched healthy controls (Liu et al., 2011). Using microarray technology the authors 
found 30 miRNAs were significantly regulated in active TB, 28 miRNAs up-
regulated and two miRNAs down-regulated. Functional analysis of miR-144, which 
was found to be up-regulated in TB, showed that it inhibited TNF and IFN-γ and T 
cell proliferation. 
 
Also in 2011, Wang et al. examined miRNA expression from PBMCs isolated from 
patients with active TB, LTBI and healthy controls (Wang et al., 2011). Utilising 
microarray technology, 17 differentially expressed miRNAs were observed between 
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the patients with active disease and those with LTBI. The majority (12 out of 17) 
were up-regulated in patients with active TB.  
 
The following year, in 2012, Walter et al. showed that THP-1 macrophages infected 
with M. tuberculosis modulated miRNA expression (Walter et al., 2012). miRNA 
expression was measured by qRT-PCR with 12 miRNAs noted to be significantly 
regulated including miR-155 and -146a. 
 
1.9.2! Serum-based studies 
It wasn’t until 2011 that the first paper profiling circulating miRNA in patients with 
active pulmonary TB was published (Fu et al., 2011). 75 patients with active 
pulmonary TB were recruited for the study together with 52 healthy age- and sex-
matched individuals. A total of 1,223 miRNAs were screened using microarray 
technology, with 92 miRNAs with significant regulation detected, 59 up-regulated, 
and 33 down-regulated. The authors found that up-regulation of miR-29 could 
discriminate TB patients from healthy controls with reasonable sensitivity and 
specificity (83% and 80%, respectively). 
 
The following year, Qi and colleagues used TaqMan Low-Density Arrays followed 
by qRT-PCR to examine miRNA expression profiles from the serum of 30 patients 
with active TB. Compared to healthy controls, the serum from patients with TB had 
90 up-regulated and seven down-regulated miRNAs. When utilising a multiple 
logistic regression, a combination of three miRNAs (miR-361-5p, -889 and -576-3p) 
achieved an area under the curve (AUC) of 0.863. 
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Abd-EL-Fattah et al. in 2013 examined miRNA expression in serum from patients 
with TB, lung cancer, and pneumonia compared with matched healthy controls (Abd-
El-Fattah et al., 2013). In the TB arm, there were 29 patients enrolled with 37 healthy 
controls. Utilising microarray profiling followed by qRT-PCR verification the 
authors observed that for the TB subjects, up-regulation of miR-197 was increased in 
patients with TB compared with normal controls. In the same year, Zhang and 
colleagues, used Solexa sequencing data that showed 91 serum miRNAs were 
differentially expressed in pulmonary TB patients, compared to healthy controls 
(Zhang et al., 2013). Using the combination of six serum miRNAs (miR-378, -483-
5p, -22, -29c, -101 and -320b) in a logistic regression analysis revealed a 95% 
sensitivity and 91.8% specificity of a TB diagnosis. 
 
1.9.3! miRNA in other tissues 
In 2012, Yi et al. profiled miRNA expression from human saliva from patients with 
pulmonary TB comparing their expression to healthy controls (Yi et al., 2012). Using 
microarrays, the authors found 95 miRNAs that were differentially expressed in 
human saliva, with miR-19b, -3179 and -147 being the most significant. 
 
The following year, Spinelli and colleagues examined the expression of six chosen 
miRNAs (miR-424, -365, -144, -421, -223 and -146a) from PBMCs obtained from 
pleural fluid as well as peripheral blood from newly diagnosed TB patients (Spinelli 
et al., 2013). These miRNAs were chosen based on studies published previously and 
as mentioned above. Interestingly, miRNA signatures from each compartment were 
different with a strong down-regulation of miR -223, -144 and -421 in the pleural 
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fluid while miR-424 was elevated in PBMCs from the peripheral blood. The down-
regulation of miR-146a was common to both tissues.  
 
As highlighted above, there is a great need for the development of new biomarkers to 
not only assist in the diagnosis of M. tuberculosis but also to monitor response to 
treatment and as an avenue to evaluate new vaccines and assist in new drug therapy 
development. miRNAs had shown promise to act as a biomarker in other diseases.  
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Table 1-3. miRNAs modulated in tuberculosis. 
Tissue/Cell)Type) miRNA) Modulation) Reference)
) ) ) )
Blood%(PBMC)% miR.144% up.regulated% (Liu%et%al.%2011)%
Blood%(PBMC)% miR.424%&%miR.
365%
up.regulated% (Wang%et%al.%2011)%
THP.1%
macrophages%
miR.155%and%
miR.146a%
up.regulated% (Walter%et%al.%2012)%
Blood%(serum)% miR.93%and%miR.
29%
up.regulated% (Fu%et%al.%2011)%
Blood%(serum)% miR.3125% down.regulated% (Fu%et%al.%2011)%
Blood%(serum)% miR.361.5p,%miR.
889%and%miR.
576.3p%
up.regulated% (Qi%et%al.%2012)%
Blood%(serum)% miR.197% up.regulated% (Abd.El.Fattah% et% al.%
2013)%
Blood%(serum)% miR.378,%miR.
483.5p,%miR.22%
and%miR.29c,%.%
up.regulated% (Zhang%et%al.%2013)%
Blood%(serum)% 101%and%.320b% down.regulated% (Zhang%et%al.%2013)%%
Sputum% miR.19b% down.regulated% (Yi%et%al.%2012)%
Sputum% miR.3179%and%
miR.147%
up.regulated% (Yi%et%al.%2012)%
Sputum% miR.29a% up.regulated% (Fu%et%al.%2011)%
Blood% (PBMC% and%
PFMC)%
miR.146a% down.regulated% (Spinelli%et%al.%2013)%
 PBMC, peripheral blood mononuclear cell; PFMC, pleural fluid mononuclear cell. 
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1.10!Aims of this study 
Despite the availability of cheap and effective therapy, TB remains a global health 
problem. Efforts to control TB infection have been hampered by the spread and co-
infection with HIV and the rise in prevalence of drug-resistant M. tuberculosis. New 
biomarkers are required to improve diagnostics, monitor response to therapy and 
develop new drugs and vaccines. miRNA has been shown to be a promising 
biomarker in other diseases such as malignancy. Therefore the aims of this study are 
as follows: 
1.! To identify miRNAs that are regulated in M. tuberculosis disease. 
2.! To determine if the expression of miRNAs can be utilised as a biomarker 
that: 
a.! Assists in the diagnosis of TB 
b.! Monitors response to TB therapy and can rapidly identify non-
responders who may therefore be suffering from drug resistant TB. 
3.! To gain a better understanding of the role that miRNAs play in TB 
pathogenesis.
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2! MATERIALS AND METHODS 
2.1! Chemicals and reagents 
The chemicals and reagents used in this study were obtained from Sigma Aldrich 
(NSW, Australia) unless otherwise stated. 
 
2.2! Sample preparation 
2.2.1! Isolation of primary human monocytes from buffy coat and 
differentiation of monocyte-derived macrophages 
Sixty mLs of buffy coat from the Blood Bank or 60 mLs of blood from healthy 
donors, was equally divided into six, 50 mL conical tubes (Life Sciences). Blood was 
diluted 1/3 with phosphate buffered saline (PBS) and underlaid with 15 mLs of Ficoll-
Paque (Amersham Pharmacia Biotech, Uppsala, Sweden), centrifuged for 30 minutes 
at 800 g at room temperature (RT) with no brake. Following centrifugation, the 
monocyte layer was collected, and washed twice with PBS and centrifuged for 10 
minutes at 800 g. The final pellet was re-suspended in 10 mLs of media and the cells 
counted.  
 
The cells were centrifuged at 2,350 g for 10 minutes and the pellet was re-suspended 
in MACS buffer (saline + 0.5% foetal bovine serum [FBS], 2 mM ethylene-diamine-
tetra-acetic acid [EDTA]) per 107 cells. 10 µl of CD 14+micro beads/107 (Miltenyi 
Biotec, NSW, Australia) was added and incubated for 15 minutes at 4°C, washed and 
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centrifuged at 550 g for 5 minutes at 4°C. The pellet was then re-suspended in MACS 
buffer with 1 mL MACS buffer per 5 x 108 cells. 
 
The LS Column (Miltenyi Biotec) was prepared by rinsing with 3 mL of MACS 
buffer. 500 µl of cell suspension was added to the LS column and run through. It was 
then washed thrice with 3 mL of MACS buffer. Positively selected cells, of which 
greater than 90% were CD14+, were eluted by removing the column from the 
magnetic field and applying plunger force. 
 
Monocytes were counted and re-suspended in Dulbecco’s modified eagle medium 
(DMEM) (Life Technologies) and differentiated into macrophages for 6 days with 10 
ng/ µl granulocyte macrophage colony stimulating factor (GM-CSF) (1000 ng/mL). 
 
2.2.2! Isolation of plasma from human blood 
A venepuncture protocol was designed and was strictly followed so as to avoid any 
potential factors that may affect miRNA levels. 10 mL of venous blood was drawn 
from the cubital fossa from each patient at each collection. Blood was collected using 
the Vaccutainer Venepuncture System (BD Biosciences, NSW, Australia) with a 22 
gauge needle into EDTA (BD Biosciences) tube, 
 
The blood was separated by centrifugation at 800 g for 10 minutes at room 
temperature. The plasma (supernatant) was separated from the cellular layer by 
pipetting and approximately 5 mL of plasma was sacrificed to prevent disturbance of 
the cellular layer.  
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The plasma was stored at -80°C in 1 mL aliquots. Samples collected from China were 
transported below -60°C to Australia where they were stored at -80°C until further 
required. 
 
Prior to RNA isolation, samples were examined for haemolysis using a haemolysis 
chart (Figure 2.1) and samples with > 100 mg/dL of haemoglobin were discarded. 
 
 
Figure 2-1. Haemolysis chart. Used to visually determine the presence of 
haemolysis after plasma separation. Plasma samples > 100 mg/dL were discarded. 
 
2.3! Molecular methodology 
2.3.1! RNA extraction (miRNAeasy [Qiagen, Limburg, Netherlands]) 
Samples in TRIzol® (Invitrogen) were thawed at room temperate. 140 µl chloroform 
was added and the samples were shaken vigorously for 15 seconds and incubated for 
2-3 minutes, then centrifuged for 15 minutes at 12 000 g at 4°C. The upper aqueous 
phase was transferred to a new 1.5 mL collection tube and 1.5 times the volume of 
100% ethanol was added. Up to 700 µl of sample was transferred into RNeasy Mini 
column and centrifuged at 8000 g for 15 seconds at RT. This step was repeated for the 
remainder of the sample. 700 µl Buffer RWT® was added to RNeasy Mini column 
and this was then centrifuged for 15 seconds at 8000 g. The flow-through was 
discarded. 500 µl of Buffer RPE® (mild washing buffer) was added to the column 
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and centrifuged at 8000 g for 2 minutes and flow through discarded. 20 µl of RNase-
free water was then added to the column in a new collection tube and centrifuged for 
1 minute at 8000 g. RNA concentration was then determined by NanoDrop 2000 
Spectrophotometer (Thermo Scientific) and stored at -80°C until use. 
 
2.3.2! RNA extraction (TRIzol® or TRIzol LS®) 
For plasma samples, TRIzol LS® was used with the same method as below with 500 
ul of plasma extracted with 1 mL TRIzol LS®. 
 
Samples were thawed at room temperature and 0.2 mLs of chloroform per 1 mL 
TRIzol® or was added to the sample. The sample was shaken vigorously for 15 
seconds incubated at RT for 2-3 minutes, then centrifuged at 12000 g for 15 minutes 
at 2-8°C. The upper aqueous phase was transferred to a 1.5 mL collecting tube and 1 
µl glycogen was added. RNA was then precipitated by the addition of isopropyl 
alcohol at 0.5 mL of isopropyl per 1 mL TRIzol® at room temperature for 10 minutes 
then centrifuged at 12000 g for 10 minutes at 2-8°C. The pellet was washed with 1 
mL 75% ethanol. The sample was vortexed for 10 seconds and then centrifuged for 5 
minutes at 7500 g at 2-8°C. The pellet was air dried for 10 minutes and re-suspended 
in 10 mLs of deionized, diethylpyrocarbonate (DEPC)-treated water (Thermo 
Scientific). 
 
1 µl of Sodium acetate was added with 40 µl 100% ethanol to each sample and 
incubated at -20°C for 12 hours, then centrifuged for 30 minutes at 14000 g at 4°C. 
The supernatant was removed and the pellet washed with 500 µl of 75% ethanol then 
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centrifuged at 14000 g for 5 minutes at 4°C. The supernatant was removed and the 
pellet was re-suspended in 10 µl of DEPC-treated water. RNA concentration was 
determined by NanoDrop 2000 Spectrophotometer (Thermo Scientific). 
 
2.3.3! RNA extraction (miRCURY™ RNA Isolation Kits [Exiqon]) 
To prepare the reagents, 80 µl of >99% RNA grade ethanol was added to the supplied 
wash solutions. RNA and cDNA spike-ins were each re-suspended with 80 µl 
nuclease-free water and kept on ice for 20 minutes.  
 
60 µl of lysis solution was added to each 200 µl of plasma together with 1 µl of spike-
in and then vortexed for 5 seconds and incubated for 3 minutes at RT. The spike-ins 
utilised were UniSp2, UniSp4, UniSp5, UniSp6 and a synthetic version of C. elegans, 
cel-miR-39-3p. The spike-ins resemble miRNAs in structure but lack close sequence 
similarities to known miRNAs. Spike-ins act as a quality control for the RNA 
isolation and the cDNA synthesis.  
 
20 µl of protein precipitant was added, vortexed for 5 seconds, incubated for 1 minute 
at RT and then centrifuged for 3 minutes at 11,000 g. The supernatant was then 
transferred to a new collection tube and 270 µl of isopropanol was added and the 
sample was loaded onto the column. 100 µl of Wash Solution 1 was added and then 
centrifuged for 30 seconds at 11,000 g with the flow through discarded. 700 µl of 
Wash Solution 2 was added, centrifuged for 30 seconds at 11,000 g with flow through 
discarded. 250 µl of Wash Solution 2 was added to the column, centrifuged for 2 
minutes at 11,000 g. 50 µl of RNAase free water was added to the column, incubated 
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for 1 minute and then centrifuged at 11,000 g for 1 minute. The purified RNA sample 
were either used immediately or stored at -80°C. 
 
2.4! RNA quality control 
2.4.1! Nanospectrophotometer 
RNA samples were run on NanoDrop 2000 Spectrophotometer (Thermo Scientific) to 
determine RNA concentrations (as measured in ng/ µl) and organic solvent 
contamination (260/230 ratio). The machine was set to a factor of 40, lid factor 10 and 
with a background “on” in order to measure the extracted RNA. Before running the 
samples the machine was “blanked” with the same nuclease free water (Invitrogen) 
that the sample had been eluted into. A 260:280 ratio > 1.7 and a 260:230 ratio >1.1 
were required in order to pass quality control. 
2.4.2! Bioanalyzer 
Prior to running samples on microarray, all RNA was quality checked on Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Two parameters of RNA 
quality were assessed; RNA integrity number (RIN) and RNA quality 28S:18S. The 
bioanalyzer measures the time the sample RNA takes to travel through the gel-filled 
microfluidic channels of an RNA Nano LabChip® and compares this to a RNA 
sample with pre-determined amounts of different sized RNA strands (known as the 
ladder). A RIN > 8 was considered to be of good integrity with a 28S:18S ≈ 2.  
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2.4.3! Ethanol precipitation 
If the RNA had a 260:230 ratio ≤ 1:1 then it underwent ethanol precipitation with the 
aim of removing inorganic solvent contamination. 3 molar Sodium acetate was added 
to the sample at a volume equal to one-tenth of the sample amount. Two-times the 
sample volume of RNA-grade 100% ethanol was added, together with 1 µl of 
glycogen (20 mg/ µl) (Riche, Basel, Switzerland) as a carrier. The solution was 
vortexed and stored at -20°C overnight. The following day the sample was 
centrifuged at 4°C at maximum speed for 30 minutes. The supernatant was carefully 
removed. 500 µl of 80% RNA-grade ethanol was added and centrifuged at maximum 
speed at 4°C for 10 minutes. The supernatant was carefully removed and the samples 
were allowed to air-dry. The RNA was re-suspended in 10 µl of RNase free water and 
then measured by nanospectrophotometer. 
 
2.4.4! qRT-PCR of miRNA (TaqMan [Life Technologies]) 
2.4.4.1! cDNA Synthesis 
The RT master mix was prepared by scaling the volumes as listed below: 
Component% Master) mix) volume) per) 15=ul))
reaction%
100mM%dNTPS%(with%dTTP)% % 0.15%μl%
MultiScibe™%Reverse%Transcriptase,%50%U/%μl% 1.00%μl%
10XReverse%Transcription%Buffer% 1.50%μl%
RNase%Inhibitor,%20%U/%μl% 0.19%μl%
Nuclease.free%water% 4.16%μl%
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Total)volume) 7.00)μl)
 
Each 15-µl RT reaction, consisting of 7 µl master mix, 3 µl of 5XRT primer and 5 µl 
RNA sample, was vortexed and then centrifuged at 12 000 g for 5 seconds. It was 
then  incubated on ice for 5 minutes before being loaded into the thermal cycler with 
the following parameters set: 
Time% Temperature%
30%minutes% 16°C%
30%minutes% 42°C%
5%minutes% 85°C%
∞% 4°C%
2.4.4.2! qPCR amplification 
Samples were analysed on Fast Optical 96-Well Plate (Life Technologies) in the 
following quantities. 
Reagent% Volume)%
Taqman™%Small%RNA%Assay% 1.00%μl%
Product%from%RT%reaction% 1.33%μl%
TaqMan™%Universal%PCR%Master%Mix%II%(2X)% 10.00%μl%
Nuclease%free%water% 7.67%μl%
Total)Volume) 20.00)μl)
 
qRT-PCR was performed on a 7900HT Fast Real-Time PCR System (Life 
Technologies) machine with the following parameters set. 
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 Run mode: Standard 
 Sample Volume: 20 µl 
 Thermal Cycling Conditions  
 
2.4.5! qRT-PCR of miRNA (GenCopoeia™ [Rockville, MD]) 
2.4.5.1! cDNA synthesis 
The RT master mix was prepared by scaling the volumes as listed below with 100 ng 
of total RNA used per 25 µl sample. 
Component% Master)mix)volume)per)
25)ul)reaction*%
Quantity%
Total%RNA% % 100%ng%
2.5%U/%μl%Poly%A%Polymerase% 1%μl% %
RTase%Mix% 1%μl% %
5X%PAP/RT%Buffer% 1%μl% %
Spike.in.control% 1%μl% %
RNase./DNase%free%water% To%final%25%μl% %
 
 
 
Step 
Optimal AmpErase® 
UNG activity 
Enzyme 
Activation 
PCR 
Step 1   Step 2 Cycle (40 cycles) 
Denature Anneal 
Temperature 50°C 95°C 95°C 60°C 
Time 2 minutes 10 minutes 15 seconds 60 seconds 
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Each 25-µl RT was vortexed and then centrifuged at 12 000 g for 5 seconds. It was 
then incubated on ice for 5 minutes before being loaded into the thermal cycler with 
the following parameters set: 
Time% Temperature%
60%minutes% 37°C%
5%minutes% 85°C%
∞% 4°C%
 
The resultant reverse transcription reaction product was diluted 50 times with sterile 
RNase-/DNase free water. 
 
2.4.5.2! qPCR amplification 
Samples were analysed on Fast Optical 96-Well Plate (Applied Biosystems) in the 
following quantities. 
Reagent% Volume%
2X%All.in.One%qPCR%Mix%% 10%μl%
All.in.One%miRNA%qPCR%(2%μM)% 2%μl%
Universal%Adaptor%PCR%Primer%(2%μM)% 2%μl%
First.strand%cDNA%(diluted%1:5)% 2%μl%
RNase./DNase%free%water) 4%μl%
Total)Volume) 20)μl)
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qRT-PCR was performed on a 7900HT Fast Real-Time PCR System (Life 
Technologies) machine with the following parameters set. 
 Run mode: Standard 
 Sample Volume: 20 µl 
Thermal Cycling Conditions 
Tm, melting temperature. 
 
2.4.6! miRNA array (Affymetrix® GeneChip®, Santa Clara, CA) 
Total RNA containing low molecular weight RNA was labelled using the Flashtag 
RNA labelling kit (Genisphere, Hatfield, PA). For each sample, 150 ng total RNA 
was subjected a tailing reaction (2.5 mM MnCl2, ATP, Poly A Polymerase - 
incubation for 15 minutes at 370C) followed by ligation of the biotinylated signal 
molecule to the target RNA sample (16 Flash Tag ligation mix biotin, T4 DNA ligase 
- incubation for 30 minutes at room temperature) and adding of stop solution. 
Each sample was hybridized to a GeneChip miRNA Array (Affymetrix) at 48°C and 
60 g for 16 hours then washed and stained on Fluidics Station 450 (Fluidics script 
FS450_0003) and finally scanned on a GeneChip Scanner 3000 7G (Affymetrix). The 
image data were analysed with the miRNA QC Tool software for quality control. 
 
 
 
Step 
Initial 
denaturation 
   
PCR 
Cycle (40 cycles) 
Denature Anneal 
Temperature 95 °C 95°C Tm -2°C 
Time 10 minutes 10 seconds 20 seconds 
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Two versions of the microarray chips were used: Version 2.0 and Version 3.0. Four 
samples (from two donors: two infected and two uninfected) were run on a Version 
2.0 miRNA microarray chip (Affymetrix) with 1105 human miRNAs and eight 
samples (from four donors: four infected and four uninfected) were run on a Version 
3.0 miRNA microRNA chip (Affymetrix) with 1693 human miRNAs. 
 
2.4.7! miRCURY™ Universal RT miRNA PCR (Exiqon) 
All methods outlined below were utilised for the study detailed in Chapter Four. All 
materials were supplied by Exiqon, unless otherwise stated.  
 
Protocol was followed according to the instruction manual and all the internal quality 
control criteria were met. In brief, 
2.4.7.1! cDNA Synthesis  
Each sample was prepared as followed: 
Reagent% Volume)%
5x%Reaction%buffer% 4.00%μl%
Nuclease.free%water% 9.00%μl%
Enzyme%mix% 2.00%μl%
Synthetic%RNA%spike.in% 1.00%μl%%
Template%total%RNA% 4.00%μl%%
Total)Volume) 20.00)μl)
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Samples were incubated for 60 minutes at 42°C followed by heat inactivation of the 
reverse transcription for 5 minutes at 4°C. Samples were either used immediately or 
stored at -20°C. 
2.4.7.2! Plasma Focus miRNA PCR Panels 
The plasma focus panels (miRCURY LNA™ Universal RT microRNA PCR 
Serum/Plasma Focus microRNA PCR Panel, 96 well, V1.RO, Exiqon, Denmark) 
were comprised of 2 plates; plate 1 and 2. In total 175 different locked nucleic acids 
(LNA) primer sets for real time amplification of human miRNAs which are known to 
be expressed in humans in both healthy and diseased states were examined. These 
panels were utilised for the Pilot Study in Chapter Four. 
 
For the validation study in Chapter Four, a total of ten miRNAs were chosen for 
further evaluation on custom-made miRNA PCR Panels (Exiqon), with miR-93 
chosen as reference miRNA. 
 
LNA are a class of nucleic acid analogues that contain one or more nucleotide 
building blocks in which a methylene bridge fixes the ribose moiety conformation 
(Vester et al., 2004) (Figure 1.5). The LNA oligonucleotides have extremely high 
hybridisation affinity toward their complementary single-stranded RNA and 
complementary single- or double-stranded DNA (Kauppinen et al., 2006).  
 
Seven microRNA LNA™ primer sets present on both plates were designated 
candidate reference genes based on the literature. Included in this was hsa-miRNA-93 
which we have shown to be a stable reference miRNA in the study population. 
 
  
61 
Each plate also contains an inter-plate calibrator in triplicate and a control primer set 
for detection of the synthetic spike-in (UniSP6).  
 
2.4.7.3! Quality Control Measures 
RNA quality was assessed using miRCURY™ QC PCR panels consisting of 96 well 
plates containing dried down LNA™ primer sets for each 10 µl set of reactions. The 
96 well plate was able to assess 8 samples with the layout of the plate as shown 
below. 
 
 
RNA quality was assessed on each plasma sample using miRCURY™ microRNA QC 
PCR Panel (Exiqon). The protocol was followed according to the manufactures’ 
instructions. Briefly, 4 µl of cDNA from RT reaction was mixed with 198 µl of 
nuclease free water (reach a 50x dilution). 60 µl of SYBR Green® Master mix was 
combined with 60 µl of the diluted cDNA and gently mixed. The PCR panel plates 
were spun gently prior to the removal of the plate seal. 10 µl Mastermix:cDNA mix 
was added to each well. The plate was sealed with optical seal as recommended by 
the instrument manufacturer.  
 
Sample quality was tested against the following; 
miR-103 miR-451 miR-191 miR-23a Uni-Sp5 Uni-Sp4 Uni-Sp2 Uni-Sp6 miR-30c 
Cel-miR- 
39-3p Uni-Sp3 miR-124 
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1.! RNA Purification – UniSp2,4 and 5 show consistent values across data set 
(<2-3Cq) and ΔCq= 5-7 between spike-ins. The presence of UniSP5 signal 
indicates efficient purification of low expressed miRNA. 
2.! cDNA Synthesis- UniSP6 and/or cel-39-3p show consistent values across the 
sample set with low variance (<1-2 Cq). 
3.! qPCR evaluation- UniSp3 shows consistent values across data-set (<2 Cp 
across the data-set). 
4.! Evaluation of haemolysis – if ΔCq (miR-23a – miR-451) is lower than 7, it is 
unlikely that the sample is haemolysed 
 
2.4.7.4! Quantitative real-time PCR 
All qRT-PCR experiments were carried out on a LightCycler®480 (Roche, Life 
Sciences, NSW, Australia). The PCR reactions were initiated with 10 min incubation 
at 95°C followed by 45 cycles of 95°C for 10 sec and 60°C for 1 minute. Melting 
curve analysis was performed at the end of amplification to verify the amplification. 
 
2.5! Cytokines assays 
2.5.1! Cytometric bead array 
Cytokines, interleukin (IL)-1β, IL-6, IL-8, macrophage inflammatory protein (MIP)-
1α, tumour necrosis factor (TNF), and interferon (IFN)-gamma inducible protein (IP)-
10, were quantified simultaneously using a human chemokine cytometric bead array 
(CBA) kit (BD Biosciences). These assay kits provided a mixture of six micro-bead 
populations with distinct fluorescent intensities (FI)-3 and were pre-coated with 
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capture antibodies specific for each cytokine. 1 µl of supernatant collected from M. 
tubculosis infected and uninfected macrophages at 24 hours post infection, or the 
provided standard cytokines, were added to the pre-mixed microbeads in Falcon tubes 
(BD Biosciences). After the addition of 10 µl of a mixture of conjugated antibodies 
against the chemokines, the mixture was incubated for 2 hours, in the dark at RT. The 
mixture was washed and centrifuged at 800 g for 5 minutes, and the pellet was re-
suspended in 300 µl of wash buffer. The LSR II flow cytometer (BD Biosciences) 
was calibrated with set-up beads and 3000 events were acquired for each sample. 
Individual cytokine concentrations were indicated by their Fl-2 and were computed 
using the standard reference curve of CELLQUEST and CBA software (BD 
Biosciences). 
 
To address intra-assay performance of the CBA chemokine assay, 10 replicates 
samples of three different levels of the chemokine standards were tested in a single 
assay. Inter-assay reproducibility was assessed using two replicate samples of three 
different levels of the human standards. Normal ranges for cytokine levels were 
established using supernatants from uninfected macrophages. Each biological sample 
had three replicates. 
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3! IDENTIFICATION OF A SUITABLE REFERENCE 
MIRNA 
3.1! Introduction 
Tuberculosis (TB) is an infectious disease caused by the bacillus, M. tuberculosis that 
normally affects the lungs. It is estimated that one third of the worlds population is 
infected with M. tuberculosis. Of those infected however, only about 10% will ever 
develop active disease (Lawn et al., 2011) whereas the rest remain in a latent state. It 
is estimated that TB results in the death of about 1.5 million individuals annually 
(World Health Organization, 2013).  
 
Initial diagnosis of TB is made most commonly by sputum smear microscopy. 
Mycobacterial culture remains the gold standard for TB confirmation and resistance 
testing, with rapid molecular tests such as genXpert® (Xpert), also employed where 
available (Boehme et al., 2010). However, lengthy delays in diagnosis are an on-
going problem in TB management. Therapy for TB disease requires a minimum of six 
months on multiple antibiotics. Monitoring a patient’s response to infection to 
identify non-responders, which may be indicative of poor compliance or drug 
resistance, is another important requirement for managing TB. Currently, conversion 
to sputum negative culture at two months is the gold standard marker of successful 
treatment, but this means it is often three months or more into therapy before non-
responders are identified, during which time they remain infectious. New biomarkers 
that aid diagnosis and identify treatment non-responders early, quickly and cheaply 
would greatly assist in reducing the burden of TB infection (Lawn et al., 2011). 
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MicroRNAs (miRNAs) are single-stranded RNA molecules of 21-23 nucleotides in 
length that play an important role in post-translational regulation of gene expression 
through targeting messenger RNA (mRNA) (Mause et al., 2010). They circulate in a 
stable, cell-free form and are increased in levels in many disease processes such as 
malignancy, schizophrenia, heart failure and sepsis (He et al., 2004; Oak et al., 2011; 
Mastronardi et al., 2012). Their use as a biomarker to aid diagnosis and predict 
response to therapy is of growing interest. They may also represent a novel 
therapeutic target to modify the host response (Osaki et al., 2008; Cho, 2011; Ochs et 
al., 2014). 
 
Normalisation of miRNA levels is critically important to enable correction of inter-
sample variation and differing reaction efficiencies. Commonly RNU6B (U6) has 
been used in many cell and tissue studies, but other studies have shown that U6 is not 
stably expressed in sera (Benz et al., 2013). To date there are no published studies that 
systematically evaluate reference miRNAs for normalizing plasma-derived miRNAs 
in the setting of TB (Ng et al., 2009; F. Ji et al., 2011) or in different ethnic and 
geographical groups to determine if these factors influence miRNA expression 
 
3.1.1! Strategies to normalise miRNA data 
There are three recognised strategies to normalise data. The study performed here 
utilised two of these: GeNorm (Vandesompele et al., 2002) and Normfinder 
(Andersen et al., 2004). The other recognised method is Bestkeeper (Pfaffl et al., 
2004). 
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GeNorm measures the geometric, as opposed to the arithmetic, mean of carefully 
selected miRNAs. It utilises a pairwise comparison to rank candidate miRNAs by 
summed individual variation and in a step-wise fashion discards the most variant gene 
before repeating the analysis. Every potential reference miRNA is assessed and given 
an M score. miRNAs with the lowest M scores are the most stably expressed and are 
deemed the suitable reference miRNA (Vandesompele et al., 2002). GeNorm works 
on the principle that the expression ratios of reference miRNAs are consistent in all 
samples regardless of the experimental condition or cell type. It is therefore 
recommended to perform an independent study of variance; in this case we performed 
a Levene’s test, an inferential statistic that is used to assess variability between two 
different sub-samples, with a p-value less than 0.05 considered to demonstrate 
significant variation between samples.  
 
Normfinder utilises a mathematical model to directly measure the expression 
variation of miRNAs between samples and conditions of interest. The application of 
the model is able to estimate the intra- and the inter-group expression variation and 
calculate a “stability value” for each candidate miRNA assessed. This model also 
relies on the careful selection of candidate miRNAs and also assumes minimal 
variation between miRNA levels within the groups studied (Andersen et al., 2004). 
 
Bestkeeper is another commonly used method for selecting a suitable reference 
miRNA. It is available as a prepared Excel spreadsheet file obtained at 
(http://www.gene-quantification.de/bestkeeper.html). It calculates the geometric 
average for the entire dataset and uses that as a global normalisation factor, or 
“bestkeeper” (Pfaffl et al., 2004). Bestkeeper assumes that as the number of miRNAs 
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measured increases variations resulting from genuine biological changes in miRNA 
expression make a progressively lower overall trend, than global variations in cDNA 
concentrations that arise from sample preparation and handling. Thereby, making 
pairwise comparisons between the expression data from miRNAs of individuals and 
the global normalisation factor, one can identify those miRNAs with the least 
variation. 
 
Both geNorm and Bestkeeper results are highly sensitive to the dataset presented; 
meaning that removal of a single high-scoring candidate reference miRNA will lower 
the correlation of similar high-scoring candidates. This will result in lower ranked 
candidates being given a higher relative pairwise correlation, and thus re-shuffling the 
order of rankings. The benefit of this is that these methods are more tolerant of 
imperfect datasets stemming from variable mRNA quality or cDNA synthesis 
(Hildyard et al., 2014). 
 
Normfinder, on the other hand, avoids direct miRNA-miRNA comparison, and 
instead focusses more on each miRNA individually, rather than giving group-wide 
averages. This technique, however, makes the assumption that the dataset averages do 
not exhibit significant intergroup variation (Hildyard et al., 2014). 
 
By using the two varied techniques in this study, we aimed to minimise the limitations 
of either method whilst benefiting from each of their strengths. Furthermore, we 
chose 12 miRNAs to study as potential candidate reference miRNAs, as generally 
these techniques benefit from larger datasets. This then adds greater confidence when 
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a particular miRNA is suggested as a suitable reference miRNA, particularly if the 
same miRNA is selected by each method. 
 
3.1.2! Other factors which may influence miRNA expression 
Recent studies have supported the notion that miRNA expression is tissue and disease 
specific, and that normalisation strategies, which are highly important to control for 
external-related variation, need to be considered for each group and disease being 
studied (Peltier et al., 2008; H. T. Zhu et al., 2012; Song et al., 2012; Chen et al., 
2013; Zheng et al., 2013; Tang et al., 2015). What is not clear is whether other 
factors, such as ethnicity and/or geographical location, also have an effect on miRNA 
expression. There have been limited studies in the literature that have reported 
significant variation in miRNA expression that seemed to be related to either 
geographical area or ethnicity (X. Chang et al., 2014; Rawlings-Goss et al., 2014; 
Wang et al., 2014). Given the unique opportunity of being able to study miRNA 
profiles in subjects from two very different geographical locations, these being 
Australia and north-west China, we also sought to examine the miRNA expression 
between these two different geographical cohorts. 
 
3.1.3! Aims 
The aims of this study were to: 
1.! Identify suitable and stable reference miRNAs for the normalisation of 
miRNA levels in patients with active TB, in comparison with individuals with 
latent tuberculosis infection (LTBI) and healthy controls. 
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2.! To examine if geographical or ethnic differences influence miRNA levels in 
TB patients in Australia and the Ningxia Hui Autonomous Region (NHAR) of 
north-west China (J. J. Liu et al., 2005).  
 
3.2! Methods   
3.2.1! Ethics statement 
This study was undertaken with the approval of the Ethics Review Committees at St 
Vincent’s Hospital, Sydney (Protocol No X11-0141 and HREC/11/RPAH/201), The 
University of Sydney (Protocol No 2012/1076) and The Ningxia Medical University, 
China (approval date 6/6/2013). All participants provided written informed consent. A 
copy of the patient information sheet, patient questionnaire and consent form, and 
ethics approval documentation are included in Appendix B. 
 
3.2.2! Australian cohort 
We invited suitable consecutive consenting patients presenting to the TB clinic at St 
Vincent’s Hospital to participate in the study (Table 3.1). Enrolment for the study 
ceased once the required enrolment quota was reached. Blood was collected from 12 
patients with culture-proven pulmonary tuberculosis, 12 with LTBI (based on a 
Tuberculin skin test induration of greater than or equal to 15 mm, a lack of symptoms 
and a normal chest radiograph), and 12 healthy controls with no exposure to TB. 10 
mL of peripheral blood was collected into EDTA tubes and processed within three 
hours.  
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3.2.3! The Peoples Republic of China (PRC) cohort  
Blood was collected from 12 patients with either culture-proven TB or TB diagnosed 
on clinical and radiological grounds, and 12 matched healthy controls. 10 mL of 
peripheral blood was collected into ETDA tubes and processed within three hours. All 
patients recruited from China were born in PRC and classified themselves of Hui 
ethnicity (Table 3.1).  
 
3.2.4! Isolation of plasma from human samples 
Ten millilitres of blood was collected from each donor and plasma separated as 
explained in Section 2.2.2 of the Materials and Methods. 
 
3.2.5! RNA extraction and quality control 
Total RNA, including small RNAs, was extracted using TRIzol LS® (Life 
Technologies) as described in Section 2.3.2 (Materials and Methods). RNA 
concentration and integrity (RIN) was measured using a nano-spectrophotometer 
(Thermoscientific, Wilmington, DE, USA). 
 
3.2.6! qRT-PCR 
Reverse transcription was carried out using All-in-OneTM miRNA First-Strand cDNA 
Synthesis kit (GeneCopoeia) as described in Section 2.4.5 (Materials and Methods). 
The following miRNAs were measured: miR-192, -22, -221, -26, -451, -16, -103, -
191, -423, -425, let-7, and U6. 
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3.2.7! Data analysis 
Data was analysed using SDS Relative Quantification Software Version 2.3 (Life 
Technologies). Endogenous controls must be consistently expressed, therefore only 
the miRNAs detected in all 60 samples were selected for further analysis using 
Normfinder and geNorm software packages (GenEx Version 5, Multi D, Göteborg, 
Sweden). Normfinder and geNorm reference gene validation software was used to 
identify the most stably expressed miRNAs.  
 
3.2.8! Statistical analysis 
The difference in miRNA expression was analysed by Mann Whitney U test for 
comparison of two groups, and Wilcoxon rank-sum test for multi-group comparisons; 
p-values below 0.05 were considered significant. 
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Table 3-1. Baseline characteristic of subjects by country of birth and disease state. 
Cohort! Australian! Australian! Australian! PRC! PRC!
Clinical0Pathological0
Variable!
TB!n=12! LTBI!n=12! Healthy!Control!n=12! TB!n=12! Healthy!Control!n=12!
Median0age,0years0
(Range)!
36!(20860)! 34!(18859)! 44!(27876)!
!
45!(16876)! 39!(16868)!
Male0(%)! 4!(33.3)! 6!(50)! 6!(50)! 11!(92%)! 7!(58)!
Place0of0Birth*! South!Asia!(n=2)!
East!Asia!(n=6)!
South!Eastern!Asia!(n=3)!!
Oceania!(n=1)!
South!East!Asia!(n=3)!!!!!!!
Southern!Africa!(n=1)!
East!Africa!(n=1)!
Eastern!Europe!(n=1)!
Oceania!(n=6)!
Oceania!(n=10)!!
East!Asia!(n=1)!!
Western!Europe!(n=1)!
PRC**! PRC**!
* Regions as classified by WHO, **All PRC subjects of Hui ethnicity.  
TB, tuberculosis; LTBI, latent tuberculosis infection. 
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3.3! Results 
The clinical characteristics of study participants are listed in Table 3.1. The Australian 
cohort patients with TB were mainly born in Asia (91%), with one third being male. 
Those with LTBI were born in a variety of regions, with 50% from the Oceania 
region. In the Australian healthy control group the vast majority were born in 
Australia (83%). All subjects in the PRC cohort were born in PRC and identified 
themselves as Hui in ethnicity; and were typically male (92%), with an average age of 
42 years. The extent of the TB disease as classified radiologically was generally less 
advanced in the Australian group compared with the PRC cohort, suggestive of later 
presentation and/or diagnosis and possible concurrent chronic lung disease in the PRC 
cohort. 
 
The quantitation cycle (Cq) values for the 13 candidate miRNAs were measured for 
all 60 individuals, with Cq thresholds ranging from 13 to 39 (Table 3.2). U6 was 
poorly expressed with Cq values  above the threshold of detection and was therefore 
excluded from further analysis. The expression levels of some miRNAs varied 
markedly between the two populations, independent of disease status (Figure 3.1 and 
Table 3.2). Two miRNAs (miR-192 and let-7) were highly variable between the 
cohorts with differences of seven to nine cycles (128-512 fold) of average values 
between the cohorts, while the level of expression of four other miRNAs (miR-26, -
16, -423, -425) were within one cycle between the PRC and Australian cohorts 
(Figure 3.1 and Table 3.2). By stratifying groups based on location we found 
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statistically significant differences in many of miRNAs examined according to cohort 
and not disease state. 
 
Table 3-2. Expression levels of candidate reference miRNAs in the Australian 
and PRC cohort, independent of disease status.  
miRNA! Cq(Mean((Range)!
Australian(cohort(
n=24!
Cq(Mean((Range)((
PRC(cohort(n=36!
Cq(mean(Variability(
between(Cohorts!
miR%192! 22.14!(15.87%33.31)! 31.46!(29.33%34.84)! 9.31!
miR%22! 29.59!(23.81%35.59)! 32.62!(28.23%36.08)! 3.03!
miR%221! 26.79!(23.41%32.95)! 31.42!(25.77%38.31)! 4.64!
miR%26! 25.90!(18.18%32.68)! 28.41!(22.42%36.34)! 2.50!
miR%451! 21.56!(13.66%33.21)! 22.37!(15.73%34.82)! 0.81!
miR%93! 25.64!(20.82%29.13)! 27.93!(25.53%30.35)! 2.29!
let$7$ 25.38!(17.77%34.41)! 32.45!(29.32%34.79)! 7.06!
miR%16! 22.69!(14.07%34.70)! 23.13!(15.67%33.86)! 0.45!
miR%103! 30.20!(21.40%37.81! 28.58!(25.70%31.07)! %1.62!
miR%191! 33.36!(28.96%39.57)! 30.20!(27.66%32.35)! %3.16!
miR%423! 31.53!(25.25%38.50)! 30.72!(27.58%34.43)! %0.81!
miR%425! 29.76!(24.26%34.71)! 29.92!(27.41%32.19)! 0.15!
Values are given as mean and range in brackets of the quantification cycle (Cq) values of candidate 
reference genes by cohort. 
miR, microRNA. 
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Figure 3-1. Expression levels of candidate reference miRNAs by cohort. 
Expression levels of the 12 candidate reference miRNAs in the combined Australian 
cohort (n= 36) and the PRC cohort (n=24) were determined by qPCR. Values are 
given as the quantification cycle (Cq mean of duplicate sample). Significant 
differences were calculated by Wilcoxon rank-sum test. *<0.05, ** <0.01, *** 
<0.001, ns= not significant. AUST, Australian cohort; CHINA, People Republic of 
China cohort.  
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3.3.1! Determination of reference miRNA expression stability using geNorm 
and Normfinder. 
GeNorm (Vandesompele et al., 2002) and Normfinder (Andersen et al., 2004) 
software were used to examine the stability of candidate reference miRNAs from the 
plasma of all groups from both cohorts. Both geNorm and Normfinder assume equal 
variance of the candidate miRNAs between the populations. Therefore Levene’s test 
of variance was carried out on all miRNAs from the respective cohorts to determine if 
there was significant variance between the groups (Larson, 2008). miRNAs with p-
values below 0.05 were considered significantly different, and were excluded from 
further analysis. In the PRC cohort four miRNAs were excluded (miR-16, -26, -221 
and -451), while none were excluded from the Australian cohort, and overall when all 
samples were examined collectively four miRNAs were excluded from subsequent 
analysis (miR-26, -192, -221 and -451). 
 
For Normfinder the maximum expression of each candidate reference miRNA (as 
given by lowest Cq value) was used as a control and set to one. Relative expression 
levels were then calculated from Cq values using the formula: 2(-∆∆C(T)), in which 
ΔCq is equal to the corresponding Cq value minus the minimum Cq value. For 
geNorm analysis, data files containing the mean Cq values as determined by SDS 
Relative Quantification Software were imported directly into GenEx software for 
analysis. GeNorm generates an M value based on the average standard deviation of 
the ratio of the pairwise normalisation miRNAs accompanied by stepwise exclusion 
of the least stable miRNA. The lower the M value, the more stable the miRNA. 
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3.3.1.1! miR-93 and miR-425 are the most stable reference miRNA in the PRC 
cohort. 
Analysis of the PRC cohort using both Normfinder and geNorm identified the 
expression of miR-93 and miR-425 to be the most stably expressed miRNAs (Figure 
3.2).  
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Figure 3-2. Stability values of candidate reference genes for the PRC cohort as determined by Normfinder and geNorm.  
Expression levels of 12 miRNAs in the plasma of newly diagnosed TB patients (n=12) and healthy controls (n =12) were subject to Levene’s test 
to determine if there was significant variance between groups. miRs -16, -26, -221 and -451 displayed significant variance between groups and 
were removed from subsequent analysis. The remaining eight miRNAs were ranked using Normfinder and geNorm. Greater expression stability 
is indicated by a lower stability value (M). Low standard deviation (SD) values indicate stable gene expression (Normfinder).
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3.3.1.2! miRs-93, -221, -22 and let-7 are the most stable reference miRNAs in the 
Australian cohort. 
geNorm and Normfinder analysis of the Australian cohort identified a panel of four 
miRNAs, including miR-93, as suitable reference miRNAs in this sample set. The 
rankings of the candidates as determined by geNorm and Normfinder are shown in 
Figure 3.3. The top five miRNAs were the same using both analysis tools, with 
similar M values, suggesting that either in combination or alone they are suitable 
normalisers for this cohort. miR-93 was found to be the most stable when utilising 
geNorm software, and even though it is ranked number four according to Normfinder, 
the stability values differed little between the top four candidates (Figure 3.3).  
 
3.3.1.3! miR-93 and miR-22 are the most stable reference miRNAs in a combined 
cohort analysis.  
When examining all patient groups from both cohorts geNorm and Normfinder 
identified miR-93 and miR-22 to be the most stable (Figure 3.4), although the stability 
values in the combined groups were higher than when each cohort was analysed 
separately. To explore this in more detail we examined miRNA variation across the 
cohorts. 
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Figure 3-3. Stability values of candidate reference genes for Australian cohort as determined by Normfinder and geNorm.  
Expression levels of 12 miRNAs in the plasma of newly diagnosed TB patients (n=12) and healthy and latent controls (n =24) were subject to 
Levene’s test which determined there was no significant variance between any of the groups. The 12 miRNAs were then ranked by Normfinder 
and geNorm. Greater expression stability is indicated by a lower stability value (M) (geNorm). Low standard deviation (SD) values indicate 
stable gene expression (Normfinder). 
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miRNA Normfinder geNorm 
Stability  
Value 
Ranking 
 Order 
Stability  
Value 
Ranking  
Order 
miR-93 1.10 1 1.65 1 
miR-22 1.76 2 1.65 1 
miR-425 2.05 3 2.43 3 
miR-423 2.37 4 2.86 4 
miR-103 2.44 5 3.24 5 
miR-191 2.93 6 3.51 6 
miR-16 3.50 7 3.88 7 
let-7 3.55 8 4.27 8 
 
 
      Figure 3-4. Stability values of candidate reference genes for all subjects as determined by Normfinder and geNorm.  
 Expression levels of 12 miRNAs in the plasma of newly diagnosed TB patients in both the Australian and PRC cohort (n=12/group) and healthy 
and latent controls (n =12/group) were subject to a Levene’s test to determine there was significant variance between groups. miRs -221, -26, -192 
and -451 displayed significant variance between groups and were removed from subsequent analysis. The remaining eight miRNAs were ranked 
using Normfinder and geNorm. Greater expression stability is indicated by a lower stability value (M). Low standard deviation (SD) values indicate 
stable gene expression (Normfinder) 
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3.3.1.4! Variation in miRNA expression may be cohort rather than disease driven. 
The Cq values for the 12 miRNAs examined in the five groups were plotted by 
disease state and geographical location (Figure 3.5). This data suggests that there is 
variation in miRNA expression that is independent of disease state, but relates to 
geographical, or potentially ethnic differences between the cohorts. Further studies in 
larger cohorts will be required to confirm this. Despite these differences in miRNA 
expression between the populations, both geNorm and Normfinder analysis 
identified miR-93 as an appropriate reference miRNA to normalise miRNA levels in 
plasma samples from both cohorts independent of disease status.  
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Figure 3-5. Expression levels of candidate reference miRNAs in healthy 
controls, latent M. tuberculosis infection, and active M. tuberculosis disease. 
Expression levels of the 12 candidate reference miRNAs in the plasma of TB 
patients, healthy controls and latently infected individuals from Australia and in TB 
patients and healthy controls from the PRC (n=12/group). Values are given as the 
cycle threshold (Cq mean of duplicate sample). 
  
  
85 
 
3.4! Discussion  
A growing body of evidence has highlighted the critical regulatory roles that miRNA 
play to tightly regulate biological processes. miRNAs are commonly found in the 
blood, often associated with cellular vesicles, such as microparticles or exosomes 
(Diehl et al., 2012; Boon et al., 2013). miRNA are stable, and numerous studies have 
investigated the potential of plasma miRNAs to serve as biomarkers for multiple 
conditions, such as cancer, stroke, and infection (Suryawanshi et al., 2013; Marcucci 
et al., 2013; Sanchez-Espiridion et al., 2013; Sozzi et al., 2014). Normalisation of 
miRNA levels in samples is an essential step in biomarker analysis. This study 
examined the suitability of 12 miRNAs to normalise miRNA levels in plasma from 
TB patients and controls in two geographical and ethnically diverse populations. We 
found significant variability in miRNA levels across these populations, independent 
of disease status. Despite these differences we have identified miR-93 to be a stable, 
plasma-based miRNA, suitable to normalise miRNA levels across diverse ethnic and 
geographical populations. 
 
Many of the current miRNA normalisation strategies have been adopted from tissue 
studies where U6 is often used as a reference to normalise miRNA data (Liang et al., 
2007). Recent studies, however, have found that U6 is not stably expressed in plasma 
(Chen et al., 2008; Appaiah et al., 2011). Our study confirmed these recent findings 
as U6 was not stably expressed in the plasma of our subjects, indeed in over 75% of 
our samples U6 was not detected within the 40 cycles of the qPCR assay (data not 
shown). For this reason U6 was excluded from further analysis as it is not suitable as 
a reference miRNA for plasma samples. Other studies have added non-human 
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miRNA from C. elegans to samples to control for technical variations, however it 
does not control for variation in the efficiency of the reverse transcription (Akbas et 
al., 2012).  
 
This study examined the expression of miRNAs previously reported as suitable to 
normalise miRNA levels in a variety of biological tissues (Davoren et al., 2008; 
Peltier et al., 2008; K. H. Chang et al., 2010; H. T. Zhu et al., 2012; Song et al., 
2012; Chen et al., 2013; Zheng et al., 2013; Z. Liu et al., 2014). The selection of 
miRNAs used to normalise is influenced not only by the tissue being examined, but 
also the disease condition being evaluated. miR-16 and -451 are commonly used to 
normalise miRNA levels in plasma samples (Song et al., 2012); however more recent 
studies have reported up-regulation of plasma miR-16 and -451 as part of the miRNA 
signature in multiple conditions, including autoimmune thyroid disease (Yamada et 
al., 2014), experimental sepsis (Wu et al., 2013), and gastric cancer (C. Zhu et al., 
2014). Another study demonstrated that miR-16 and -451 are highly expressed in red 
blood cells so that any haemolysis of blood samples strongly affects their level in 
plasma (Kirschner et al., 2011). We found variable expression of miR-16 and -451 
between individuals, such that these miRNAs did not meet the criteria for inclusion 
as a stable reference for changes in TB disease in either population.  
 
It is clear from the literature that utilising different reference miRNAs can greatly 
affect the profiles of target miRNAs. Recently Tang and colleagues compared the 
expression of five miRNAs: miR- 16, -219, -221, -55 and let-7, in plasma from a 
group of patients with gastrointestinal diseases (hepatocellular carcinoma, gastric 
malignancy, hepatic cirrhosis and hepatitis B) to that of healthy subjects, utilising 
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either U6, miR-106a, -21 or the geometric mean of miR-106a and -21 as reference 
miRNAs (Tang et al., 2015). Not unexpectedly they found quite significant 
variations in the target miRNAs expression depending on which reference miRNA 
was used. U6 is often used to normalise miRNA data, however this study showed 
that when normalising with U6, the results failed to detect a statistical difference in 
the expression profile of miRNAs shown to regulated in gastric malignancy. The 
results from this study highlight the bias introduced, and erroneous results generated, 
when utilising non-validated reference miRNAs. 
 
A secondary aim of our study was to determine if there was any miRNA variation 
that was cohort specific rather than disease based. Even though the sample size was 
small this study identified significant variability in miRNA expression in different 
cohorts. This has important implications for not only identifying suitable reference 
miRNAs, an essential component in accurately analysing qRT-PCR data, but also 
when considering utilising miRNA expression as a potential biomarker. Whilst the 
reason for this variation has not as yet been determined recent reports have shown 
the miRNA expression can be influenced by ethnic diversity (Wang et al., 2014). 
One possible explanation may relate to inherent genetic variation in miRNA 
expression. Rawlings-Goss and colleagues utilised whole genome sequencing to 
examine genetic variation in 1,524 miRNAs in a group of 69 unrelated otherwise 
healthy individuals from 14 global populations, and identified 31 miRNA variants 
that were population-differentiated in terms of frequency between African and non-
African populations (Rawlings-Goss et al., 2014). These variations were not thought 
to be somatic, as un-described mutations identified in a single individual were 
removed from the analysis.  
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As has been demonstrated, there is an important need to accurately correct for non-
biological variation with stable reference genes that are suitable for the population 
being studied, otherwise important regulated miRNAs that may have a role as 
biomarkers of disease, may be missed. These data demonstrate the importance of 
determining the suitability of a reference miRNA directly in the study population to 
account for variations in miRNA expression attributable to ethnic and environmental 
factors. 
 
In general this study found that individuals from the PRC grouped together more 
closely than the Australian cohort, whose ethnic background was far more 
heterogeneous and included individuals born in nine different countries. In the PRC 
population, in part due to the tight clustering of the samples, Levene’s test of 
variance identified four miRNAs that were differentially regulated and were 
therefore excluded from further analysis in that cohort. When the Australian cohort 
was analysed alone no miRNAs were excluded after Levene’s test, but the stability 
values demonstrate that, when compared to the PRC cohort, there was a greater 
degree of variability in this sample set. geNorm analysis, which indicates the optimal 
number of miRNAs that should be used to normalise the samples, found that the best 
stability values were achieved with analysing four miRNAs for the Australian cohort, 
but only two miRNAs was required to achieve a similar stability value in the PRC 
cohort. When the two cohorts were combined a number of miRNAs were again 
removed after application of the Levene’s test.  
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The baseline expression of some miRNAs, most notably miR-192 and let -7, differed 
by 128-512 fold between the Australian and PRC cohort. Most of this variation was 
cohort and not disease driven, suggesting that ethnic and/or environmental factors 
contribute to baseline miRNA levels in the blood. The increased variability seen in 
the Australian cohort may also reflect the increased ethnic variation in the subjects or 
other undefined environmental factors. However the individuals participating in this 
study were not screened or asked about other potentially confounding factors. 
Comorbidities, such as diabetes or concurrent infections, are likely to also influence 
miRNA expression, and further research is required to evaluate the impact of 
comorbidity factors on an individual’s miRNA disease signature. 
 
miR-93 has been identified as a suitable reference miRNA to normalise miRNA 
levels in studies of disparate diseases from gastric cancer to major depression 
disorders (Song et al., 2012; Z. Liu et al., 2014). Other studies in ovarian and breast 
cancer have found that miR-93 is differentially regulated in cancer tissue and levels 
may be predictive of disease state (Eichelser et al., 2013; T. Ji et al., 2014), further 
highlighting the need to confirm the suitability of selected miRNAs to normalise 
miRNA levels depending upon the tissue under investigation, the disease state and 
potentially the ethnicity of the subject population. In summary, miR-93 is a suitable 
reference miRNA for analysing miRNA levels in TB patients, however ethnic and 
environmental factors influence miRNA expression in addition to the effect of 
specific diseases and the suitability of a reference miRNA should be assessed 
directly in each study population.   
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4! PLASMA MICRORNAS AS BIOMARKER FOR 
TUBERCULOSIS 
4.1! Introduction 
Tuberculosis remains a major global health problem and is second only to HIV as the 
leading cause of death from a single infectious disease (World Health Organization, 
2014). The host’s control of the disease is dependent on both the innate and adaptive 
immune system (Kleinnijenhuis et al., 2011) (Ottenhoff et al., 2005). The immune 
response determines whether the infection is eliminated, arrested in the latent state, 
or progresses to active disease either as pulmonary or extra-pulmonary infection 
(Lawn et al., 2011). Approximately 90% of those infected will remain in the latent 
state, with the remaining 10% developing active disease, either at the time of 
infection or later in their life. It is assumed, therefore, that genetic factors, in addition 
to environmental factors such as malnutrition and HIV co-infection, play an 
important role in regulating the progression of disease (Frahm et al., 2011; Azad et 
al., 2012). 
 
Improving the diagnosis of LTBI, recognising those most likely to progress to active 
disease, promptly diagnosing pulmonary and extrapulmonary disease, identifying 
those who are most likely to relapse, and identifying drug resistance, are 
fundamentally important and critically required in order to curtail the rate of disease 
and its associated morbidity and mortality. In order to achieve this, a detailed 
molecular and immunological understanding of the pathogen and the host’s response 
to the Mycobacterium is essential. 
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The potential impact of developing a reliable biomarker is substantial. There are the 
obvious clinical benefits, such as an improved prediction of those that will require 
chemopreventative therapy and earlier recognition of treatment failure and drug 
resistance. These tests, however, may also be helpful to be use as surrogate endpoints 
in late phase drug and vaccine studies, as this would greatly reduce the prolonged 
follow-up period currently required (Nahid et al., 2011; Kim et al., 2012). 
 
Current standard treatment for TB consists of six months of multi-drug 
chemotherapy. Although this is generally well tolerated, this prolonged treatment 
regime does have myriad potential serious side-effects, including hepatitis, optic 
neuritis, and drug interactions. Ensuring compliance for such a long period of time 
can also be problematic. Failure to complete an adequate course of therapy can lead 
to treatment failure, drug resistance and on-going transmission of the disease. 
Although durable rates of cure with three to four months of treatment are inferior to 
the standard six months of therapy, the identification of suitable biomarkers may be 
able to identify early responders for whom shorter courses would be suitable. 
 
Diagnosing and managing children and adolescents with TB has also proven to be 
very challenging. Often children cannot produce sputum, making diagnosis and 
monitoring of the response to treatment difficult. They also often do not have what 
would be considered the “typical” radiographic features of TB. These problems have 
been amplified by the HIV epidemic, that has increased the number of children with 
TB and made the clinical and radiological means of diagnosing the disease even 
more difficult (Ansari et al., 2003; Coulter, 2008). Biomarker work in adult 
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populations with TB may be transferable to the paediatric group. However, specific 
studies in this population will need to be undertaken. 
 
4.1.1! miRNA as a potential biomarker 
The ideal biomarker must meet certain criteria in order for it to be considered 
worthwhile. A good biomarker needs to be highly sensitive and specific and it must 
be practicable, meaning that the sample must be easily obtained by the least invasive 
measure. It also needs to be a reliable indicator of disease before clinical symptoms 
appear (early detection), sensitive to changes in pathology (disease progression or 
therapeutic response) and readily translatable from model systems to humans. A 
biomarker needs to be predictable with a relatively long half-life in blood that 
ensures its detection in plasma. Finally, it must be robust, meaning that detection 
methods need to be quick, reliable, sensitive, accurate, preferably inexpensive and 
able to be performed at point-of-care. 
 
Human miRNAs isolated from plasma are highly stable and remain so when 
subjected to prolonged periods at room temperature or freeze-thawing a number of 
times. It is thought that they exist in a form that is resistant to plasma RNase activity 
(Turchinovich et al., 2011). Blood is easily accessible. MiRNA are remarkable stable 
in blood and expression patterns seem to be tissue specific. Recently, circulating 
miRNAs have been studied as surrogate markers of diseases such as cardiovascular 
disease, a prognosticator for malignancy and infectious diseases (Chen et al., 2008; 
Li et al., 2010; Feng et al., 2011). 
 
This project will examine the expression of specific miRNA in the plasma derived 
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from patients with pulmonary TB and healthy controls to determine if miRNA 
expression can be used as a biomarker of TB disease and as an early marker of 
response to treatment. 
 
GENERAL HYPOTHESES 
1.! miRNA expression profiles measured in the blood are differentially 
expressed in patients with TB compared with healthy controls. 
2.! Blood miRNA levels normalise with effective treatment for TB. 
3.! Failure of miRNAs to normalise with treatment is a marker of treatment 
failure. 
 
OVERARCHING AIM 
To develop an effective biomarker that will: 
   a. aid in the diagnosis of TB. 
   b. be used as a marker to monitor treatment progress and detect treatment failure. 
 
SPECIFIC AIMS 
1.! Measure miRNA expression in 100 patients with active TB disease and 100 
healthy controls over the course of treatment to determine if miRNA 
expression differs between the two populations. 
2.! To determine if miRNAs normalise with effective treatment. 
3.! To determine if failure of normalisation of regulated miRNAs is predictive of 
treatment failure. 
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4.2! Methods 
4.2.1! Recruitment of study subjects 
The subjects recruited for the studies described below can be divided into two groups 
– those with recently diagnosed TB, who were treatment naïve, and healthy controls. 
All individuals were unrelated. 
4.2.2! Study area 
The Peoples Republic of China (PRC) is an upper middle-income country located in 
East Asia. It is the world’s most populous country with a population of 1.35 billion 
with approximately 50% residing in rural areas (Bureau, 2015). It is a single party 
state that is governed by the communist party. The country’s largest cities are 
Shanghai in the east (23.7 million people) and its northern capital, Bejiing (21.1 
million people). Data from the World Bank estimates that nearly 99 million people in 
PRC still live below the poverty line (Chaudhuri, 2009). 
 
PRC is still profoundly affected by TB and has the second largest number of TB 
cases, only behind India (World Health Organization, 2014). It is estimated that one 
million new cases of TB develop every year, accounting for 11% of global TB 
incidence (World Health Organization, 2014). Further, 80% of TB cases are in rural 
areas, especially in the poorest provinces in the north and north-western areas, 
including Ningxia Hui Autonomous region (NHAR) (Liu et al., 2005).  
 
During the 1990s, the country began to address the TB problem by implementing a 
national TB control programme, containing key elements of the internationally 
recommended directly observed treatment, short-course (DOTS) strategy. Since the 
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implementation of the DOTS programme there has been a reported 30% reduction in 
TB prevalence in areas that implemented the strategy in the ten years between 1990 
and 2000 (Wang et al., 2014). The estimated overall prevalence in 2010 was 108 
cases per 100 000 and this compares favourably to the 1990 estimate of 210 per 100 
000 (World Health Organization, 2014). 
 
Our study was undertaken in Ningxia Hui Autonomous region (NHAR) in north-
western China. It is one of five provincial level autonomous regions in PRC. It has 
an area of 66 400 square km and a population of 6.3 million. NHAR is bounded to 
the east by the Shaanxi province; to the south, west and east by the Gansu province; 
and to the north by Inner Mongolia Autonomous Region. NHAR is divided into 5 
prefectures, located in three geographic zones (Figure 4.1). Areas included in the 
study included Tongxin County, Zhongwei County and Haiyuan in Central NHAR, 
and Yuanzhou City in South NHAR. 
 
Most of the region is desert, however there is a vast plain, Huang He (Yellow River) 
in the north that has been irrigated for agriculture for many centuries. This fertile 
plain presents ideal conditions for growing crops, breeding livestock and commercial 
fishing. This greatly benefits the northern Yellow River areas, notably Wuzhong and 
Zhongwei as well as its capital city, Yinchuan. In the south, however, it is very 
mountainous with low production levels and poor economic development (Yang et 
al., 2010). This disparity in the natural environmental resources has led to 
considerable variability in gross domestic product, with the highest levels in urban 
Yinchuan and surrounding counties in the north and the lowest levels in the south 
and central areas of NHAR. 
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Figure 4-1. Geographical areas of Ningxia Hui Autonomous Region. Figure from 
Yang et al. (Yang et al., 2012). 
 
PRC is comprised of 56 ethnic groups with nearly 92% being Han Chinese (Bureau, 
2015). In NHAR, Han still make up the majority ethnic group, however, Hui 
(Chinese Muslims) make up about a third of the population, the largest minority 
group. In addition there are the Manchu ethnic group and a small number of persons 
from Tibet and Mongolia. Most people speak Mandarin Chinese, with some speaking 
Mongolian and Tibetan. The predominant religions are Buddhism and Islam 
(primarily among the Hui).  
 
Hui Chinese are dispersed throughout all parts of China with one of the major 
concentrations within NHAR. The Hui trace back to the mid-seventh century when 
Arab and Persian merchants came to China to settle. The Hui have a distinct identity 
that differentiates them from Han Chinese, mainly in clothing, diet and religion. The 
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Hui are relatively poor compared with the Han and this may be secondary to 
historical marginality. Within NHAR, the Hui are generally concentrated in the 
poorer farming areas.  
 
4.2.3! Tuberculosis in NHAR 
A retrospective analysis was undertaken that examined TB cases in the NHAR from 
2005-2009. The authors found TB to be hyper-endemic with an estimated 75.5 
incident cases per 100 000 population in 2008. 94% of TB cases were new, with no 
prior history of TB in the past. The vast majority were pulmonary (97%), 2.8% were 
pleural and the remainder were extra-pulmonary. The rates of extra-pulmonary 
disease, however, are likely to be underestimated as the extra-pulmonary TB cases 
are often registered at general hospitals and not at TB dispensaries. About two-thirds 
of pulmonary cases were sputum-smear positive at the time of diagnosis with many 
cases considered advanced at the time of diagnosis. Incident rates were higher in men 
than in women. Standard short course therapy duration is six months, however 30% 
of patients at the time of the study were on treatment for greater than 12 months and 
42% were found to have continuing treatment for longer than two years (Yang et al., 
2012). 
 
In 2004, 93% of the county and township levels in NHAR were covered by the 
DOTS programme. Diagnosis of TB is made on the basis of clinical examination, 
sputum microscopy and culture and chest radiography. Following diagnosis, patients 
are enrolled into the DOTS programme. Treatment for drug-susceptible TB is 
provided free of charge through the National Tuberculosis Programme (NTP). 
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4.2.4! Ethics statement 
This study was undertaken with the approval of the University of Sydney Ethics 
Review Committee (Protocol No 2012/1076) and The Ningxia Medical University 
Human Ethics Committee (approval date 6/6/2013). Written informed consent was 
obtained prior to their enrolment in the study. 
 
4.2.5! Study design 
A multi-phase, cohort study was designed to identify plasma miRNA as surrogate 
markers for pulmonary TB. In NHAR, all patients suspected of having TB are 
referred to specific TB clinics in the provincial towns for formal diagnosis and 
commencement of treatment. These clinics are funded by a WHO initiative for TB 
control. All clinics currently implement the DOTS strategy for diagnosis and 
treatment, involving routine sputum tests and x-rays, as well as sputum cultures and 
computerised tomography (CT)-scans if additional information is required for 
diagnosis. As part of the programme, all medication is provided free of charge to the 
patient. Part of the DOTS strategy is directly observing patients as they are taking 
their TB medication so to ensure treatment compliance and improve outcomes. The 
district nurse or a community representative routinely carries out this essential part of 
treatment. Patients enrolled were required to attend regular follow-up clinics to 
determine the efficacy of treatment and to monitor their recovery.  
 
Patients who were diagnosed with TB for the first time and had not commenced 
treatment were invited to take part in this study. In total, we aimed to recruit 100 
cases and 100 controls in NHAR, and follow these cases through the course of their 
treatment. Patients were asked to peer-nominate age- and sex-matched controls. Prior 
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to enrolment it was emphasised to the patient that they were under no obligation to 
take part and that it would not affect their treatment should they refuse to participate. 
They were informed as to the nature and scope for the project and their role and 
rights as a participant prior to providing written consent.  
 
Patients were compensated with 10 Yuan to cover the return bus fare to the clinic. 
Control participants were compensated with 10 Yuan to cover the return fare to the 
clinic. In addition, 50 Yuan was reimbursed for the time that they had to spend away 
from their work (loss of wages). 
 
All study documents, including Patient Consent, Patient Questionnaire, and Ethics 
Clearance in both English and Chinese can be viewed in Appendix C.  
 
4.2.6! Rationale for study design 
We aimed to collect a total of four samples from the pulmonary TB patients: 
1.!Time Point A - at the time of diagnosis prior to or within 24 hours of 
commencing treatment 
2.!Time Point B - one month after commencement of treatment 
3.!Time Point C – two months after commencement of treatment 
4.!Time Point D – six months after commencement of treatment 
One blood sample was collected from healthy subjects. 
 
We aimed to measure the miRNA expression over the course of each TB patient’s 
treatment. Time point A was chosen with the aim of identifying miRNAs that were 
significantly regulated in TB compared to healthy subjects prior to the instigation of 
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anti-tuberculous chemotherapy. Identifying significantly regulated miRNAs at this 
time point opens up the possibility of utilising the regulated miRNAs as a diagnostic 
biomarker. 
 
Time point B was chosen as we sought to gain a better understanding of miRNA 
expression after treatment commencement. At present sputum-smear conversion to 
acid-fast bacillus (AFB)-negative is a surrogate used after two months of therapy to 
determine if treatment is working or not. This poses two major problems:  
1.! AFB identification and later M. tuberculosis culture is not achievable in all 
patients (in this cohort only 33 out of the 100 subjects had AFB detected in 
their sputum). In cases of extra-pulmonary disease it is not possible to collect 
a two-month sample for testing and therefore determination of treatment 
success is by clinical assessment only. 
2.! Getting results from the two-month culture often takes six to eight weeks. 
During this time, if the patient is not improving (often a sign of drug-
resistance) there is ongoing transmission of disease to others and further 
amplification of drug resistance as the patient remains on inadequate therapy. 
We wished to determine the nature of miRNA expression in patients on treatment 
and to determine if those that ultimately failed treatment could be identified early 
during the course of their therapy. 
 
Time Point C marks the end of the intensive phase of a patient’s therapy. After this 
time the patient’s medications are usually reduced from the standard four-drug 
regime (isoniazid, rifampicin, ethambutol and pyrazinamide) to two drugs (isoniazid 
and rifampicin) for the remainder of their treatment (usually total of six months of 
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treatment). This reduction of therapy is not usually done until the results of the two-
month sputum culture are known. As mentioned, this can often take six to eight 
weeks and is not possible for many patients as highlighted above. In some cases, 
where culture is not possible and drug-sensitivity profiles of the organism are not 
known, patients will often remain on four-drug chemotherapy for the duration of 
treatment. In those with fully sensitive M. tuberculosis, this is ultimately 
unnecessary. The continuation of ethambutol and pyrazinamide increases the risk of 
side effects which is particularly important with ethambutol as toxicity is driven by 
cumulative dosing (Griffith et al., 2005). Ethambutol can cause serious ocular 
toxicity, manifested by optic or retrobulbar neuritis, which can result in irreversible 
blindness (Griffith et al., 2005). Identifying a biomarker that is a point-of-care tool, 
which can predict early treatment failure or success, would reduce the unnecessary 
continuation of drugs in those who do not require them and therefore reduce 
potential side effects relating to those agents and again, as highlighted above, 
recognise those failing therapy earlier than current methods. A reliable biomarker at 
both one- and two-month time points may also be useful in new drug and vaccine 
development as it would allow treatment efficacy to be examined earlier than what is 
currently possible. 
 
The final collection at six months (Time Point D) was chosen as most cases of 
pulmonary TB are treated for six months. We hypothesised that if a patient achieved 
treatment success, their miRNA profile would return to healthy control baseline.  
 
Studying miRNAs over a time course improves the understanding of their biology 
and to date has not been reported in the literature.  
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4.2.7! Data collection 
Patients diagnosed with TB between June 2013 and May 2014 were invited to 
participate in the study. All new cases of TB were reported to the Division of 
Tuberculosis Control of the Department of Public Health of NHAR. There is a 
provincial level electronic reporting system that was introduced in 2005 to NHAR. 
Data collected at the time of diagnosis included age, sex, ethnicity and domicile. 
Clinical information included: 
•! Date of diagnosis  
•! Clinical site/sites of disease 
•! Result of microbiology tests (sputum smear, culture and drug sensitivity 
(DST) profile) 
•! Chest radiography both at time of diagnosis and at completion of treatment 
•! Treatment regime  
•! Treatment outcome. 
 
4.2.8! Data storage 
Records from the clinic were collected for each patient with regard to their diagnosis, 
relevant medical history, culture DST results, demographic data and exposure. These 
data were pseudo-anonymised so that the samples were not able to be identified by 
the researcher. Each sample was allocated a unique index number, and only the 
original provider of the information, who was not directly carrying out the research 
outlined, had the means of identifying individuals. The electronic databases 
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containing the recoded patient data were locked so that only authorised individuals 
directly involved in the project could access the information.  
 
4.2.9! Case management 
Diagnosis of TB is made based on clinical grounds, sputum smear and culture and 
chest radiography. Following diagnosis, patients are commenced on DOTS which 
consists of short course chemotherapy comprising an intensive two-month phase of 
four drugs followed by four-month continuation phase of two drugs, as outlined 
above. This is in alignment with the current WHO guidelines for the management of 
treatment naïve pulmonary TB with either sputum smear/culture positivity and/or 
chest radiography highly suggestive of active pulmonary disease (World Health 
Organization, 2010b).  
 
4.2.10! Patients and control subjects 
For the pilot study, 20 newly diagnosed patients with pulmonary TB and 20 age-
matched controls, were recruited. Consenting patients were enrolled consecutively 
from each of the nominated enrolment centres. The patients with the following 
criteria were included: age greater than 18; no previous history of treated or 
untreated TB; and, not known to be infected with HIV. Diagnosis of TB was made 
on clinical grounds, sputum smear results, bacterial culture and radiographic 
findings. 
 
For the validation study, we enrolled 100 patients with either microbiologically 
proven pulmonary TB or those with suspected pulmonary TB based on clinical 
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suspicion coupled with chest radiograph consistent with active disease. Patients were 
enrolled at the time of the diagnosis and prior to the commencement of anti-
tuberculous chemotherapy. The same inclusion criteria as for the pilot study was 
followed.  
 
For both the pilot and validation studies, TB participants were asked to peer-
nominate controls. They were asked to take an information sheet home and to invite 
friends/neighbours to participate in the study. The invitee should have no history of 
TB, be of similar age, sex and ethnicity and, if they agreed to participate, they would 
join the patient on his/her next clinical follow-up. 
 
Following written formal consent, 10 mL of blood was drawn into EDTA tubes and 
processed as described in Section 2.2.2 of the Materials and Methods Chapter. 
Plasma samples were stored at -20°C at the collection centre and then, in batches, 
transported to Yinchuan Medical University where they were stored at -80°C.  
4.2.11! Establishing the study 
Prior to the commencement of the study a site visit to Ningxia was undertaken. Visits 
to all participating sites were carried out to ensure adequate facilities such as a 
suitable centrifuge and adequate storage existed for samples. During this time we 
met the key personnel who would be assisting in the study. An educational seminar 
was given to all staff that would be involved in the study, outlining the project with 
our aims and expected outcomes based on previous miRNA biomarker studies in 
other diseases. A Standard Operating Procedure was prepared (Appendix D), 
translated into Chinese Mandarin and discussed during the visit. 
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A person in NHAR was employed to oversee the running of the study. The job of the 
study assistant was to support and assist in the training of staff, manage the database 
that recorded enrolments, results of diagnostic tests such as sputum smear and 
radiography, and ensure the safe transport of samples from the provinces to 
Yinchuan Medical University. She also made available chest radiographs of patients 
prior to the commencement of their treatment and at the time of completion of 
therapy. Frequent contact was made with this person, either when visiting PRC or via 
email and Internet video chat (Skype) during the course of enrolment and collection 
of samples.  
 
During the second visit, a training day was organised. It aimed to teach and train the 
staff that would ultimately be involved with consenting the patients, collecting and 
processing the samples and recording the necessary details of each person enrolled. 
One of the most important elements covered during this training workshop was the 
importance of obtaining written informed consent from those eligible to enrol into 
the study. The patient was made aware of their right to not participate or withdraw 
from the study and that such an action would in no way influence their treatment.  
 
During subsequent visits the study progress was reviewed and any difficulties or 
problems that the team might be experiencing in relation to any part of the study was 
discussed and appropriately dealt with. Samples were transported back to Australia 
frozen with Techni Dry Ice Packs (Techni Ice, Victoria, Australia). Permission was 
obtained from the relevant Chinese authorities to export the samples and 
documentation was presented to Australian Customs to allow the importation of 
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plasma samples. Following arrival into Australia, samples were transported frozen 
and then stored at -80°C at Centenary Institute until required for further processing. 
 
4.2.12! Isolation of plasma from human samples 
Ten mL was collected from each donor and plasma collected as explained in Section 
2.2.2 of the Materials and Methods. 
 
4.2.13! RNA extraction and quality control 
Total RNA was extracted using miRCURY™ RNA Isolation Kit (Exiqon) as 
described in Section 2.3.3 of the Materials and Methods. Quality control was 
undertaken for pilot study utilising the miRCURY™ QC PCR panel as described in 
Section 2.4.7 of the Materials and Methods. 
 
4.2.14! qRT-PCR 
Reverse transcription was carried out using miRCURY™ Universal RT cDNA Kit 
(Exiqon) as described in Section 2.4.7 of the Materials and Methods.  
 
RNA for the training set was loaded onto Plasma Focus miRNA PCR Panels 
(Exiqon) with a list of all miRNAs measured in Appendix A. qRT-PCR was 
performed on LightCycler®480 (Roche Life Sciences) as described in Section 2.4.7 
of the Materials and Methods. 
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RNA for the validation set was loaded onto custom-made qRT-PCR PCR Panels 
(Exiqon) with the following miRNAs measured: miR-21-5p; -99b-5p; -29a-5p; -223-
5p; -221-3p; -146a-5p; -26a-5p; -28-5p; -133a; and, -652-3p with miR-93 acting as a 
reference miRNA. qRT-PCR was performed on LightCycler®480 (Roche) as 
described in Section 2.4.7.4 of the Materials and Methods. 
 
4.2.15! Statistical analysis  
miRNA expression was determined by qRT-PCR with data normalised to miR-93. 
miR-93 was chosen as a reference miRNA based on our findings from Chapter 
Three. The Cq is defined as the fractional cycle at which the fluorescence exceeds 
the defined threshold. The relative expression levels of each target miRNA were 
calculated according to the difference in Cq values between the target miRNA and 
miR-93 using the 2-ΔΔCT. Data were logarithmically transformed to achieve a normal 
distribution before a Student’s t-test was used for comparisons between two groups. 
P-values less than 0.05 were deemed significant.  
 
For the validation set, miRNA expression was determined by qRT-PCR with 
miRNA-93 as the reference miRNA. The relative expression of each miRNA was 
calculated using the 2(-∆∆C(T)) method. Further analysis was undertaken in 
GraphPad Prism 6 (Graphpad Software Inc., San Diego, CA, USA) and SPSS 
Predictive Analytic Software V.21 (IBM Corp, Chicago, Illinois). Student’s t-tests 
along with descriptive statistics, linear and logistic regression were performed and 
receiver operating characteristic (ROC) was generated. A one-way analysis of 
variance (ANOVA) was performed to determine differences in miRNA expression 
within the TB cohort over the four collection points. 
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Following consultation with the Sydney University Medical School Statistician, it 
was thought impossible to perform a power calculation to determine an adequate 
sample size.  Due to the nature of miRNAs with the effect of most variables, such as 
age, sex, ethnicity, time of day of sampling and other factors, still unknown it was 
deemed impossible to do an accurate power calculation in order to determine an 
adequate sample size. We instead examined the literature to determine sample sizes 
used in other miRNA work. For both the pilot and validation study, our sample size 
was much larger than previously published works.   
4.3! Results 
4.3.1! Pilot study 
4.3.1.1! Patient and Control Subjects 
A summary of patient characteristics is outlined in Table 4.1. In total, 20 patients 
with newly diagnosed TB, with an average age of aged 46 (range 18-69) were 
recruited between June 2013 and September 2013. Patients and their matched 
controls were recruited from Tongxin and Yuanzhou districts in the province of 
Ningxia. Most patients and their matched controls were of Hui ethnicity with just one 
pulmonary TB case and one healthy control of Han ethnicity. There were ten men 
(50%). The healthy controls had 50% men with an average age of 37/(18-67). 50% of 
patients enrolled had a diagnosis based on sputum smear that was positive for AFB; 
the remainder were diagnosed based on clinical grounds with symptomatology 
suggestive of pulmonary TB coupled with chest radiography in keeping with the 
diagnosis. 
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4.3.1.2! QC Panel 
All 20 pulmonary TB and healthy control samples were run on QC Panel (as 
described in Section 2.4.7.3 of Materials and Methods) prior to proceeding to the 
focus panels. Following the QC analysis six samples from the healthy control group 
and one sample from the pulmonary TB group were eliminated due mainly to 
haemolysis of the sample. This meant that in total the plasma from 19 patients with 
newly diagnosed pulmonary TB and 14 healthy controls were analysed. 
 
4.3.1.3! PCR Focus Panel 
Among the 175 miRNAs studied, 87 with significantly altered expression between 
pulmonary TB patients and healthy controls by qRT-PCR were identified, of which 
69 were down-regulated and 18 were up-regulated in pulmonary TB patients (Table 
4.2 and Table 4.3 respectively). 
 
Of the 87 significantly regulated miRNAs, ten miRNAs were selected to examine in 
the validation set. These miRNAs were chosen based on a mean fold change ≥ 1.5, a 
p-value < 0.01, strength of expression in the assay with Cq values < 35, and with 
miRNAs previously reported in the literature to be regulated in the setting of TB, 
other infections or known to be important in macrophage function were of particular 
interest. Of the ten miRNAs chosen, four were up-regulated and the remaining down-
regulated in pulmonary TB (Figure 4.2 and Table 4.4).  
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Table 4-1. Patient characteristics for test and validation studies.  
  
! TB# Healthy#Controls#
Test#
Set#
Validation#
Set#
Test#
Set#
Validation#
Set#
Total#Number# 20! 100! 20! 100!
Gender#(male/female)# 10/10! 58/42! 10/10! 57/43!
Age#(years,#average;#range)# 46!(18-
69)!
!
43!(19-91)!
!
37(18-
67)!
!
35(18-78)!
Ethnicity## Han# 1! 42! 1! 46!
Hui# 19! 58! 19! 54!
Region# Yuanzhou# Han#
Hui#
1!
15!
17!
32!
1!
15!
9!
24!
Zongwei# Han#
Hui#
-!
-!
22!
0!
-!
-!
30!
0!
Penyang# Han#
Hui#
-!
-!
3!
6!
-!
-!
7!
5!
Tongxin# Han#
Hui#
0!
4!
0!
20!
0!
4!
0!
25!
Sputum#Smear#Positive# 5! 33! !
Sputum#Culture#Positive# 5! 10!!
Culture#DST# 2! 10!!
Chest#XNray# 20! 100!
Treatment#success#(%)# 14!(60%)! 89!(89%)!
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Table 4-2. Down-regulated miRNAs in plasma of pulmonary tuberculosis 
patients compared with healthy donors.  
miRNA# Fold#change# pNValue#
letN7a# -2.15! 0.002!
letN7c# -2.02! 0.006!
letN7d# -2.24! 0.005!
letN7d*# -2.08! <0.001!
letN7e# -3.08! <0.001!
letN7f# -2.53! <0.001!
letN7g# -1.50! 0.003!
letN7i# -1.42! 0.045!
miRN103# -2.22! 0.005!
miRN106b*# -2.71! 0.004!
miRN107# -2.11! 0.007!
miRN126# -1.93! 0.001!
miRN127N3p# -2.17! 0.040!
miRN128# -1.80! 0.037!
miRN133a# -2.94! 0.002!
miRN133b# -3.42! 0.005!
miRN139N5p# -2.62! <0.001!
miRN140N5p# -2.16! 0.001!
miRN142N3p# -3.59! <0.001!
miRN146a# -2.29! 0.002!
miRN148a# -1.55! 0.047!
miRN148b# -1.67! 0.018!
miRN151N3p# -2.35! 0.001!
miRN151N5p# -2.38! <0.001!
miRN152# -2.50! <0.001!
miRN15b# -1.82! <0.001!
miRN17# -1.26! 0.023!
miRN181a# -1.84! 0.004!
miRN182# -2.01! 0.033!
miRN186# -1.42! 0.003!
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miRN18a# -1.37! 0.028!
miRN18b# -1.39! 0.046!
miRN197# -1.91! 0.013!
miRN1974# -3.02! 0.003!
miRN199aN3p# -1.97! 0.031!
miRN20a*# -3.07! 0.002!
miRN21N5p# -2.28! <0.001!
miRN223*# -1.83! 0.011!
miRN23a# -2.25! <0.001!
miRN23b# -2.28! <0.001!
miRN24# -2.48! <0.001!
miRN26a# -2.10! 0.001!
miRN26b# -1.41! 0.032!
miRN27a# -1.61! 0.015!
miRN28N3p# -2.66! <0.001!
miRN28N5p# -2.93! <0.001!
miRN301a# -1.45! 0.043!
miRN30d# -1.58! 0.002!
miRN30e# -1.39! 0.025!
miRN30e*# -1.95! 0.001!
miRN320a# -1.98! <0.001!
miRN320b# -1.90! 0.001!
miRN328# -1.78! 0.016!
miRN335# -1.69! 0.015!
miRN338N3p# -1.88! 0.049!
miRN361N3p# -2.68! 0.019!
miRN374a# -1.83! 0.001!
miRN374b# -2.18! 0.002!
miRN421# -2.04! 0.005!
miRN425*# -1.74! 0.029!
miRN484# -1.54! 0.004!
miRN505# -2.25! <0.001!
miRN532N5p# -1.69! 0.014!
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miRN574N3p# -1.66! 0.043!
miRN584# -2.59! 0.001!
miRN590N5p# -1.53! 0.019!
miRN652# -1.73! 0.020!
miRN766# -2.24! 0.001!
All data normalised to miR-93. Fold change calculated using ∆∆CT method. p-value calculated using 
Student’s t-test (normal distribution assumed as data logarithmically transformed). 
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Table 4-3. Up-regulated miRNAs in plasma of pulmonary tuberculosis patients 
compared with healthy donors. 
miRNA# Fold#change# pNValue#
miRN125aN5p# 2.83! <0.001!
miRN145# 1.81! 0.023!
miRN191# 2.09! 0.001!
miRN191N3p# 2.26! 0.001!
miRN20a*# 2.28! <0.001!
miRN2110# 1.78! 0.037!
miRN221# 2.56! 0.003!
miRN223# 2.09! 0.002!
miRN29a*# 2.79! 0.006!
miRN30b# 1.93! 0.003!
miRN30c# 2.18! <0.001!
miRN324N5p# 2.06! 0.006!
miRN339N3p# 2.35! 0.002!
miRN339N5p# 2.05! 0.040!
miRN423N3p# 2.61! 0.001!
miRN423N5p# 1.77! 0.019!
miRN423*# 1.69! 0.040!
miRN720# 2.66! 0.004!
miRN99b# 2.54! <0.001!
All data normalised to miR-93. Fold change calculated using ∆∆CT method. p-value calculated using 
Student’s t-test (normal distribution assumed as data logarithmically transformed). 
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Figure 4-2. Plasma levels of miRNAs in test set of 19 TB patients and 14 healthy 
controls. Expression levels of miRNAs from 19 TB patients prior to commencement 
of treatment and 14 healthy controls were measured by using miR-93 as a reference 
miRNA. Significant up-regulation of miR-99b-5p, -29a-5p, 223-5p and -221-3p (B, 
C, D, E) and down-regulation of miR-21-5p, -146a-5p, -26a-5p, -28-5p and -652-3p 
was observed. The relative expression of miRNAs was determined using 2(-
∆∆C(T)). Results are depicted using a boxplot with median and interquartile range 
within the box and +/- 1.5 interquartile range to the inner fences. Outliers are plotted 
individually. The differences were calculated by a Student’s t-test with a p-value 
<0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001. 
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Table 4-4. Selected candidate miRNAs from test phase result. 
miRNA# Regulation# Fold#Change# pN#
Value#
Sequence#
21N5p# Down! -2.28! <0.001! UAGCUUAUCAGACUGAUGUUGA!
!
99bN5p# Up! 2.54! <0.001! CACCCGUAGAACCGACCUUGCG!
!
29aN5p# Up! 2.79! 0.006! ACUGAUUUCUUUUGGUGUUCAG!
!
223N5p# Up! 2.09! 0.002! CGUGUAUUUGACAAGCUGAGUU!
!
221N3p# Up! 2.56! 0.003! AGCUACAUUGUCUGCUGGGUUUC!
!
146aN5p# Down! -2.29! 0.002! UGAGAACUGAAUUCCAUGGGUU!
!
26aN5p# Down! -2.10! 0.001! UUCAAGUAAUCCAGGAUAGGCU!
!
28N5p# Down! 2.93! <0.001! AAGGAGCUCACAGUCUAUUGAG!
!
133a# Down! -2.94! 0.002! UUUGGUCCCCUUCAACCAGCUG!
!
652N3p# Down! -1.73! 0.020! AAUGGCGCCACUAGGGUUGUG!
!
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4.3.2! Validation set 
4.3.2.1! Patient characteristic 
A total of 100 patients with newly diagnosed pulmonary TB who were treatment 
naïve were successfully followed for six months, together with matched healthy 
controls (Table 1.1). For the TB group, plasma samples were collected at four time 
points with plasma miRNAs measured at each point. The mean age for TB cases was 
43 (19-91) and 35 (18-78) for healthy controls. 57% were male in the TB group and 
59% male in the healthy control group. There were 42 (42%) Han Chinese and 58 
(58%) Hui Chinese in the TB group and 46 (46%) Han Chinese and 54 (54%) Hui 
Chinese in healthy subjects. In the TB group 33 were smear positive for AFB (Ziehl-
Neelsen staining). All sputums found to be positive for AFB were sent for culture on 
two slopes of Lowenstein Jensen medium per specimen. Of the 33 sent for culture, 
five were found to have resistance to at least one first line agent with one patient 
resistant to isoniazid and rifampicin (multi-drug resistant). 89 were successfully 
treated, with 11 classified as treatment failure based on radiological progression or 
end-of-treatment sputum results. 
 
4.3.2.2! Newly diagnosed TB compared with healthy controls 
We examined the ten selected miRNAs that were identified in the test study as 
significantly regulated in 100 patients with pulmonary TB and their matched healthy 
controls. miRNAs were normalised to miR-93. At Time Point A, prior to the 
commencement of treatment we set out to explore whether there was any statistical 
significant differences between miRNA expression in patients with M. tuberculosis 
infection and their matched healthy controls. Graphical representation of relative 
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expression of miRNA is presented in Figure 4.3. In order to explore this, we first 
performed a Student’s t-test. This found that miR-21-5p, -99b-5p, -29a-5p, -146a-5p 
and -652-3p were specifically discordantly regulated. Specifically, TB patients were 
found to have significantly lower means with respect to miR-21-5p, -146a-5p and -
652-3p, meaning miRNAs were down-regulated, while miR-99b and -29a-5p were 
significantly up-regulated with statistically significant higher mean values (Table 
4.5). 
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Figure 4-3. Plasma levels of miRNAs in validation set of 100 treatment naïve TB 
patients prior to therapy and 100 healthy controls. Expression levels of miRNAs 
from 100 TB patients prior to commencement of treatment and 100 healthy controls 
were measured by qRT-PCR using miR-93 as a reference miRNA. Significant up-
regulation of miR-99b-5p and -29a-5p (B and C) and down-regulation of miR-21-5p, 
-146a-5p and -652-3p (A, F and J) was observed. The relative expression of miRNAs 
was determined using 2(-∆∆C(T)). Results are depicted using a boxplot with median 
and interquartile range within the box and +/- 1.5 interquartile range to the inner 
fences. Outliers plotted individually. The differences were calculated by a Student’s 
t-test with a p-value <0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001. 
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Table 4-5. Expression profiles of 10 candidate miRNA on qRT-PCR in 
validation set from TB patients prior to the commencement of therapy. 
miRNA# Fold#Change# p#–Value*#
miRN21N5p! -1.83! 0.005#
miRN99bN5p! 1.52! 0.002#
miRN29aN5p! 4.09! <0.001#
miRN223N5p! -1.01! 0.767!
miRN221N3p! 1.47! 0.176!
miRN146aN5p! -2.66! <0.001#
miRN26aN5p! -1.26! 0.192!
miRN28N5p! 1.72! 0.105!
miRN133a! -1.08! 0.305!
miRN652N3p! -1.37! <0.001#
 
To determine if any of the significantly regulated miRNAs could successfully 
differentiate TB from healthy controls, a ROC was constructed for the five miRNAs 
that were significantly regulated (Figure 4.4). miR-146a had the highest ROC of 0.69 
(p <0.001, 95% CI 0.62-0.76) with the others as follows: hsa-miR-29a, 0.70 (p 
<0.001, 95% CI 0.63-0.77); hsa-miR-99b-5p, 0.64 (p = 0.001, 95% CI 0.56-0.71); 
hsa-miR-21-5p, 0.70 (p = 0.001, 95% CI 0.62-0.77); and, hsa-miR-652-3p 0.64 (p = 
<0.001, 95% CI 0.56-0.71) 
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Figure 4-4. Receiver operating characteristic curves for the ability of the five 
individually significantly regulated miRNAs to differentiate the TB patients 
from the control group at Time Point A. (A), miR-21-5p, (B) miR-99b-5p, (C) 
miR-29a-5p, (D) miR-146a-5p and (E) miR-652-3p. AUC: area under the curve.  
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A good biomarker needs to be both sensitive and specific. A logistic regression 
analysis was performed in order to determine if measuring miRNA expression 
utilising a number of miRNAs would improve the accuracy. The data consisted of all 
healthy subjects (n=100) and all TB subjects at Time Point A (n=100) (prior to the 
commencement of therapy). The following regression equation was built: Logit (p) = 
−3.648 − 0.997*(hsa-miR-21-5p) − 2.022*(hsa-miR-99) − 1.013*(hsa-miR-29a-5p) 
− 0.350*(hsa-miR-223-5p) − 2.092*(hsa-miR-221-3p) + 3.791*(hsa-146a-5p) + 
1.214*(hsa-miR-26a-5p) − 0.836*(hsa-miR-28-5p) + 0.314*(hsa-miR-133a) + 
1.004*(hsa-miR-652-3p) (Table 4.6).  
 
When a logistic regression is calculated, the exponential function of the regression 
co-efficient is the odds ratio associated with a one-unit increase in the exposure. 
Each unit increased (in this case miRNA expression) is associated with the odds of 
being in the healthy control group as compared with the TB group. Examining Table 
4.6, we see that for every unit increase in miRNA expression in miR-29a-5p there is 
0.363 (95% CI 0.21-0.63) chance of being in the healthy control group or inversely a 
2.75 times chance of being in the TB group. Conversely, as miR-146a-5p was shown 
to be down-regulated in the setting of TB disease, increase expression of miR-146a is 
associated with a 44 times increase in the likelihood of being in the healthy control 
group.  
 
Using all ten miRNAs in combination, the logistic regression equation yielded a 
sensitivity of 94.6%, specificity of 88.8% with a positive predictive value (PPV) of 
88% and a negative predictive value (NPV) of 95%. Predictive values are critically 
dependent on the population chosen and the prevalence of a disease. These tests tend 
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to perform less well when the prevalence of disease is low. Predictive values can 
generally not be transferred to another setting or population. Likelihood ratios, on the 
contrary, are independent of disease prevalence (Attia, 2003). The positive likelihood 
ratio was calculated to be 8.44 meaning that, regulation of these miRNAs is 
associated with a nearly 8 ½ fold increase in the chance of having TB. The negative 
likelihood ratio is 0.06 meaning that if these miRNAs are not regulated there is a 
large and often conclusive decrease in the likelihood of disease (Table 4.7). 
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Table 4-6. Logistic regression analyses of a combination of ten plasma miRNAs 
for the diagnosis of pulmonary TB in validation set. 
*Odds ratio (OR) can be interpreted as: each unit increase (in this case miRNA expression) is 
associated with an odds of being in the healthy control group category as compared with the TB group 
which, is increased by a factor equal to that of the OR. 
 
  
Logistic#Regression#Analyses#
Coefficients#and#standard#errors#
Variable# Coefficient# Std.#error# pNvalue#
miRN21N5p# -0.997! 0.775! 0.198!
miRN99bN5p# -2.022! 0.600! 0.001!
miRN29aN5p# -1.013! 0.282! <0.001!
miRN223N5p# -0.350! 0.303! 0.248!
miRN221N3p# -2.092! 0.544! <0.001!
miRN146aN5p# 3.791! 0.834! <0.001!
miRN26aN5p# 1.214! 0.662! 0.067!
miRN28N5p# -0.836! 0.306! 0.006!
miRN133a# 0.314! 0.209! 0.133!
miRN652N3p! 1.004! 0.709! 0.157!
Constant! 3.648! 0.627! <0.001!
Logit# (p)# =# −3.648# −# 0.997*(hsaNmiRN21N5p)# −# 2.022*(hsaNmiRN99)# −# 1.013*(hsaNmiRN29aN5p)# −#
0.350*(hsaNmiRN223N5p)#−#2.092*(hsaNmiRN221N3p)#+#3.791*(hsaN146aN5p)#+#1.214*(hsaNmiRN26aN
5p)#−#0.836*(hsaNmiRN28N5p)#+#0.314*(hsaNmiRN133a)#+#1.004*(hsaNmiRN652N3p)!
Odds#ratios*#and#95%#confidence#intervals#
Variable# Odds#Ratio# 95%#CI# !
miRN21N5p# 0.369*! 0.08-1.69!
miRN99bN5p# 0.132*! 0.04-0.43!
miRN29aN5p# 0.363*! 0.21-0.63!
miRN223N5p# 0.704*! 0.39-1.28!
miRN221N3p# 0.123*! 0.04-0.36!
miRN146aN5p# 44.320*! 8.65-227.20!
miRN26aN5p# 3.366*! 0.92-12.33!
miRN28N5p# 0.433*! 0.24-0.79!
miRN133a# 1.369*! 0.91-2.06!
miRN652N3p# 2.730*! 0.68-10.96!
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Table 4-7. Accuracy of plasma miRNAs at predicting TB prior to the 
commencement of treatment. 
Category# Sensitivity# Specificity# PPV# NPV# PLR# NLR#
TB# versus#
Healthy#
Controls#
94.6%! 88.8%! 88.0%! 95.0%! 8.4! 0.06!
PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, 
negative likelihood ration. 
 
The logistic regression, utilising all ten miRNAs, was able to differentiate healthy 
individuals from TB subjects with a high degree of accuracy. Next, we wanted to 
determine if a cut-off that could potentially separate according to disease status was 
possible using a single miRNA. As shown below in a series of histograms, in Figure 
4.5, this was not possible as there was an extreme degree of overlap between healthy 
and TB subjects with regards to these data, suggesting that these individual miRNA 
expression levels could not be reliably used to separate persons on this basis (Figure 
4.5).  
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Figure 4-5. Histogram plots of miRNA expression as measured in fold change 
from the plasma of tuberculosis patients prior to treatment and their matched 
healthy controls. Expression levels of miRNAs from 100 TB patients prior to 
commencement of treatment and 100 healthy controls were measured by qRT-PCR 
using miR-93 as a reference miRNA. The mean difference reported represents the 
mean expression of miRNA in TB patients minus the mean expression of miRNA 
from healthy controls. There is considerable overlap in expression levels between TB 
and healthy subjects, meaning that the level of miRNA expression could not be 
reliably used to separate persons with TB from healthy controls. 
 
4.3.2.3! miRNA expression after one month of TB therapy. 
Next, changes in the expression of miRNA over the course of treatment for the TB 
patients was examined for the ten miRNAs at one month relative to levels at time 
point zero, before the commencement of therapy. Table 4.8 shows the fold change 
along with their corresponding p-value. One hypothesis being tested was that 
miRNAs would return to that of the baseline seen in the healthy controls with 
effective treatment. Examining the miRNA expression after one-month of therapy, 
only miR-99b fulfilled this hypothesis (Figure 4.6 B). miR-99b was significantly up-
regulated in the TB subjects prior to commencement of therapy (Figure 4.3 B) and 
following one month of therapy, no significance was found between the TB subjects 
and the healthy controls (Figure 4.6 B). 
 
There were five miRNAs that were differentially expressed after one month of 
therapy (Figure 4.6). miR-29a was the only miRNA to remain significantly up-
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regulated. There were four down-regulated miRNAs: miR-21-5p; miR-146a-5p; -
26a-5p; and, miR-652-3p (Figure 4.6 A, F G and J). Interestingly miR-26a-5p, which 
was found not to be significantly differentially expressed in the TB subjects 
compared to the healthy controls prior to the commencement of therapy, was 
significantly down-regulated following one month of anti-tuberculous therapy. The 
reason/s for this observation is unclear but may relate to a delayed inflammatory 
response accompanying M. tuberculosis infection. 
 
 
Table 4-8. Expression profiles of 10 candidate miRNAs from plasma as 
measured by qRT-PCR in validation set from TB patients after one month of 
therapy. 
miRNA# Fold#Change*# p#Value#
miRN21N5p! -2.15! <0.001#
miRN99bN5p! -1.30! 0.653!
miRN29aN5p! !1.48! 0.031#
miRN223N5p! -1.52! 0.426!
miRN221N3p! !1.05! 0.689!
miRN146aN5p! -3.04! <0.001#
miRN26aN5p! -1.52! 0.003#
miRN28N5p! !1.16! 0.908!
miRN133a! -1.49! 0.156!
miRN652N3p! -1.71! <0.001#
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Figure 4-6. Plasma levels of miRNAs in validation set of 100 TB patients after 
one month of anti-tuberculous chemotherapy and 100 healthy controls. 
Expression levels of miRNAs from 100 TB patients after one month of treatment and 
100 healthy controls were measured by qRT-PCR using miR-93 as a reference 
miRNA. Significant up-regulation of miR-29a-5p (C) and down-regulation of miR-
21-5p, -146a-5p, -26a-5p and -652-3p (A, F, G and J) was observed. The relative 
expression of miRNAs was determined using 2(-∆∆C(T)). Results are depicted using 
a boxplot with median and interquartile range within the box and +/- 1.5 interquartile 
range to the inner fences. Outliers are plotted individually. The differences were 
calculated by a Student’s t-test with a p-value <0.05 deemed significant. *p <0.05, 
**p <0.01, ***p <0.001.  
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4.3.2.4! miRNA expression after two months of TB therapy 
Following two months of therapy there were again five miRNAs that remained 
discordantly regulated. These were the same five miRNAs significantly regulated 
after one month of therapy (Table 4.8). The fold change along with their 
corresponding p-value are presented in Table 4.9. miR-29a-5p was the only miRNA 
to be up-regulated (Figure 4.7 C). miR-21-5p, -146a-5p, 26a-5p and -652-3p were all 
down-regulated following two months of therapy (Figure 4.7 A, F, G and J). miR-
99b-5p expression remains not statistically different to healthy subjects (Figure 4.7 
B).  
 
 
 131 
 
Figure 4-7. Plasma levels of miRNAs in validation set of 100 TB patients after 
two months of anti-tuberculous chemotherapy and 100 healthy controls. 
Expression levels of miRNAs from 100 TB patients after two months of treatment 
and 100 healthy controls were measured by qRT-PCR using miR-93 as a reference 
miRNA. Significant up-regulation of miR--29a-5p (C) and down-regulation of miR-
21-5p, -146a-5p, -26a-5p and -652-3p (A, F, G and J) was observed. The relative 
expression of miRNAs was determined using 2(-∆∆C(T)). Results are depicted using 
a boxplot with median and interquartile range within the box and +/- 1.5 interquartile 
range to the inner fences. Outliers are plotted individually. The differences were 
calculated by a Student’s t-test with a p-value <0.05 deemed significant. *p <0.05, 
**p <0.01, ***p <0.001. 
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Table 4-9. Expression profiles of 10 candidate miRNAs on qRT-PCR in 
validation set from TB patients after two months of therapy. 
miRNA# Fold#Change# p#Value#
miRN21N5p! -1.92! 0.002#
miRN99bN5p! -1.06! 0.410!
miRN29aN5p! !1.80! 0.004#
miRN223N5p! -1.20! 0.928!
miRN221N3p! !1.21! 0.407!
miRN146aN5p! -2.22! <0.001#
miRN26aN5p! -1.33! <0.001#
miRN28N5p! !1.27! 0.298!
miRN133a! -1.28! 0.178!
miRN652N3p! -1.45! <0.001#
 
4.3.2.5! miRNA expression after six months of TB therapy 
Six months is the standard duration of treatment for fully sensitive pulmonary TB. 
Following clinical assessment, which would routinely include sputum culture for M. 
tuberculosis and chest radiography, if there are no contraindications, a patient’s 
therapy is usually ceased. We collected plasma from all enrolled subjects following 
six months standard short course therapy. Fold change with the associated p value is 
shown in Table 4.10. 
 
We hypothesised that miRNA levels would return to healthy control levels with 
treatment. Interestingly this was not the case for all regulated miRNAs. Of the six 
miRNAs that were regulated in the plasma of TB patients, only two returned to 
levels seen in the healthy control: miR-99b-5p at the one month collection time point 
(Figure 4.6 B); and, miR-29a-5p at the final collection point at six months (Figure 
4.8 C). At the conclusion of treatment, four miRNAs remained that were 
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differentially modulated in the plasma of TB patients: miR-21-5p; -146a-5p; 26a-5p; 
and, 652-3p. (4.8 A, F, G and J). All of these miRNAs were down-regulated.  
Table 4-10. Expression profiles of 10 candidate miRNAs by qRT-PCR in 
validation set from TB patients after six months of therapy. 
miRNA# Fold#Change# p#Value#
miRN21N5p! -2.32! 0.002#
miRN99bN5p! !1.11! 0.170!
miRN29aN5p! !1.19! 0.257!
miRN223N5p! -1.10! 0.935!
miRN221N3p! !1.24! 0.603!
miRN146aN5p! -2.23! <0.001#
miRN26aN5p! -1.70! <0.001#
miRN28N5p! -1.02! 0.320!
miRN133a! -1.76! 0.217!
miRN652N3p! -1.58! <0.001#
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Figure 4-8. Plasma levels of miRNAs in validation set of 100 TB patients after 
six months of anti-tuberculous chemotherapy and 100 healthy controls. 
Expression levels of miRNAs from 100 TB patients after six months of treatment 
and 100 healthy controls were measured by qRT-PCR using miR-93 as a reference 
miRNA. Significant down-regulation of miR-21-5p, -146a-5p, -26a-5p and -652-3p 
(A, F, G and J) were observed. The relative expression of miRNAs was determined 
using 2(-∆∆C(T)). Results are depicted using a boxplot with median and interquartile 
range within the box and +/- 1.5 interquartile range to the inner fences. Outliers are 
plotted individually. The differences were calculated by a Student’s t-test with a p-
value <0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001. 
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4.3.2.6! Examining the miRNAs over the six-month time course 
Examining the expression levels of miRNAs over the six-month time course allows 
us to explore the trends in expression levels that occur with TB treatment and may 
help to improve current knowledge relating to the functional roles of these miRNAs. 
One of the hypotheses of this study was that miRNA expression would return to 
levels seen in healthy controls with anti-tuberculous chemotherapy. For the majority 
of miRNAs modulated in TB disease this was not the case. Figure 4.9 illustrates the 
expression of miRNAs at all collection time points and with calculated significance 
based on healthy control levels. Figure 4.10 documents the significance of the 
miRNA expression change within the TB group only.  
 
Of the regulated miRNAs, miR-99b-5p and -29a-5p (Figure 4.9 B and C) are the 
only miRNAs to return to healthy control levels and they both do so after one month 
of therapy. The reduction in miRNA expression levels in both miRNAs is 
significantly less (Figure 4.10 B and C). 
 
Some miRNAs remain persistently down-regulated and were so over the course of 
therapy (miR-21-5p, miR-146a-5p, 26a-5p and -652-3p) (Figure 4.9 A, F, G and J). 
miR-21-5p and -652-3p levels do not vary over the course of TB treatment (Figure 
4.10 A and J). Whereas miR-146a-5p levels fall significantly following the initiation 
of therapy being the most down-regulated at one month following the 
commencement of therapy. The expression levels at two and six months remain low 
and did not vary significantly (Figure 4.10 F). miR-26a-5p expression levels in the 
TB subjects appears to fall throughout the course of TB treatment, however this does 
 136 
not reach statistical significance until the final collection at six months (Figure 4.10 
G).  
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Figure 4-9. Plasma levels of miRNAs in validation set of 100 TB patients and 
their matched healthy controls at all collection time points. The plasma from TB 
subjects was collected prior to the commencement of therapy (0 months) and at one, 
two and six months following treatment commencement. miRNAs levels were 
examined by qRT-PCR with miR-93 used as a reference miRNA. miR-21-5p (A) is 
significantly down-regulated prior to TB treatment and remains significantly down-
regulated during the course of treatment. miR-99b (B) is significantly up-regulated 
prior to the commencement of TB therapy and then following one month of therapy 
and beyond, miR-99b levels return to healthy control baseline. miR-29a-5p (C) is 
significantly up-regulated prior to the commencement of therapy and at one month 
and beyond expression levels are not significantly different to healthy controls. miR-
146a-5p (F) remains significantly down-regulated throughout the six months of 
therapy. miR-26a-5p (G) is down-regulated which reaches statistical significance at 
one month measure. With time, miR-26a-5p levels reduce in TB patients despite 
therapy. miR-652-3p (J) is significantly down-regulated at all collection time points. 
miR-223, -221, -28 and -133 (D, E, H and I) are not significantly regulated in TB 
compared with healthy controls. The relative expression of miRNAs was determined 
using 2(-∆∆C(T)). Results are depicted with mean with 95% confidence intervals. 
Logged data was assumed to be normally distributed. Comparisons of variables 
between multiple groups were done using ANOVA. In instances where p-value was 
< 0.05, additional two-group comparison were done by a Student’s t-test. A p-value 
<0.05 deemed significant.*p <0.05, **p <0.01, ***p <0.001. 
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Figure 4-10. Plasma miRNA expression levels within TB group at all collection 
time points. The plasma from TB subjects was collected prior to the commencement 
of therapy (0 months) and at one, two and six months following treatment 
commencement. miRNAs levels were examined by qRT-PCR with miR-93 used as a 
reference miRNA. A one-way analysis of variance (ANOVA) with multiple 
comparisons was performed to detect significant variation in miRNA expression 
from the TB patients over the course of their treatment. On the far left of each graph 
are the healthy controls for reference. miR-21-5p (A) was significantly down-
regulated in the TB patients compared with healthy controls. Over the course of 
therapy miR-21 remained relatively unchanged with no statistical significant 
variation. miR-99b-5p (B) was up-regulated in the TB patients prior to the 
commencement of therapy. After one month of treatment there has been a significant 
fall in miR-99b-5p levels, where the levels remain. miR-29a-5p (C) was also 
significantly up-regulated prior to the commencement of therapy. After one month of 
treatment plasma levels were significantly reduced. Levels of miR-146a-5p (F) were 
significantly reduced in the plasma of TB patients and further significantly reduced 
following the commencement of therapy. Levels of miR-26a-5p (G) reduced over the 
course of treatment, reaching significance at the six-month time point. miR-28a-5p 
(G) was up-regulated in the TB patients at Time Point A, although did not reach 
statistical significance. Following one month of therapy there was a significant fall in 
miR-28a-5p (H) levels in the TB subjects. miR-21-5p, -223-5p, -221-3p, -133a and -
652-3-p miRNA expression did not change significantly with treatment (A, D, E,I 
and J). p-value <0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001. 
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4.3.3! Sub-group analysis 
To explore whether other factors may be influencing miRNA expression we looked 
more closely at treatment outcome (success versus failure), ethnicity (Han versus 
Hui), and sex. 
 
4.3.3.1! Treatment failure versus treatment success. 
One of the secondary aims of this study was to determine if the miRNAs that we 
selected would be useful to predict treatment failure in early stages of a patient’s 
course of therapy. It was interesting to observe that miRNA expression in the TB 
cohort remained discordantly modulated in four of the six significantly regulated 
miRNAs. However, not all patients that were treated were treated successfully. It 
was not clear what the effects of the treatment failure subjects were having on overall 
miRNA expression from the whole TB cohort. To explore this further we divided the 
TB cohort according to their outcome. Of the 100 patients treated for six months, 11 
failed treatment and 89 were successfully treated. Given the small number of patients 
that were deemed to have failed treatment, caution will need to be taken when 
analysing the data, particularly from the treatment failure group. 
 
We examined the expression of the ten miRNAs stratified according to treatment 
outcome below. Comparisons of variables between multiple groups were done using 
ANOVA as normal distribution was assumed due to logged data. In instances where 
the ANOVA p-value was <0.05, additional two-group comparisons were done using 
a Student’s t-test. A p-value <0.05 was deemed significant. A pictorial of all miRNA 
expression based on treatment outcome as well as associated fold change and p-value 
is presented in Figure 4.11. 
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4.3.3.1.1! miR-21-5p 
miR-21-5p (Figure 4.11 A) is down-regulated during TB disease and this was 
maintained when stratifying according to treatment outcome. What was apparent was 
that those who eventually failed treatment had greater down-regulation, particularly 
during the first month of treatment. At the six-month time point, the levels of miR-
21-5p were similar in both the treatment success and failure groups.  
 
4.3.3.1.2! miR-99b and -29a-5p 
The levels of miR-99b and -29a-5p (Figure 4.11 B and C) are up-regulated in the 
treatment success group and not significantly varied in the treatment failure group. In 
the treatment success group there is nearly a five-fold (4.73) increase in miR-29a-5p 
levels in the treatment success group compared to their matched healthy controls.  
 
4.3.3.1.3! miR-221-3p 
The expression profile of miR-221-3p (Figure 4.11 E) was quite varied between the 
treatment success and the treatment failure individuals. Prior to treatment 
commencement the treatment success group was significantly up-regulated and the 
treatment failure group was significantly down-regulated. Following a month of 
therapy both groups were trending towards healthy controls with no significant 
differences detected in either group after the first month of therapy. 
 
4.3.3.1.4! mir-146a-5p, -26a-5p, -133a and -652-3p  
The overall trend for all these miRNAs (Figure 4.11 F, G, I and J) is that there was 
more significant down-regulation in the treatment failure group especially prior to 
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the commencement of therapy and after one month of treatment. At the two-month 
collection point and at the final collection point at six months, the levels in treatment 
failures were trending towards the treatment success individuals. With the exception 
of miR-26a, the levels are continuing to fall in the treatment success patients. All 
other miRNA levels in those that successfully completed therapy were moving 
towards healthy control levels of expression.  
 
4.3.3.1.5! miR-28a-5p 
When examining the expression profile of miR-28-5p (Figure 4.11 H) in the TB 
cohort, there was no statistically significant variability between healthy controls and 
TB subjects. When stratifying according to treatment outcome, we see that the 
expression level of miR-28-5p in the plasma was significantly down-regulated with a 
greater than four-fold decrease in expression levels following two-months of therapy 
and greater than two-fold decrease in expression levels following six-months of 
treatment (Figure 4.11 H).  
 
There was neither significant variation in the expression of miR-223-5p (Figure 4.11 
D) in the plasma from TB patients who ultimately failed treatment nor those that 
successfully completed therapy compared to healthy controls. 
 
Overall we observed quite marked variation in the expression levels in those that 
completed treatment successfully with those that did not for most of the miRNAs 
examined in the plasma. Caution needs to be taken however, especially when 
interpreting the results from the treatment failure group, in view of the modest 
numbers in this group.  
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Figure 4-11. Plasma miRNA levels from validation set from 100 TB patients and 100 healthy controls as determined by 
treatment outcome. The plasma from TB subjects was collected at four time points (prior to treatment commencement, one, two and 
six months following commencement of therapy). Plasma from healthy controls was collected at one time point. miRNA expression was 
measured by qRT-PCR with miR-93 used as a reference miRNA. The TB group was separated according to treatment outcome 
following six months of therapy. Healthy controls are depicted in black, treatment success in red and treatment failures in blue. In total 
89 patients were successfully treated and 11 failed TB treatment. Accompanying each figure is a table which states the fold change and 
p-value for each miRNA in the TB group compared with healthy controls. The relative expression of miRNAs was determined using 2(-
∆∆C(T)). Results are depicted with mean with 95% confidence intervals. Logged data was assumed to be normally distributed. 
Comparisons of variables between multiple groups were done using ANOVA. In instances where p-value was < 0.05, additional two-
group comparison were done by a Student’s t-test. *p <0.05, **p <0.01, ***p <0.001. 
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4.3.3.2! Ethnicity 
Previous studies have demonstrated ethnic diversity in miRNA expression (Bovell et 
al., 2013; Rawlings-Goss et al., 2014). We also demonstrated significant differences 
in miRNA expression when identifying a suitable reference miRNA (Chapter 3). 
This difference, however, was between Hui Chinese and an Australian cohort with 
many ethnic variances.  
 
To further examine this, miRNA data from healthy controls and TB patients from 
Time Point A (prior to the commencement of therapy) were divided according to 
ethnicity. Normal distribution was assumed as all data was logged. A Student’s t-test 
was performed with ethnicity as the dichotomous variable for healthy control 
subjects. Comparisons of variable over the time course of therapy in the TB subjects 
were done using ANOVA. In instances where the ANOVA p-value was <0.05, 
additional two-group comparisons were done using a Student’s t-test. A p-value 
<0.05 was deemed significant. The results are presented in Figure 4.12. Within the 
healthy control cohort there were 46 that identified themselves as Han Chinese and 
54 as Hui Chinese. Within the TB cohort there were 42 that identified themselves as 
Han and 58 as Hui Chinese. 
 
In total, from the healthy control group there were four miRNAs which were 
significantly differentially expressed amongst the two ethnic groups: miR-99b-5p; -
221-3p; -146a-5p; and, 652-3p (Figure 4.12 B, E, F and J). Looking at the miRNA 
expression level over the course of treatment course, the pattern of miRNA 
expression is similar, though for miR-29a-5p (Figure 4.12 C), there is a marked up-
regulation in the Hui Chinese. 
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Figure 4-12. Plasma levels of miRNA from validation set divided according to ethnicity and disease state. The plasma of TB 
subjects was collected prior to the commencement of therapy (0 months) and at one, two and six months following treatment 
commencement. Plasma from matched healthy control individuals was collected at one time point. miRNA levels were examined by 
qRT-PCR with miR-93 used as a reference miRNA. Cohorts were separated according to ethnicity. In total there were 42 Han and 58 
Hui in the TB group and 46 Han and 54 Hui in the healthy control group. Each miRNA is presented in a separate column with Han in 
blue and Hui depicted in red. In four of the ten miRNAs measured there was significant variation between the miRNA expression of the 
Han and Hui healthy subjects (B, E, F, J). The overall trend of miRNA expression in TB subjects across the four time points was similar, 
however the degree of modulation varied between the two ethnicities. The relative expression of miRNAs was determined using 2(-
∆∆C(T)). Results are depicted with mean with 95% confidence intervals with significance calculated between healthy controls of the 
two ethnic groups and within the same ethnic group compared to healthy controls of the same ethnicity The differences between the 
healthy controls were calculated by a Student’s t-test with a p-value <0.05 deemed significant. Comparisons of variables between 
multiple groups were done using ANOVA. In instances where p-value was < 0.05, additional two-group comparison were done by a 
Student’s t-test. *p <0.05, **p <0.01, ***p <0.001.  
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4.3.3.3! Variation in miRNA expression according to gender 
We next examined if gender influenced miRNA expression. There have been no 
published reports in the literature regarding miRNA expression variability related to 
sex, however as miRNA quantification is a fairly new field we felt it important to 
determine if there were any significant variations. In the healthy control group there 
were 57 males and 43 females. In the TB cohort there were 58 males and 42 females 
(Table 4.1). A Student’s t-test was performed for each cohort with gender as the 
dichotomous variable with the results presented in Figure 4.13. Overall there is little 
variability between the male and females with more obvious variation being seen 
according to disease state (healthy or TB). miR-221-3p and -133a (Figure 4.13 E and 
I) showed significant variation within the TB cohort. This will need further 
clarification but may be due to confounding elements such as: other co-morbidities; 
timing of presentation to medical facility which may be different for males and 
females and may translate to later presentation for a particular sex with more 
advanced disease; and, smoking status, much more common in Chinese males, may 
also have a gender effect. All of these factors are likely to contribute to miRNA 
expression.  
 150 
 
Figure 4-13. Plasma miRNA expression in healthy controls and TB subjects 
prior to commencement of treatment stratified according to gender. Of the 100 
healthy controls there were 57 males and 43 females and in the TB cohort there were 
58 males and 42 females. Expression levels of plasma miRNAs were measured by 
qRT-PCR using miR-93 as a reference miRNA. The relative expression of miRNAs 
was determined using 2(-∆∆C(T)). Results are depicted with mean with 95% 
confidence intervals. The differences were calculated by a Student’s t-test with a p-
value <0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001.  
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4.4! Discussion 
TB remains a major global health problem, causing morbidity in millions of people 
each year. Urgent steps are needed to curtail these alarming figures. Such steps 
would include the development of new biomarkers that assist in disease diagnosis 
and that are able to predict with accuracy early treatment failure. These factors are 
important so as to provide prompt and effective treatment, thus limiting on-going 
disease transmission. New therapies are also required to treat those with both active 
disease and latent infection and more efficient ways are needed to evaluate new drug 
and vaccine development.  
 
With the aim of identifying diagnostic and predictive biomarkers in TB we examined 
the expression of 175 miRNAs in the plasma of 19 TB patients and 14 healthy 
controls from China by qRT-PCR. From the initial pilot study, we observed a total of 
87 significantly regulated miRNAs in TB patients; 18 up-regulated and 69 down-
regulated. To our knowledge, this is the first study that has detailed miRNA 
expression longitudinally. Subgroup analyses were performed to examine whether 
treatment outcome (success or failure), gender or ethnicity altered miRNA 
expression. Of the 100 patients enrolled into the study, 33% were diagnosed based 
on microbiological grounds, with the remainder diagnosed following clinical and 
radiological assessment.  
 
4.4.1! miRNA as a diagnostic biomarker 
A biomarker is a measurable indicator of a biological state, either normal or 
diseased. While a lot of research to date has focused on assessing the accuracy of a 
single biomarker, there is increasing interest in panels of biomarkers composed of 
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multiple candidates, in this case miRNAs, which when used alone are not adequately 
specific nor sensitive to allow clinical application, but when used in combination 
show good performance. Of the ten candidate miRNAs selected for further screening 
in this cohort of 100 patients with pulmonary TB and their matched healthy controls 
we found five miRNAs with significant variance. There were two significantly up-
regulated (miR-29a-5p and -99b) and three significantly down-regulated (miR-21-5p, 
-146a-5p and -652-3p). miR-29a-5p and -21-5p individually had the best sensitivity 
and specificity each with a ROC of 0.70. However, by performing a multivariate 
logistic regression and examining the ten miRNAs collectively, the sensitivity 
reached nearly 95% without compromising specificity, which was close to 89%. This 
then achieved an 88% positive predictive value and 95% negative predictive value. 
The results showed that a combination of miRNAs could discriminate pulmonary TB 
patients from healthy controls with an excellent sensitivity and specificity. 
 
The study of miRNAs as a potential biomarker is a relatively new field. Calculating 
appropriate sample sizes is difficult due to the large number of miRNAs often 
screened and the lack of knowledge about their various functions. Many studies that 
have examined miRNAs as biomarkers have used relatively small sample sizes. 
Wang and colleagues examined the expression of miRNA in PBMCs obtained from 
TB subjects and healthy controls with 29 TB subjects and 18 healthy controls 
enrolled into the study (Wang et al., 2011) and the study by Qi et al. that examined 
miRNA expression from the serum of TB patients had 30 TB subjects (Qi et al., 
2012). What became apparent from this study, was that even though the pilot sample 
examined miRNA expression in 19 TB patients and 14 healthy controls, of the ten 
selected miRNAs that had both significant p values (< 0.01) and fold changes of ≥ 
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1.5, only five of these miRNAs were significantly modulated in the treatment naïve 
TB subjects compared to healthy controls in the larger cohort study. This highlights 
the significant variation in miRNA expression that occurs as a result of normal 
human variance and demonstrates the importance of screening an adequate sample 
size to ensure that the findings that are made are true and representative of the target 
population.  
  
4.4.2! Functional assessment of modulated miRNAs 
Functions of many of the differentially expressed miRNAs are still largely unknown. 
Comparing findings from different studies can be problematic, even if samples are 
from the same tissue or cell type, due to variance in methodology including miRNA 
quantification techniques employed and normalisation strategies. Very few 
comparative studies have examined miRNA from blood samples and most miRNA 
studies that have examined miRNA expression in the setting of mycobacterial 
infection have utilised in-vitro models of infection, usually utilising macrophages 
from either patient samples or cell lines. Our study examined miRNA expression 
from the plasma of individuals with pulmonary TB. It is likely that the circulating 
miRNAs that were quantified reflect those not only secreted by macrophages but also 
from other cells, including platelets, dendritic and endothelial cells. Notwithstanding 
these limitations, we review the knowledge of the discordantly regulated miRNAs in 
the current literature. 
 
miR-29 has been shown in in-vitro as well as in clinical studies to be up-regulated in 
the setting of mycobacterial infection (Fu et al., 2011; Yi et al., 2012). Our study 
showed a greater than four-fold increase in miR-29 levels in those with TB compared 
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to healthy controls prior to the commencement of therapy. A study by Zhang et al., 
which measured the expression of miRNA in the serum of newly diagnosed TB 
patients also found elevated miR-29 levels in active TB patients before 
commencement of therapy (Zhang et al., 2013). Our study extends these findings and 
shows that miR-29 levels dropped markedly by one-month post initiation of therapy. 
Interestingly, patients who failed therapy had a smaller increase in miR-29 
expression compared to healthy controls initially but still recorded a small decline in 
miR-29 levels at one month. 
 
The decline in miR-29 expression noted in our study may relate to its functional 
effects. While the function of miR-29 is incompletely understood, studies have 
shown that miR-29 suppresses the immune response by directly targeting IFN-γ (Ma 
et al., 2011). miR-29 targets the 3’UTR of IFN-γ mRNA as well as enhancing the 
association between IFN-γ and Argonaute (AGO) 2 protein to form an RNA-induced 
splicing complex (RISC). This has the effect of supressing IFN-γ expression post-
transcriptionally (Ma et al., 2011). IFN-γ has an important role in activating the 
innate immune system in mycobacterial infection.  Knockdown mice deficient in 
miR-29 show a more potent TH1 adaptive response to intra-cellular mycobacterial 
infections with lungs from BCG-infected mice deficient in miR-29 showing less 
inflammation with less infiltrating polymorphonuclear cells than control mice (Ma et 
al., 2011). miR-29 has also been shown to target anti-apoptotic pathways, a 
mitochondrial pathway that involves myeloid cell leukaemia-1 (mcl-1) and B-cell 
lymphoma 2 (Bcl-2) (Xiong et al., 2009) highlighting its role in regulating apoptosis 
in immune cells. These functions of miR-29 may help to explain how M. 
tuberculosis is able to evade the immune system, it could be that up-regulation of 
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miR-29 may lead to inhibition of IFN-γ release and associated apoptosis of immune 
cells involved in the anti-tuberculosis response. 
 
The underlying mechanism by which M. tuberculosis infection leads to increase 
levels of miR-29a expression in human plasma is not yet known. Questions that 
remain unanswered include whether M. tuberculosis infection can directly up-
regulate miR-29a or if the host immune response generated following M. 
tuberculosis infection itself leads to increased levels of miR-29a or if it is a 
combination of both pathogen and host regulation that regulates this response.  
 
While IFN-γ is absolutely essential for protective immunity to M. tuberculosis 
infection, excessive IFN-γ can lead to damaging inflammation (Lin et al., 2013). 
Using a transgenic mice model in which IFN-γ is overexpressed, Shelton et al. 
showed that increased IFN-γ, led to necrotising inflammation within muscles 
(Shelton et al., 1999). Similarly though, mice deficient in IFN-γ also show increased 
inflammation (Chen et al., 2001). This serves to highlight the pleiotrophic nature of 
IFN-γ whereby it can heighten innate and adaptive immune responses and at the 
same time promote immune homeostasis. Therefore, regulating IFN-γ levels, in M. 
tuberculosis infection, is a key host response to ensure adequate macrophage 
activation without inducing excessive inflammation.  
 
This study found that miR-99b was also significantly elevated in the plasma of 
patients with TB. Whilst there have been no published studies reporting miR-99 in 
the plasma of persons with TB, Singh and colleagues noted up-regulation of miR-99 
in M. tuberculosis-infected dendritic cells (Singh et al., 2013). By utilising 
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antagomirs, Singh et al. performed loss-of-function experiments and found that 
inhibition of miR-99b resulted in enhanced clearance of the mycobacteria from 
infected dendritic cells. Associated with this was significantly up-regulated pro-
inflammatory cytokines such as IL-6, IL-12, IL-1β and TNF. These studies by Singh 
et al. then went on to demonstrate that miR-99b acts by targeting TNF mRNA. 
 
miRNAs act to regulate mRNA (Asirvatham et al., 2009; Lu et al., 2009), Singh et 
al. found that miR-99b binds to 3’UTR region of TNF mRNA and destabilises the 
transcripts thereby reducing TNF production (Singh et al., 2013). TNF plays a key 
role in controlling TB through the establishment and maintenance of the granuloma 
as well as directing inflammatory cells to the site of infection (Lin et al., 2007). 
Blocking TNF biosynthesis in human macrophages allows M. tuberculosis to evade 
host immune responses. Indeed, reactivation of latent TB infection is a major risk 
factor for individuals taking anti-TNF therapy, highlighting the importance of TNF 
and its regulation, in host immunity.  
 
This study is the first to demonstrate a significant down-regulation of miR-21 in the 
plasma of pulmonary TB patients compared with healthy controls. miR-21 has been 
shown to regulate multiple mRNAs and to be involved in progression of colorectal 
malignancy by reducing the expression of the tumour suppressor gene PDCD4 
(Peacock et al., 2014). Previous work has reported up-regulation in miR-21 levels in 
human PBMCs obtained from patients with TB compared to healthy controls (Wang 
et al., 2011). Indeed, our work as discussed in Chapter Five, which examined miR-21 
expression in M. tuberculosis infected macrophages, also noted significant up-
regulation. It can be speculated that this apparent dichotomy reflects the exquisite 
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cell type-specific nature of miRNAs. miR-21 has been shown to inhibit pro-
inflammatory cytokine production and at the same time enhance the anti-
inflammatory cytokine, IL-10 (Sheedy et al., 2009). In M. bovis infection of murine 
dendritic cells and macrophages, miR-21 was up-regulated through various pathways 
including Erk and NF-ĸB (Wu et al., 2012). Furthermore, miR-21 was found to 
impair T cell responses and protective immunity and directly stimulate IL-12 and 
Bcl-2 mRNA resulting in increased antigen presenting cell apoptosis (Wu et al., 
2012). Up-regulation of miR-21, as noted in macrophage studies, may therefore 
protect the host from excessive inflammatory response, whereas by down-regulating 
levels of miR-21 in the plasma the host may prevent the reduction in T cell responses 
resulting in potent anti-mycobacterial immunity.  
 
Another of the miRNAs that was found to be markedly down regulated in the plasma 
of the TB patients was miR-146a, indeed this was the most down regulated miRNA 
measured in the plasma of TB patients during treatment. miR-146 is an early-
response miRNA induced by various microbial components and pro-inflammatory 
mediators (Taganov et al., 2006; Fu et al., 2011). In the first published study that 
examined circulating miRNAs as potential biomarkers in TB, Fu et al. reported 92 
miRNAs that were significantly regulated (Taganov et al., 2006; Fu et al., 2011; 
Hassan et al., 2012). One of the miRNAs significantly regulated was miR-146 which 
was down-regulated in the sera of TB patients as compared with their matched 
healthy controls. Similarly, our study also observed significantly down-regulated 
levels of miR-146 in TB patients from plasma samples. The biological function of 
miR-146 as a negative regulator of inflammation has been extensively studied. miR-
146 has been shown to directly target the 3’UTR of TNF receptor-associated factor 6 
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(TRAF-6) and IL-1 receptor-associated kinase 1 (IRAK-1) and its down-regulation is 
thought to initiate the inflammatory response (Taganov et al., 2006; Hassan et al., 
2012). Conversely, a study by Perry et al. found that while up-regulation of miR-146 
resulted in increased expression of pro-inflammatory chemokine IL-8, this was 
independent of TRAF-6 and IRAK-1 (Perry et al., 2008), indicating there are 
additional mechanisms of action of miR-146 that are still to be identified. These 
functional studies have shown the pivotal role that miR-146 plays in regulating 
severe inflammation during the innate immune response such as what occurs 
following TB infection. Notwithstanding inflammation being an essential component 
of the immune response, if it remains unregulated it can lead to serious disease in the 
host. 
 
In our study we observed the progressive down-regulation of miR-26a-5p. 
Kleinsteuber and colleagues also recently noted down-regulation of miR-26a in 
whole blood from children with TB compared to healthy children with LTBI. miR-
26a release from TH1 cells from the same individuals was also down-regulated 
(Kleinsteuber et al., 2013). Interestingly a recent study by Ni et al. examined the 
expression of miR-26a in primary human macrophages infected with M. tuberculosis 
and found significant up-regulation in infected cells (Ni et al., 2014). This again 
serves to highlight the variability of miRNA expression noted with different cell 
types and conditions studied (in vivo and in vitro models) compounded by the 
varying techniques employed to quantify their expression. Ni et al. utilised miRNA 
mimics to induce miR-26a expression and discovered that it acts as a negative 
regulator of macrophage function through IFN-γ which effectively acts to limit the 
immune response as well as tissue damage to lung parenchyma (Taganov et al., 
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2006; Ni et al., 2014). Conversely, down-regulation, we can deduce, would have the 
opposite effect with increasing levels of IFN-γ inducing cytokine and chemokine 
release effecting a potent anti-microbial immune response.  
 
We also observed a significant down-regulation in miR-652 prior to the 
commencement of anti-tuberculosis therapy. There have been no published studies 
that have specifically examined miR-652 in the plasma from patients with active TB. 
Fu et al. examined miRNA expression in CD4+ T cells from individuals with latent 
and active TB. In this study miR-652 was significantly up-regulated in the TB group 
(Fu et al., 2014). Contra to these findings, a study by Roderburg et al. found that 
stimulating U937 cells with LPS led to significant down-regulation of miR-652 
levels (Roderburg et al., 2012). The function and putative targets of miR-652 have 
yet to be defined, the Targetscan® predictive software identified only 8 predictive 
targets of miR-652 and further work is required to determine how miR-652 may be 
influencing immunity to M. tuberculosis infection. 
 
4.4.3! miRNA timecourse 
A hypothesis that was explored in this thesis related to miRNA expression over the 
course of treatment. We postulated that miRNA expression would return to levels not 
dissimilar to healthy controls with treatment. This was the first study, to our 
knowledge, that had examined miRNA longitudinally over the course of therapy. 
 
As we hypothesised, miR-99b-5p which was initially significantly up-regulated 
returned to levels equivalent to healthy controls within a month of starting anti-
tuberculosis chemotherapy. miR-29a-5p also returned to normal baseline, however 
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this did not occur until the six-month mark, although the levels were falling 
significantly following the commencement of therapy. What was interesting and 
somewhat unexpected was the profile of the remaining discordantly regulated 
miRNAs.  
 
miR-21-5p and -652-3p were significantly down-regulated and remained so with 
little variation throughout the duration of therapy. miR-146a-5p and -26a-5p, which 
were also down-regulated in the plasma from TB patients, were even further down-
regulated over the course of therapy. The reasons for these findings are unclear. 
Perhaps the persistent down-regulation of miR-146a-5p may be a protective measure 
to control for the possible deleterious effects of an unregulated inflammatory 
response and may counteract the effects of the pro-inflammatory effects thought to 
be associated with down-regulation of miR-21a-5p and -26a-5p. Another explanation 
may be that the miRNAs remained down-regulated due to on-going lung 
inflammation and parenchymal re-modelling that accompanies resolving pneumonic 
infection.  
 
As the function and targets of miR-652 are yet to be explored, the reason for its 
persistent down-regulation are unclear.  
 
It was hypothesised that the expression of miRNAs in individuals that failed therapy 
would differ both from those that succeeded and from healthy controls. To better 
explore this we stratified according to treatment outcome (defined as sputum 
positivity at six months or failure to reduce lung inflammation). By virtue of the 
modest sample size of 11 treatment failures, it is difficult to draw conclusions when 
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examining miRNA expression according to outcome, especially in the small 
treatment failure group. Nonetheless the data demonstrates a number of interesting 
trends in miRNA expression when stratifying according to treatment outcome. 
Overall, miRNAs that were down-regulated in TB infection tend to be more 
significantly down-regulated in those patients classified as treatment failure. In 
general, however the miRNA expression pattern that was seen during the treatment 
course followed a similar pattern between those that were successfully treated to 
those who inevitably failed therapy. 
 
We postulated that the expression of miRNAs could act as a determinant of treatment 
outcome, and clinically this would be most important early in the treatment phase, as 
it would allow modification of therapy for those who are failing treatment. This 
would limit the ongoing transmission of the infection to others and would halt the 
propagation of drug resistance in an already failing therapy. It is not clear from the 
analysis of data collected from this study, if the miRNAs measured could be 
successfully used to delineate those that will fail treatment from those that will not. 
There are a number of factors that need considering: for example, of the 11 patients 
that were deemed to have failed therapy, we are unaware as to the reason they did 
not respond to the treatment prescribed. There are a number of possibilities including 
that the individual was infected with a drug-resistant organism significant enough to 
not respond to standard therapy. In those persons, we would anticipate early miRNA 
expression differences between TB patients. The second possibility is that the 
individual developed drug resistance at some stage during their treatment. This later 
development of drug-resistance may have arisen secondary to non-adherence of 
therapy, intermittent dosing of antibiotics or even malabsorption of medications. 
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What is also unclear is the potential role of other factors that may have impacted 
miRNA expression such as intercurrent illness of enrolled subjects, duration of 
illness prior to enrolment, and smoking history. All of these factors would need to be 
addressed and a larger cohort of patients enrolled in order to determine whether 
miRNA expression patterns could be used successfully as a predictor of treatment 
outcome. However, from these data there was significant differential expression of 
miRNAs in patients that ultimately failed treatment compared with those that were 
cured. We observed considerable variation in expression of miR- 21-5p, -29a-5p, -
221-3p, -146a-5p, -26a-5p, -133a and-652-3p, all of which were more down-
regulated in the treatment failure group. This supports the notion that miRNAs could 
be used in the clinical setting to determine likelihood of treatment outcome. 
 
4.4.4! Ethnic variation in miRNA expression 
The use of miRNA as a clinical biomarker and diagnostic tool has been actively 
investigated, particularly over the last decade. Little work however has focused on 
possible genetic variability. As described in Chapter Three, when we sought to 
identify suitable reference miRNAs for plasma studies in TB subjects, we observed 
quite significant variability between the Chinese cohort (Hui Chinese) and the 
Australian cohort (numerous ethnic backgrounds). This study presented a unique 
opportunity to explore the possibility of ethnic variation influencing miRNA 
expression in two distinct ethnic groups within China, the Han and the Hui Chinese.  
 
We observed four miRNAs (miR-99b-5p, -221-3p, -146a-5p and -652-3p) that were 
significantly differentially expressed in the healthy control subjects based on 
ethnicity. We also noted differences in miRNA expression in the TB subjects, even 
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though the overall trend of expression (either up- or down-regulated) was similar. A 
recent study by Rawlings-Goss utilising whole genome sequencing also observed 
variation in miRNA expression among African and non-African persons in the 
setting of malignancy (Rawlings-Goss et al., 2014). Overall the researchers found 
that miRNA sequences were similar across the sampled populations, however they 
did observe differences in 33 variances that occurred in more than a single person, 
with some being population specific. This finding may help to explain the disparity 
observed with regards to survival rates of certain malignancies of the same stage and 
grade that are noted in persons of different ethnic backgrounds (Aizer et al., 2014). 
Although the miRNAs examined by Rawlings-Goss were different to the miRNAs 
studied in this body of work, ethnicity may influence susceptibility or response to 
therapy in TB.  
 
Another recent study by Chang and colleagues also noted variation in miRNA 
expression that was associated with ethnic origin (Chang et al., 2014). The authors 
noted the six-fold increased likelihood of type-2 diabetes mellitus in Han Chinese 
compared with the Kazak Chinese. Utilising qRT-PCR, Chang et al. observed a 
three-fold increase in miR-375 levels in the Han Chinese. These findings further 
support our findings that miRNA expression levels are influenced by ethnicity. 
 
With regards to our study, there are other factors that may have contributed to the 
differences in miRNA expression observed between the two ethnic groups. Overall 
the Hui Chinese are poorer and are more likely to work in agricultural subsistence 
farming, meaning that they are often living further away from urban areas thus 
limiting their access to medical services. Living in rural areas, away from medical 
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facilities compounded by poverty, means that the Hui Chinese may be more likely to 
seek medical attention later during the course of illness and are therefore more likely 
to have more advanced disease at the time of diagnosis compared to the urban 
dwelling and wealthier Han Chinese. More advanced TB is likely to be accompanied 
by a heightened inflammatory response within the lung parenchyma, which may 
influence miRNA expression. With regards to the healthy controls’ variation in 
miRNA expression, this may relate to such factors as co-morbid conditions, smoking 
rates and general health, all of which are also likely to be affected by socioeconomic 
status. 
 
Other variability, not studied here, relates to actual functional roles of miRNA. 
Zhang et al. discovered single nucleotide polymorphisms (SNPs) within precursor 
miRNAs that were associated with susceptibility to pulmonary TB in Chinese Uygur, 
Kazak and Southern Han populations (X. Zhang et al., 2015). SNPs of precursor 
miRNAs can alter miRNA processing and expression and they may also contribute to 
the development or the progression of the disease. Therefore, not only are the 
expression of miRNAs different in different ethnic groups, there also appears to be 
functional differences of miRNAs that in some cases are secondary to inheritable 
SNPs. 
 
This study has shown significant variability between the two ethnic populations. This 
may be due to inheritable differences in miRNA expression. These differences may 
also or alternatively be secondary to environmental, socioeconomic factors or may be 
secondary to other factors such as co-morbid illness or disease. Future studies to 
further examine the role of ethnic variation are needed. 
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4.4.5! Next steps 
The aims of this study did not extend to examine miRNA targets and ultimately 
determining their function. This however, is the logical next step for this project. 
Independent of the platform utilised or the statistical analyses performed, the end 
point of all global miRNA expression profiling is a list of differentially expressed 
miRNAs. The function of any given miRNA is determined by the genes that it 
ultimately targets. Having an understanding of the genes targeted by specific 
miRNAs is important as it provides a better understanding of the pathophysiology of 
the disease and also opens up the possibility of directed and targeted therapies via the 
manipulation of specific miRNAs. In Chapter Five, where we profile miRNA 
expression in M. tuberculosis infected macrophages in an in vitro environment, we 
will discuss the ways to explore miRNA function through molecular and 
computational methodologies with the aim of identifying miRNA targets.  
 
4.4.6! Identifying and overcoming limitations of study 
4.4.6.1! Effect of haemolysis on miRNA expression 
In the pilot study, increased variation in miR-23a and miR-451 were used as markers 
of haemolysis and this method is supported by the literature (Kirschner et al., 2011). 
Plasma samples for the validation set were only visually inspected for haemolysis, 
however no further steps were taken to ensure haemolysis of the sample had not 
occurred. The impact of haemolysis on miRNA expression has been well 
documented in the literature (Kirschner et al., 2011; Blondal et al., 2013; Köberle et 
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al., 2013), however it has not often been considered in other studies (Mitchell et al., 
2008; Blondal et al., 2013; W. Zhang et al., 2014). In addition to visual inspection, 
samples can be inspected by spectrophotometry, with A414 > 0.2 (absorbance peak 
of haemoglobin) and additional at peaks 541 and 576nm (Kirschner et al., 2011). 
Future studies are required to determine if haemolysis is having any impact on the 
miRNAs being measured. 
 
4.4.6.2! Identifying those with LTBI 
Our studies involved collecting plasma from individuals with newly diagnosed 
pulmonary TB and their matched healthy controls and comparing miRNA expression 
both prior to treatment outcome and then over the course of treatment for the TB 
cohort. We noted significant variation in some miRNA expression both at the time of 
diagnosis and also during treatment. TB is endemic in China and given the 
worldwide estimate that one in three has LTBI (World Health Organization, 2014), it 
is highly likely that many of the persons in the healthy control group had LTBI. This 
was not assessed as part of healthy control recruitment. It is unclear what effect 
LTBI has on miRNA expression. Future studies that screen all healthy controls for 
LTBI and then incorporate this group as a third arm of the study would be helpful to 
determine if miRNA expression is affected by latent infection with M. tuberculosis. 
 
4.4.6.3! Measuring healthy controls subjects at more than one-time point 
Limited by budgetary constraints, we screened the healthy controls at only one-time 
point. It would have been very informative to screen the healthy controls at the same 
four time points as the enrolled TB subjects. Currently it is not known what normal 
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fluctuation occurs in miRNA expression as part of normal and healthy variance. 
Certainly though, if only examining at Time Point A in the TB patients, it is clear 
that some of the miRNAs are significantly different in the TB population with 
excellent sensitivity, specificity, negative and positive predictive values, making 
them a plausible diagnostic marker. 
 
4.4.6.4! Explore the role of ethnicity in miRNA expression 
There appeared to be variation in miRNA expression that was related to ethnicity. As 
mentioned above, there are many confounding factors, most notably socioeconomic 
status and poverty, which may have contributed to this variability. To explore this 
further, a more detailed questionnaire enquiring about co-morbid illness, duration of 
illness prior to seeking medical attention, smoking status, as well as collecting 
information about socioeconomic issues, would be helpful. If taking all of these 
factors into consideration, a larger cohort would be required to give the study 
suitable power to detect if differences in miRNA expression can be used as a 
biomarker of active TB disease. 
 
4.4.6.5! Gain a better understanding of the miRNA expression in treatment failure 
and treatment success patients  
Being able to detect treatment failure early is very important, not only for the 
individual but for the greater community. Unless current therapy is adjusted, 
amplification of drug resistance is likely to occur, leading to greater morbidity and 
even mortality for the individual and prolongation of therapy using agents with 
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greater toxicity. Compounding this is on-going transmission of potential drug-
resistant M. tuberculosis to the community. 
 
Our results were promising, however, due to the small number of patients who were 
deemed to have failed treatment, it is hard to draw any conclusions. A larger study 
cohort would likely increase the number of patients in the treatment failure arm. 
Better case definition that allows stratification of treatment failures based on 
aetiology would also be helpful. Reasons that patients fail treatment are varied and 
are likely to affect miRNA expression. Such factors would include: infection with a 
drug-resistant organism; acquired drug-resistance (usually due to poor compliance); 
and, co-morbid illness such as HIV (Dooley et al., 2011; Jibrin et al., 2012). 
 
4.4.6.6! Exploring the expression of miRNA in other lung infections 
Our study consisted of two groups, those with active TB and those who were healthy. 
The diagnostic dilemma often with TB is being able to differentiate it from other 
pneumonic infections (Storla et al., 2008). Radiologically both pneumonic infections 
secondary to M. tuberculosis, or other pathogens, can look identical, with similar 
symptoms (McAdams et al., 1995; World Health Organization, 2014). M. 
tuberculosis is usually more insidious in nature, however, particularly in the setting 
of immune-compromise, TB presenting in a similar fashion to other pneumonic 
infections is not uncommon (Levy et al., 1987; Kunimoto et al., 2005; Nyamande et 
al., 2007). Being able to differentiate M. tuberculosis infection from other causes of 
pneumonic infection is very important, as the treatments are vastly different, utilising 
different therapies with very different duration of treatment (Kunimoto et al., 2005). 
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Future studies examining miRNA expression in not only TB but other pneumonic 
infections are required.  
4.4.6.7! Examining miRNA expression in extra-pulmonary TB 
Extra-pulmonary TB was not studied as part of this study. It would be interesting to 
profile miRNA expression in this subset of M. tuberculosis disease. It would be most 
interesting to determine if miRNA expression was different and was instead more 
closely aligned with the tissue/organ involved.  
 
4.4.6.8! Discordant results between similar studies 
There have been several studies that have examined extracellular circulating 
miRNAs from M. tuberculosis-infected individuals and controls, however common 
biomarker candidates have not been identified. There are several reasons why this 
may have occurred including; heterogeneous study design with inconsistent 
definitions of cohorts; varying profiling techniques yielding different expression 
profiles; lack of consistent normalizing strategies; significant inter-individual 
variability confounded at times by small study group sizes; and, other confounding 
factors which are not accounted for such as ethnicity, socioeconomic status and co-
morbid conditions that may impact miRNA expression. To improve this, future 
biomarker studies should aim to define the criteria for disease more stringently and 
focus on well-defined study groups, such as LTBI with a known index case and have 
more standardized analysis and data evaluation. 
 
This body of work has identified a number of miRNAs that were significantly 
regulated in pulmonary TB. Used in combination, these miRNAs give both an 
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excellent sensitivity without compromising specificity that enables differentiating 
those with pulmonary TB from those who are healthy with a good degree of 
accuracy. This is the first study, to our knowledge, that has examined miRNA 
expression longitudinally. Our findings were not as expected as miRNA expression 
did not always return to healthy baseline with treatment. This serves to highlight the 
current gaps in knowledge pertaining to miRNA functionality and purpose. We also 
noted varying miRNA expression with treatment outcome, either success or failure, 
and even though our cohort of treatment failures was small, it is encouraging that 
perhaps miRNAs could be utilised early during TB management as a biomarker to 
predict treatment outcome. As has been found in a few studies, we also found 
significant variation between the two ethnic populations, both in the healthy controls 
and the active TB group. Whilst some of these differences may be attributable to 
socio-economic differences between the groups, there may also be an inheritable 
difference in miRNA expression. This may translate to certain populations being 
more susceptible to TB and furthermore their immunological response to TB 
infection may be different. 
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5! M. TUBERCULOSIS INFECTION IN 
MACROPHAGES 
5.1! Introduction 
Alveolar macrophages are the first cell type from the innate immune system to 
encounter the bacterium and they provide the first line of defence against the 
invading pathogen. As M. tuberculosis is an intracellular pathogen, following its 
phagocytosis by macrophages, its ability to survive and replicate is dependent on a 
degree of tolerance from the host immune system (Aderem et al., 1999). 
 
Augmentation of the host transcriptome occurs as a response to the encounter 
between M. tuberculosis and host macrophages (Ehrt et al., 2001) and is triggered by 
pattern recognition receptors. As a result, numerous pro-inflammatory mediators 
such as chemokines and cytokines are released that aid the antigen-specific acquired 
immune response to the pathogen. However, tight regulation of host cellular immune 
pathways needs to occur to prevent an excessive and inappropriate inflammatory 
response that causes host tissue damage (Ehrt et al., 2001).  
 
Previous work has shown the important role that miRNAs play in modulating 
immune responses (Asirvatham et al., 2009; Oglesby et al., 2010). Their ability to 
tightly modify and calibrate key immune responses forms a critical part in the 
immune pathway. Recent attempts have been made to determine the effects that M. 
tuberculosis infection has on the expression of miRNA in the host (Wang et al., 
2011; Fu et al., 2011). However, there are limited studies that have explored the 
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effect that M. tuberculosis infection has on host macrophages. Schnitger et al. 
examined the role of miRNAs in other intracellular pathogens, namely Listeria 
monocytogenes (Schnitger et al., 2011). The authors found significant regulation of 
miRNAs that specifically target macrophage-innate immune response at post-
transcriptional levels.  
 
There has been much effort recently to understand the role of miRNAs in innate 
immunity and macrophage inflammatory response. Identifying key miRNAs 
involved in M. tuberculosis infection will help gain a better understanding of its 
pathogenesis, and may identify miRNAs as targets for new therapies.  
 
Here we explore miRNA expression in human macrophages infected with M. 
tuberculosis with the following hypothesis and aims. 
 
HYPOTHESIS 
M. tuberculosis infection modulates miRNA expression in infected macrophages 
resulting in varying expression of inflammatory cytokines. 
 
AIMS 
1.! To identify key miRNAs released by macrophages during M. tuberculosis 
infection. 
2.! To determine if miRNA changes are reflective of inflammatory cytokine 
expression. 
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5.2! Methods 
5.2.1! Human macrophages infected with M. tuberculosis or stimulated with 
LPS 
Primary human monocytes were isolated from freshly collected buffy coats from six 
healthy voluntary blood donors (Australian Red Cross Blood Service, Sydney, 
Australia) as described in Section 2.2.1 of the Materials and Methods. Monocytes 
were plated at 1 x 106cells/well and differentiated into macrophages as described in 
Section 2.2.1 of Materials and Methods, with 18 wells in total.  
 
On day five, 100 units of interferon-γ (Sigma-Aldrich) were added to each well. On 
day six, six wells per donor were infected with H37Rv M. tuberculosis at a 
multiplicity of infection (MOI) of 1, six wells were treated with 100 ng/mL 
lipopolysaccharide (LPS) (Sigma-Aldrich) and the remainder were 
uninfected/untreated controls. LPS is known to induce transcription of genes that 
drive pro-inflammatory regulators of the immune response (Hambleton et al., 1996) 
and it has been extensively used in models studying inflammation as it induces many 
inflammatory cytokines such as TNF-α, IL-1β and IL-6 (Ngkelo et al., 2012). Cells 
and supernatant were collected from half of the total wells at six-hour post-infection 
time point with the remainder harvested at the 24-hour time point. Triplicate samples 
were assayed for colony forming units (CFU). Culture medium was removed and 
cells lysed with Triton X-100 lysis buffer (Sigma-Aldrich). Serial dilutions of the 
bacterial suspensions were plated (three replicates for each dilution) on Middlebrook 
7H10/OADC agar plates. CFUs were counted after 21 days of incubation at 37°C.  
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5.2.2! RNA extraction and quality control 
RNA was isolated using Trizol as described in Section 2.3.2 of Materials and 
Methods, and concentration and quality were determined by NanoDrop 2000 
Spectrophotometer (Thermo Scientific) as described in Section 2.4.1 of Materials 
and Methods.  
 
5.2.3! qRT-PCR 
100 ng of total RNA was reverse-transcribed using All-in-One miRNA first cDNA 
synthesis kit (Gencopoeia) as described in Section 2.4.5 of Materials and Methods.  
 
Based on current literature and results obtained examining the expression of miRNA 
from the plasma of M. tuberculosis patients from the Chinese cohort (Chapter Four), 
the expressions of seven miRNAs (miR-99b, miR-7a, miR146a, miR-21, miR-221, 
miR-26, and miR-29) were examined in macrophages infected with M. tuberculosis 
or stimulated with LPS and compared to uninfected/untreated macrophages. RNU6 
was used to normalise the data. 
 
5.2.4! Cytometric bead array 
Cytokines, interleukin (IL)-1β, IL-6, IL-8, macrophage inflammatory protein (MIP)-
1α, tumour necrosis factor (TNF)-α, and interferon-γ-inducible protein (IP)-10, were 
quantified simultaneously using a human chemokine CBA Kit (BD Biosciences), as 
described in Section 2.4.1 of Materials and Methods. 
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5.2.5! Data analysis 
5.2.5.1! miRNA array 
miRNA expression data were imported into Partek Genomics Suite (Partek, St Louis, 
MO) as CEL files. Version 2.0 and Version 3.0 Affymetrix chips were analysed 
separately. Principal-component analysis was performed to identify outliers and to 
evaluate whether study date or individual variation affected the result.  
 
5.2.5.2! miRNA array validation with qRT-PCR 
Data were analysed using SDS Relative Quantification Software Version 2.3 with 
automatic baseline (3-15 cycles) and threshold (0.2) settings for quantification cycle 
(Cq) determination. The threshold cycle Cq is defined as the fractional cycle number 
at which the fluorescence passes the fixed threshold (0.2). The mean Cq values for 
duplicate wells were then calculated. 
 
5.2.5.3! qRT-PCR 
qRT-PCR data were analysed using SDS Relative Quantification Software Version 
2.3. For CBA, individual cytokine concentrations were indicated by their fluorescent 
intensities (Fl-2) and were computed using the standard reference curve of 
CELLQUEST and CBA software (BD Biosciences). 
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5.2.6! Statistical analysis 
5.2.6.1! miRNA array 
The differences in miRNA expression based on disease status were analysed by 
Student’s t-tests for comparison of two groups and Wilcoxon rank-sum test for multi-
group comparisons. P-values below 0.05 were considered significant. Differential 
expression analysis was performed using one-way analysis of variance (ANOVA). 
5.2.6.2! qRT-PCR 
The 2(-∆∆C(T)) method was employed to analyse the relative changes in miRNA 
expression from qRT-PCR. The difference in miRNA expression was analysed by 
Student’s t-tests for comparison of two groups in GraphPad Prism 6 (Graphpad 
Software Inc., San Diego, CA, USA). 
5.2.6.3! CBA 
The statistical significance of findings pertaining to cytokine expression measured 
from the supernatant of M. tuberculosis-infected and uninfected macrophages were 
determined by Wilcoxon rank-sum test using GraphPad Prism (Graphpad Software 
Inc.).  
 
5.3! Results 
5.3.1! miRNA array 
With the aim of identifying novel miRNAs and to gain a better understanding of the 
macrophage inflammatory response to M. tuberculosis infection we initially began 
our work utilising miRNA microarrays. Microarray technology is a powerful high-
throughput tool capable of monitoring the expression of thousands of miRNAs at 
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once and in parallel. It can be used to quantify differences in the abundance of, in 
this case, miRNA (also DNA and RNA) between two different entities (for example, 
one which is infected with M. tuberculosis and the other which is not). It has been 
extensively used and validated to examine expression of miRNA of normal and 
diseased samples, such as malignancy, and to distinguish expression signatures 
associated with diagnosis, prognosis and therapeutic interventions (Zhang et al., 
2008; Baffa et al., 2009; Ueda et al., 2010). 
 
Six samples of human monocyte-derived macrophages with and without infection 
with M. tuberculosis were tested on miRNA arrays. Two different versions of 
microarray chips (GeneChip® miRNA 2.0 and GeneChip® miRNA 3.0 [Affymetrix]) 
were used to measure miRNA expression. The results from the microarrays were 
analysed using Genomics Suite® Software (Partek). The current software does not 
allow microarray chips from different versions to be analysed concurrently. For this 
reason, analysis was undertaken separately for Version 2.0 and Version 3.0 
microarray chips. In total, RNA from two donors was loaded onto Version 2.0 
microarray chips and RNA from four donors was loaded onto Version 3.0 microarray 
chips. 
 
There was a marked variation in the expression profile of miRNA between samples 
from different individuals when comparing infected versus uninfected macrophages. 
From principal component analysis the expression profile for miRNAs was more 
closely aligned for an individual, rather than for comparison of infected and non-
infected miRNA expression for all donors (Figure 5.1). This is likely to be 
representative of normal human variance. For this reason it was decided to study the 
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variance of miRNA expression in each subject and then determine if there were any 
miRNAs commonly modulated across the donors. Differential expression analysis 
was performed using one-way analysis of variance (ANOVA) with infection as a 
variance. Gene lists were created using a cut-off of two-fold change (either two-fold 
increase for up-regulation or two-fold decrease for down-regulation) (Table 5.1).  
 
Examining the results of Version 3.0 microarray chips (total of four donors), 
comparing miRNA expression from infected and uninfected macrophages, there 
were no miRNAs that had a fold change of greater than two in all four samples. 
However there were several miRNAs that were common to three donors. Lists of 
these miRNAs are given with their corresponding fold change in Table 5.1 (up-
regulated miRNAs) and Table 5.2 (down-regulated miRNAs). 
 
Examining the list of miRNAs up-regulated greater than two-fold from Version 2.0 
microarray chips, there were two miRNAs (miR-1246_st and miR-125-3p_st) that 
were also up-regulated greater than two-fold in three of the four RNA samples 
infected with M. tuberculosis analysed on Version 3.0 microarray chips. There was 
one greater than two-fold down-regulated miRNA (miR-324-3p_st) from Version 2.0 
microarray chips that was common to three of the four donors from Version 3.0 
microarray chips. 
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Figure 5-1. Principal component analysis (Version 3.0 microarray chips). 
miRNA expression was measured from PBMCs from four donors which were then 
either infected with M. tuberculosis, or uninfected controls, using microarray. Each 
colour corresponds to a different donor. The close proximity of both spheres of the 
red and purple donors suggests that there is minimal detectable difference between 
their miRNA expression in the infected and uninfected PBMCs. There was no clear 
cluster of infected and uninfected chips demonstrating quite distinct miRNA 
expression in each donor. 
 
Table 5-1. Up-regulated miRNAs in human macrophages infected with M. 
tuberculosis.  
miRNA& Fold&Change&Donor&1&
Fold&Change&
Donor&2&
Fold&Change&
Donor&3&
Fold&Change&
Donor&4&
4532_st& 7.58% 2.43% 2.50% 1.47%
1246_st& 7.22% 2.71% +1.24% 25.77%
125a<3p_st& 2.69% 3.37% 1.03% 3.03%
193a<3p_st& 2.76% 2.30% 0.68% 5.37%
3135b_st& 6.69% 2.43% 0.81% 3.00%
3178_st& 26.32% 3.03% 0.74% 19.28%
3197_st& 61.73% 5.47% 1.98% 44.19%
4484_st& 34.10% 6.75% 0.61% 77.36%
U41_x_st& 6.28% 1.66% 7.82% 2.52%
3613<5p_st& 16.62% +3.42% 2.87% 2.11%
940_st& 2.85% 1.55% 3.99% 5.12%
miRNA expression from monocyte-derived macrophages infected with H37Rv M. tuberculosis at 
MOI 1 compared with no infection control, analysed with Affymetrix miRNA microarray.  
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Table 5-2. Down-regulated miRNAs in human macrophages infected with M. 
tuberculosis. 
miRNA Fold Change Donor 1 
Fold Change 
Donor 2 
Fold Change 
Donor 3 
Fold Change 
Donor 4 
324-3p_st -2.71 -1.03 -4.55 -2.85 
3911_st -19.32 1.63 -10.52 -2.11 
425-star_st -3.61 -1.56 -30.96 -2.32 
4743_st -6.71 1.17 -4.93 -2.39 
574-3p_st -3.12 -1.00 -6.24 -2.08 
339_st -1.38 -2.27 -2.10 1.20 
85-26_st -1.99 -2.25 -2.32 -2.26 
miRNA from PBMC derived macrophages infected with H37Rv M. tuberculosis at 
MOI 1 compared with no infection control, analysed with Affymetrix miRNA 
microarray. 
 
5.3.2! Validation 
To assess the reliability of the data between the two different chip versions miRNA 
expression from the same donor was measured using both Version 2.0 and Version 
3.0 chips. There was a large difference in miRNA expression across the majority of 
miRNAs measured (Figure 5.2). It was clear that some miRNAs that were up-
regulated in one chip were down-regulated in the other, despite loading identical 
RNA from the same donor. Technical quality control was satisfactory for both 
microarray chips. 
 
To assess further the reliability of the array data presented, the relative expressions of 
three miRNAs (miR-155, miR-146a and miR-29a) were measured. These miRNAs 
were selected because even though they did not feature in the arrays as being 
significantly modulated, previous work that we have undertaken had shown their 
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significant modulation with infection. Furthermore, they are frequently found in the 
literature to be regulated in M. tuberculosis infection (Fu et al., 2011; Wu et al., 
2012; Kleinsteuber et al., 2013). 
 
qRT-PCR was performed on the RNA samples using TaqMan® PCR Kit as described 
in Section 2.3.4 of Materials and Methods. In four of the five donors the expression 
of miR-146a between the array and qRT-PCR was conflicting. For example, Donor 
One had an approximately six-fold increase in miR-146a expression as measured by 
qRT-PCR, whereas the microarray reported a downregulation of miR-146 (Figure 
5.3 A). Similar discordant results were observed with miR-155 and miR-29a (Figure 
5.3 A, B).  
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Figure 5-2. miRNA fold change from human macrophages infected with H37Rv M. tuberculosis measured by microarray. Two 
different versions of the Affymetrix microarray chips (Version 2.0 and 3.0) were used to quantify miRNA expression from identical 
RNA samples. There was marked variation in miRNA expression. The miRNAs shown here are a sample of the 1105 (Version 2.0) and 
1693 (Version 3.0) miRNAs, which showed similar variation.  
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Figure 5-3. Validation of microarray results by qRT-PCR for selected miRNAs. 
Fold change in miRNA in M. tuberculosis infected samples with respect to 
uninfected samples for five donors as measured by microarray and qRT-PCR. There 
is clear difference in the expression profile in four out of five miRNA for miR-146 
(A) and -155 (B) and all six donors for miR-29a (C). 
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 184 
Numerous studies exist in the literature, which have profiled miRNA expression 
utilising microarrays with concordant qRT-PCR results (O'Connell et al., 2007; 
Singh et al., 2013). However, we found that our microarray results could not be 
verified with qRT-PCR. Furthermore, identical RNA from the same donor loaded 
onto different microarray chips yielded different results.  
 
Due to the unreliability of the data obtained, miRNA expression was examined by 
qRT-PCR as detailed below.  
 
5.3.3! miRNA expression in M. tuberculosis infected macrophages 
The expression of seven miRNAs in human monocyte-derived macrophages infected 
with M. tuberculosis, activated by LPS, or uninfected was examined from six donors. 
These miRNAs were chosen due to their significant regulation in the Chinese cohort 
(Chapter Four) or their reported regulation during M. tuberculosis infection (Wang et 
al., 2011; Fu et al., 2011; Yi et al., 2012). To better understand the complexity and 
variability of miRNA expression, we examined miRNA expression at two time 
points: six- and 24-hours after infection. All miRNAs were normalised to RNU6. 
Mean raw Cq values together with the range of all miRNAs are given in Table 5.3.  
 
RNU6 was abundantly and consistently expressed across all samples, and there was 
no statistically significant variability in Cq values across the three conditions, 
making it a suitable reference miRNA (Table 5.3 and Figure 5.4 H). As would be 
expected, all Cq values for the seven miRNAs in uninfected macrophages at six- and 
24-hours of culture were similarly expressed and within one cycle of each other 
(Table 5.3). When normalised to RNU6, there was no statistically significant 
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variability in the seven miRNAs between the uninfected samples at the six- and 24-
hour time points (Figure 5.5). 
 
5.3.3.1! Growth of M. tuberculosis bacterial populations 
Growth of M. tuberculosis within the macrophages was assessed after six and 24 
hours of infection. CFU assays were performed manually following a 21-day 
incubation. For dilutions of 1:10-1 and 1:10-2, CFUs were too numerous to count; at 
dilutions of 1:10-3 and 1:10-4, linear CFU counts were noted. 
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Table 5-3. Expression levels of miRNAs as measured by qRT-PCR. 
miRNA&
Cq&Mean&(range)&
UI&6h&
Cq&Mean&(range)&
UI&24h&
Cq&Mean&(range)&
M.#tb&6h&
Cq&Mean&(range)#
M.#tb&24h&
Cq&Mean&(range)&
LPS&6h&
Cq&Mean&(range)&
LPS&24H&
let(7! 16.2(14.3(21.5)+ 15.4(13.3(19.2)+ 15.2(12.5(18.3)+ 16.2(13.1(21.8)+ 15.6(14.2(17.5)+ 15.4(13.0(17.3)+
miR;146a& 27.9(24.5(35.8)+ 26.8(23.3(32.6)+ 23.1(19.1(27.5)+ 25.1(22.0(34.0)+ 24.5(21.0(30.2)+ 25.4(22.8(29.5)+
miR;21& 14.0(11.7(16.3)+ 13.5(10.5(15.3)+ 12.2(9.8(13.6)+ 11.0(8.2(15.3)+ 12.7(10.1(14.7)+ 11.7(9.9(13.6)+
miR;221& 20.3(17.7(24.2)+ 20.3(17.0(23.9)+ 21.3(18.2(25.0)+ 24.7(20.4(31.7)+ 23.3(18.8(25.4)+ 24.1(20.9(25.7)+
miR;26& 16.6(14.7(21.0)+ 16.1(14.5(20.2)+ 18.5(15.8(22.0)+ 20.2(17.9(29.3)+ 18.2(15.5(22.2)+ 18.2(15.4(22.3)+
miR;29& 16.0(14.6(18.9)+ 16.0(14.6(18.8)+ 14.0(12.4(18.1)+ 13.7(12.3(16.5)+ 14.8(13.1(16.6)+ 14.3(12.9(16.1)+
miR;99b& 26.4(23.9(28.9)+ 26.3(23.3(29.6)+ 22.9(21.1(25.0)+ 22.2(19.9(31.9)+ 23.3(19.0(26.1)+ 26.5(24.3(28.6)+
RNU6& 18.0(15.7(22.0)+ 18.0(15.8(21.3)+ 18.3(15.7(21.8)+ 19.1(15.3(31.1)+ 18.1(15.5(21.6)+ 17.9(15.8(21.0)+
Raw data presented as mean of triplicate for all 6 donors. miRNA, microRNA; Cq, Quantification of cycle; UI, Uninfected; M. tb, Mycobacterium tuberculosis; 
LPS, Lipopolysaccharide; 6h, 6 hours of incubation; 24h, 24 hours of incubation. 
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Figure 5-4. Expression levels of eight miRNAs in M. tuberculosis infected and 
uninfected macrophages. Expressions of miRNAs in monocyte-derived 
macrophages from six donors were measured in triplicate by qRT-PCR using 
RNU6B as a reference miRNA. The relative expression of miRNAs was determined 
using 2(-∆∆C(T)). Results from each donor are depicted in a different colour. Bars 
indicate mean with 95% confidence intervals. The differences were calculated by a 
Student’s t-test with a p-value <0.05 deemed significant. *p <0.05, **p <0.01, ***p 
<0.001, ns= not significant. UI, uninfected; M. tb, Mycobacterium tuberculosis.  
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Figure 5-5. Expression levels of eight miRNAs in uninfected macrophages. 
Expression of miRNA in monocyte-derived macrophages from six donors was 
measured in triplicate by qRT-PCR using RNU6B as a reference miRNA. The 
relative expression of miRNAs was determined using 2(-∆∆C(T)). Results from each 
donor are depicted in a different colour. Bars indicate mean with 95% confidence 
intervals. The differences were calculated by a Student’s t-test with a p-value <0.05 
deemed significant. ns= not significant. UI, uninfected.  
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5.3.3.2! M. tuberculosis-infected macrophages determined by qRT-PCR 
Examining the miRNA expression of M. tuberculosis infected macrophages and 
comparing it to uninfected macrophages, all of the miRNAs examined showed 
significant altered regulation, though at varying time points. Fold change and 
probability values for each miRNA examined at the varying time points are 
presented in Table 5.4. 
 
All except miR-221 and let-7 were significantly differentially regulated at six hours 
post M. tuberculosis infection (Table 5.4 and Figure 5.4 [B and E]). Of the 
significantly regulated miRNAs, only miR-26 was down-regulated. All of the others 
(miR-99b, -146a, -21, and -29a) showed significant up-regulation with miR-146 and 
-99b having the most significant fold change (Table 5.4 and Figure 5.4 [A and C]). 
 
Results indicate that miR-99, let-7 and miR-21 (Figure 5.4 and 5.6 [A, B and D]) 
were up-regulated since six hours post-infection with increased expression of these 
miRNAs over time. Whereas miR-146a up-regulation peaked at six hours and 
seemed to be trending back down towards uninfected levels of expression at 24-hour 
time point, though the variation between the six- and 24- hour expression was not 
significant (Figure 5.4 and 5.6 [C]). 
 
miR-221 and -26 had the greatest down-regulation at 24 hours post infection (Figure 
5.4 [E and F]). miR-221 was found to be not significantly different at the 6-hour time 
point. It is clear from examining the data represented in Figure 5.4 (E) and Figure 5.6 
(E) that there seems to be considerable variability between infected donors at this 
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six-hour time point, with some donors (as depicted in red) up-regulated at this time 
point and others (as depicted in orange) down-regulated. At the 24-hour time point 
though, all donor expression of miR-221 is significantly down-regulated. This 
highlights individual variability that is often seen when examining human 
macrophages from different donors when compared with examining cell lines where 
variability is minimal.  
 
When examining the mean miRNA expression for each donor at the varying time 
points in M. tuberculosis infected and uninfected samples, the expression of some 
miRNAs show a consistent pattern across all six donors (Figure 5.6). miR-99b 
(Figure 5.6 [B]) was found to be clearly up-regulated in all six donors following six 
hours of infection and then was further up-regulated at 24 hours post infection. miR-
146a was up-regulated early at six hours but then was seen to be reduced in five of 
the six donors at 24 hours, though not to the levels seen in the uninfected controls 
(Figure 5.6 [C]). miR-21 and -29 demonstrate up-regulation in all donors at six hours 
and then further up-regulation in most donors at 24 hours (Figure 5.6 [D and E]). For 
miR-26 all donors show down-regulation at six hours post infection with further 
significant down-regulation at 24 hours (Figure 5.6 [F]). 
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Table 5-4. miRNA expression in M. tuberculosis infected or LPS stimulated in 
human macrophages as compared with uninfected macrophages. 
miR$ Condition$ Fold$Change$ p$value$
99b$ M.#tb!6h! 2.22! 0.113!
$ M.#tb!24!h! 127.23! <!0.001!
$ LPS!6h! 17.55! <!0.001!
$ LPS!24!h! 2.86! 0.037!
let$7a' M.#tb!6h! 2.22! 0.113!
$ M.#tb!24!h! 3.75! 0.030!
$ LPS!6h! 1.58! 0.328!
$ LPS!24!h! 1.08! 0.799!
1468a$ M.#tb!6h! 30.52! <0.001!
$ M.#tb!24!h! 28.44! 0.037!
$ LPS!6h! 14.43! 0.017!
$ LPS!24!h! 4.26! <!0.001!
21$ M.#tb!6h! 4.39! <!0.001!
$ M.#tb!24!h! 24.81! <!0.001!
$ LPS!6h! 2.82! <!0.001!
$ LPS!24!h! 5.64! <!0.001!
221$ M.#tb!6h! 0.84! 0.358!
$ M.#tb!24!h! 0.13! <!0.001!
$ LPS!6h! 0.35! <!0.001!
$ LPS!24!h! 0.14! <!0.001!
26$ M.#tb!6h! 0.37! <!0.001!
$ M.#tb!24!h! 0.22! <!0.001!
$ LPS!6h! 0.40! <!0.001!
$ LPS!24!h! 0.31! <!0.001!
29$ M.#tb!6h! 7.38! !0.007!
$ M.#tb!24!h! 15.04! <!0.001!
$ LPS!6h! 3.44! <!0.001!
$ LPS!24!h! 3.32! !0.002!
miR, microRNA, M. tb, Mycobacterium tuberculosis; LPS, lipopolysaccharide; 6h six hours; 24h, 24 
hours 
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Figure 5-6. Change in miRNA expression measured at six- and 24-hours of 
incubation. Macrophages were inoculated with MOI 1, cultured for six or 24 hours 
as indicated, harvested and RNA isolated using Trizol. miRNA expression was 
measured by qRT-PCR in triplicate from each of the six donors. The relative 
expression of miRNA was determined using 2(-∆∆C(T)) and are presented as fold 
change. RNU6 was used as the reference miRNA. The average of miRNA expression 
for each donor is presented here with individual donors represented by a different 
colour. UI, uninfected; M. tb, Mycobacterium tuberculosis.  
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5.3.3.3! Macrophages stimulated with LPS  
LPS has been widely used to mimic bacterial infections, including M. tuberculosis 
infection in the in-vitro model (Ngkelo et al., 2012). It is well known and understood 
that LPS induces many cytokines and chemokines that are important in controlling 
M. tuberculosis infection and initiating the adaptive immune response (Rossol et al., 
2011). It is for this reason that we chose to explore miRNA expression during LPS 
stimulation.  
 
As with M. tuberculosis infected macrophages, there was significant regulation of 
miRNAs following LPS stimulation, however there were some notable differences. 
miR-99b was again up-regulated following six-hour LPS stimulation, however the 
fold change was not as marked as macrophages infected with M. tuberculosis, 
likewise macrophages stimulated with LPS were not as significantly up-regulated at 
the 24- hour time point (Table 5.4 and Figure 5.7 [A]).  
 
A similar pattern of miRNA regulation was noted with miR-146a, -21, -221, -26 and 
-29 in both the M. tuberculosis and LPS models, however the degree of modulation 
was far less in the LPS stimulated macrophages (Table 5.4 and Figure 5.7 [C-G]). 
Interestingly, let-7, which was shown to be significantly up-regulated by more than 
four-fold during M. tuberculosis infection following 24-hour incubation, was not 
significantly modulated during LPS stimulation. Examining the individual donors in 
the LPS model reveals that let-7 expression is more variable than was seen in the M. 
tuberculosis infected macrophages at the six-hour time point, suggesting a more 
variable individual response to LPS stimulation. 
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Figure 5-7. Expression levels of eight miRNAs in LPS-stimulated and uninfected 
macrophages. Expression of miRNA in monocyte-derived macrophages from six 
donors was measured in triplicate by qRT-PCR using RNU6B as a reference 
miRNA. The relative expression of miRNAs was determined using 2(-∆∆C(T)). 
Results from each donor are depicted in a different colour. Bars indicate mean with 
95% confidence intervals. The differences were calculated by a Student’s t-test with 
a p value <0.05 deemed significant. *p <0.05, **p <0.01, ***p <0.001, ns= not 
significant. UI, uninfected; LPS, lipopolysaccharide. 
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5.3.3.4! Cytokine and chemokine examination in human macrophages infected with 
M. tuberculosis 
Six key inflammatory cytokines (Figure 5.8 [A-C]) and chemokines (Figure 5.8 [D-
F]): IL-1β; IL-6; TNFα; MIP-1α (CCL3); IL-8 (CXCL8); and, IP-10 (CXCL-10), 
were examined by cytometric bead array in supernatants obtained from M. 
tuberculosis-infected and -uninfected macrophages following 24-hour incubation for 
the same six donors. The mean concentrations of each cytokine in M. tuberculosis-
infected and -uninfected macrophages are presented in Table 5.5.  
 
Previous studies have demonstrated the crucial role that these cytokines and 
chemokines play in controlling M. tuberculosis infection (Lewis, 1990; Kaufmann, 
2002; Algood et al., 2004; Mootoo et al., 2009), however there is a paucity of 
literature examining their levels from M. tuberculosis-infected macrophages.  
 
There was a marked increase in all cytokines and chemokines levels in supernatants 
obtained from macrophages infected with M. tuberculosis across most donors (Figure 
5.8). The most marked increase was IL-8 and IP-10 from the supernatant of M. 
tuberculosis-infected macrophages (Figure 5.8 [E and F]). The IFN-inducible 
chemokine, IP-10, was increased in the supernatant from M. tuberculosis-infected 
macrophages in all six donors (Figure 5.8 [F]). IL-8, a pro-inflammatory cytokine 
secreted from macrophages, plays an important role in the innate immune response. 
It has been found to be significantly elevated in the supernatants of macrophages and 
in bronchial alveolar lavage fluid from persons with pulmonary TB compared to 
healthy controls (Y. Zhang et al., 1995; Friedman et al., 2009). Four of the six donors 
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had increased levels of IL-8 during infection, however donors D and F had lower 
levels in the supernatants from M. tuberculosis-infected macrophages. Interestingly, 
donors D and F also demonstrated much higher levels of IP-10 in the supernatant 
from uninfected macrophages than all other donors. It may be that the supernatant for 
these donors was inadvertently contaminated or that the donor was suffering from an 
inflammatory illness at the time of blood donation, however, with only a small 
sample size and without any further medical information, it is difficult to draw any 
conclusions. 
 
Levels of IL-1β (Figure 5.8 [A]), IL-6 (Figure 5.8 [B]), TNF-α (Figure 5.8 [C]), and 
MIP-1α (Figure 5.8 [D]) were all markedly increased in the supernatants of M. 
tuberculosis infected macrophages.  
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Table 5-5. Mean concentrations of cytokines in macrophages with and without 
M. tuberculosis infection. 
! UI!Mean!(SD)!
(pg/mL)!
M.#tb!mean!(SD)!
(pg/mL)!
p!Value!
ILB1β! 0(0)! 58!(60.5)! <!0.0001!
ILB6! 1893(3360.3)! 11467(1560.2)! <!0.0001!
TNFα! 49(116.3)! 5067(4948.1)! <!0.0001!
MIPB1α! 1396!(3284.2)! 13133(3442.4)! <!0.0001!
ILB8! 28300(22364)! 58214(42188.0)! ns!
IPB10! 6343(6624.3)! 18044(3554.6)! <!0.0001!
UI, uninfected; M. tb, Mycobacterium tuberculosis; SD, standard deviation; IL, interleukin; TNF, 
tumor necrosis factor; MIP, Macrophage inflammatory protein; IP, Interferon-γ-inducible protein; 
pg/mL, pictograms per millilitre; ns, not significant. 
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Figure 5-8. Cytometric Bead Array measuring cytokine levels from 
supernatants from H37Rv-infected and -uninfected macrophages collected at 24 
hours post infection from six donors. Each biological sample had three replicates. 
Mean concentrations are given (pg/mL) with standard error. UI, uninfected; TB, 
H37Rv M. tuberculosis infection. 
 
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
50
100
150
200
250
pg
/m
L 
(M
ea
n+
/-S
EM
)
A B C D E F
A. IL-1β
Condition
Donor
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
5000
10000
15000
C. TNFα
A B C D E F
Condition
Donor
pg
/m
L 
(M
ea
n+
/-S
EM
)
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
50000
100000
150000
pg
/m
L 
(M
ea
n+
/-S
EM
)
A B C D E F
E. IL-8
Condition
Donor
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
5000
10000
15000
A B C D E F
B. IL-6
Condition
Donor
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
5000
10000
15000
20000
25000
A B C D E F
D. MIP-1α
Condition
Donor
UI TB  UI TB  UI TB  UI  TB  UI  TB UI TB
0
5000
10000
15000
20000
25000
F. IP-10
A B C D E F
Condition
Donor
 199 
 
5.4! Discussion 
miRNAs are non-coding RNAs that are emerging as key players in regulating gene 
expression. Our understanding of their role in the innate immune response and their 
ability to orchestrate cytokine and chemokine release is currently limited (O'Connell 
et al., 2007; Welker et al., 2007; Asirvatham et al., 2008). A greater understanding of 
their role in the immune response to M. tuberculosis infection has the potential to 
lead to new, targeted therapies through drug and vaccine development. Macrophages 
are the first immune cells to encounter M. tuberculosis and they are considered to 
play a key role in protecting the host by a means of phagocytosis and mycobacterial 
killing, as well as induction of the inflammatory cascade. Previous studies have 
shown that macrophages contribute to the immune response by modulating both 
cellular and humoral immunity, particularly through the synthesis and release of 
immunoregulatory cytokines and chemokines. There is also growing evidence that 
bacteria modulate immune responses by altering the expression of host miRNAs. Our 
study supports this concept, as it was evident that M. tuberculosis infection altered 
the expression of both miRNAs and cytokine production in human macrophages.  
 
Initially this study measured miRNA expression using high throughput microarray 
technology, with the aim of identifying novel miRNAs that were regulated during in 
vitro M. tuberculosis infection. An essential component of this technology however, 
is to verify findings with qRT-PCR. Not only did the qRT-PCR data not correlate 
with the microarray data, but identical RNA from the same donor loaded onto two 
different microarray chips also demonstrated discordant results. It was therefore 
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concluded that the microarray results were unreliable for this purpose. Others have 
also reported problems with microarray accuracy; Kothapalli et al. examined the 
accuracy of several different microarray platforms and, among other things, found 
significant discrepancy in fold-change across the varying platforms (Kothapalli et al., 
2002). Sato et al. compared repeatability and comparability across five different 
microarray platforms (including Affymetrix) and similarly found significantly poor 
inter-plate concordance, highlighting the problems of current miRNA microarray 
platforms (Sato et al., 2009). It has been suggested that the development of a set of 
commercially available standard miRNAs or samples would be helpful as it would 
allow comparison between different results from miRNA profiles (Cummins et al., 
2006) thus overcoming some of the current difficulties encountered by this 
technology.  
 
At the commencement of this study there was a paucity of published works that 
examined the role of miRNAs in not only mycobacterial infections but also 
infections in general. The emphasis of work that had been published at the time was 
primarily examining the role of miRNAs in malignancy. We had aimed to identify 
regulated miRNAs by utilising high-throughput technology. However, as this was 
not possible we then examined miRNAs which we had shown to be regulated in the 
plasma of patients with M. tuberculosis (Chapter Four), many of which had also been 
shown to be modulated in the literature. 
 
This investigation studied the expression of seven miRNAs (miR-99b, -146a, -21, -
221, -26, -29a and let-7) from human peripheral monocyte-derived macrophages 
from six donors, which were experimentally infected with M. tuberculosis, 
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stimulated with LPS, or used as uninfected baseline controls; RNU6 was utilised to 
normalise the qRT-PCR data. miRNA expression profiles were measured at both the 
six- and 24-hour time-point. This study has identified significant modulation of all 
seven miRNAs analysed during both M. tuberculosis infection and LPS stimulation 
of human macrophages. The pattern of expression, although not as significantly 
regulated, was similar in the LPS model and is concordant with most of the current 
literature that has examined macrophage-miRNA expression in the setting of 
infection or other inflammatory conditions (Taganov et al., 2006; Sheedy et al., 
2009; J. Sharbati, et al., 2011a; Singh et al., 2013; Furci et al., 2013; Das et al., 
2013). 
 
When examining the expression of miR-99b, we found a marked and statistically 
significant up-regulation, especially in the M. tuberculosis model. This mirrored the 
results of our plasma study as described in Chapter Four. Similarly, Singh et al. 
found that the expression of miR-99b was highly up-regulated in murine 
macrophages infected with H37Rv M. tuberculosis. The authors also found that 
knockdown of miR-99b resulted in up-regulation of cytokines such as IL-1β, IL-6 
and TNF (Singh et al., 2013). In our study, however we found a noticeable up-
regulation of these cytokines in the setting of miR-99b up-regulation. The varying 
cytokine expression noted in this study may be due to the influence of other miRNAs 
on cytokine expression. This highlights the complexity of the innate and adaptive 
immune system and serves to highlight the need for a better understanding of the 
biological function of these miRNAs. 
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The miR-146 family comprises of two members: miR-146a and miR-146b. Our 
study of M. tuberculosis-infected human macrophages observed significant up-
regulation of miR-146a that peaked at six hours post infection. Findings were similar 
in the LPS stimulated macrophages, however the degree of up-regulation was not as 
great.  
 
Taganov and colleagues first reported that miR-146 modulates macrophage function 
and showed that it is a negative regulator of NF-ĸB activation. NF-ĸB plays a critical 
response in controlling host response to infection (Brasier, 2006).They also showed 
that in THP-1 cells, a human macrophage-like cell line, LPS stimulation resulted in 
the up-regulation of miR-146a. miR-146a expression peaked at around eight hours 
following LPS induction, after which its levels plateaued (Taganov et al., 2006). 
Similarly, this study found the highest expression at the earlier, six-hour time point. 
Human monocyte-derived macrophages from patients with Mycobacterium avium 
complex (MAC), which is less pathogenic than M. tuberculosis, have also been 
found to have increased expression of miR-146 (J. Sharbati et al., 2011). In an in 
vitro infection of macrophages with MAC, miR-146a was induced shortly after 
infection and showed slightly increased expression up to 48 hours post infection. 
These results differ from our findings, in that miR-146 reached maximum expression 
at the six-hour time point, however this may relate to the degree of pathogenesis of 
the mycobacterial species, with the less virulent MAC resulting in different miR-146 
expression. Alternatively, it may be connected to the complexity and interdependent 
nature of miRNA expression in diseased states. 
 
 203 
Interestingly, we observed down-regulation of plasma-derived miR-146a in patients 
with pulmonary TB compared to healthy controls (Chapter Four). Up-regulation of 
miR-146a, as observed in M. tuberculosis-infected macrophages, has been shown to 
result in a decreased inflammatory response with decreased levels of pro-
inflammatory cytokines and down-regulation of TRAF6, IRAK1 and IRAK2 and 
NF-κB (Sharma et al., 2015). Conversely down-regulation of miR-146a has been 
shown to initiate an inflammatory response (Taganov et al., 2006; Hassan et al., 
2012). Inflammation plays a critical role in host defence against invading microbial 
pathogens. The discrepancy in miR-146a expression between plasma and 
macrophages may be a result of the fine balance and orchestration of the innate 
immune system to limit the deleterious effects to host tissue of persistent 
inflammation. It may also represent manipulation of cellular miR-146a by M. 
tuberculosis to augment cellular inflammatory response in order to create a 
favourable cellular environment for the bacteria’s survival.  
 
Our study has shown that miR-21 is induced by both M. tuberculosis infection and 
LPS stimulation of macrophages. A study by Wang and colleagues examined 
macrophages obtained from patients with proven M. tuberculosis and compared the 
expression of several miRNAs to healthy subjects. Similar to our findings, miR-21 
was also significantly up-regulated in the macrophages obtained from the TB 
subjects (Wang et al., 2011). It has been previously shown that LPS stimulation of 
macrophages induces miR-21 which indirectly results in the production of IL-10 
(Sheedy et al., 2009b). Although not studied here, IL-10 has been found to be 
increased during M. tuberculosis infection and it has been proposed that IL-10 is 
linked with the ability of M. tuberculosis to evade host immune responses, possibly 
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by inhibiting the formation of the phagolysosome (Redford et al., 2011). Our results 
demonstrate that there is increased macrophage miR-21 expression over time 
following both infection with M. tuberculosis and stimulation with LPS. This aligns 
with findings from Sheedy and colleagues who found miR-21 expression in 
RAW264.7 cells, a murine leukaemic monocyte-macrophage cell type, increased 
over time when stimulated with LPS.  
 
miR-21 was one of the first mammalian miRNAs identified. Despite this, there has 
been no published work that has examined the function of miR-21 in infection. Most 
work to date has examined the role of miR-21 in malignancy with more recent work 
examining its role in cardiac disease (Papagiannakopoulos et al., 2008; Dong et al., 
2009; Patrick et al., 2010; Zheng et al., 2011). More work is needed to uncover the 
functional role of miR-21 in M. tuberculosis infection.  
 
This study observed significant down-regulation of miR-221 in both M. tuberculosis 
infection (at 24 hours post infection) and with LPS stimulation (at six and 24 hours 
post incubation) which is consistent with findings from Furci and colleagues who 
found miR-221 was down-regulated in response to M. tuberculosis infection of 
macrophages and also down-regulated in response to less the virulent M. bovis (Furci 
et al., 2013). Stimulating THP-1 cells with LPS, Gazzar et al. observed early up-
regulation in miR-221 levels, which is in opposition to this study’s findings of 
significant down-regulation of miR-221 stimulated with LPS at the six- and 24-hour 
time points (Gazzar et al., 2010). The mechanism of action of miR-221 is not clear. 
However a study by Lu et al., which examined the effects of miR-221 on human 
monocytes-derived dendritic cells found that silencing miR-221, using knockdown 
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probes, resulted in increased apoptosis of dendritic cells (Lu et al., 2011). Down-
regulation of miR-221, as was observed in this study, may be a protective effect to 
limit dendritic cell apoptosis and enhance the innate response to M. tuberculosis 
infection. 
 
The area of miRNA research is in its infancy and, as such, little is known about the 
role and function of many miRNAs including miR-26. TargetScan® analysis of 
potential binding sites of miR-26 identified over 1000 conserved sites, including a 
number of known immune genes and kinases to name a few. This study observed 
significant down-regulation with both M. tuberculosis infection and LPS stimulation. 
Further studies are required to identify the key mRNAs targeted by miR-26 and to 
determine if down-regulation of this miRNA provides a survival advantage for the 
M. tuberculosis bacilli or is advantageous for the host response to M. tuberculosis 
infection.  
 
miR-29a is known to control adaptive immune responses to bacterial infections by 
targeting IFN-γ (Ma et al., 2011). Studies demonstrated that miR-29a directly targets 
the 3’UTR of IFN-γ mRNA leading to suppressed IFN-γ production (Ma et al., 
2011). IFN-γ plays a critical role in host defence against M. tuberculosis. In addition, 
several studies have reported that miR-29 also targets anti-apoptotic proteins such as 
Bcl-2 and Mcl-1 thus demonstrating another important role that miR-29 has in 
regulating the apoptotic pathway in immune cells (Park et al., 2008; Xiong et al., 
2009). 
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This body of work has shown significant up-regulation of miR-29a during both M. 
tuberculosis infection and LPS stimulation of human macrophages as well as from 
human plasma from patients with active TB compared to no infection. In the plasma 
from newly diagnosed TB subjects we observed a four-fold increase in miR-29a 
levels compared to their matched healthy controls. A study by Das et al. also 
observed modest up-regulation, with a 1.86 fold change in THP-1 cells infected with 
H37Rv M. tuberculosis compared to no infection (Das et al., 2013). Similarly, Fu et 
al. observed up-regulated miR-29 in the setting of M. tuberculosis infection with 
significantly increased levels found in plasma, serum and saliva of human subjects 
with the disease compared to healthy subjects (Fu et al., 2011; Yi et al., 2012). 
Interestingly though, research examining miR-29 in other intracellular infections 
have reported significant down-regulation in murine macrophages when infected 
with L. monocytogenes (Ma et al., 2011). Overexpression of miR-29 in M. 
tuberculosis infection may explain one mechanism by which M. tuberculosis is able 
to evade macrophage digestion by inhibiting the secretion of IFN-γ, which is 
essential to fully activate infected macrophages.  
 
The down-regulation of let-7 in the setting of infection and inflammation is well 
documented (Rijavec et al., 2014) (Pandit et al., 2010). However, few studies to-date 
have examined the expression of let-7 in M. tuberculosis-infected macrophages. 
Furci and colleagues observed a reduction in let-7 expression from monocyte-derived 
macrophages infected with M. tuberculosis (Furci et al., 2013). Sharbati however 
found increased expression of let-7e from human macrophages infected with M. 
avium. (J. Sharbati et al., 2011) Our findings also showed an increase (three-fold) in 
the expression of let-7a in the setting of M. tuberculosis infection, but interestingly 
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no significant change following LPS stimulation. Our findings, together with those of 
Sharbati et al. were in contradiction to these earlier studies and require further 
evaluation. Other factors that could possibly explain the conflicting results that need 
consideration include the complex interplay and effect of other miRNA modulation 
in the setting of M. tuberculosis infection with resultant cytokine and chemokine 
augmentation and the effect this has on let-7 expression.  
 
5.4.1! Future directions 
We have identified miRNAs that are modulated during in vitro M. tuberculosis 
infection of human macrophages. At the same time, we identified a number of key 
cytokines that are up-regulated during infection. The next step is to try to understand 
and determine the functions and targets of these miRNAs, and to gain a better 
understanding of the interrelation between miRNAs and the innate immune response. 
The reason for doing this is two-fold: firstly, it will allow a more detailed 
understanding of the pathogenesis and biology of disease; and, secondly it has the 
potential to represent a new class of directed therapeutics, which may yield patient 
benefits that are simply unattainable with current therapy.  
 
The cytokines measured during M. tuberculosis infection were all significantly up-
regulated. The association between miRNA and cytokine production and release is 
not well understood. What is apparent from the current literature is that a clear 
understanding of miRNA functions and their specific targets, especially in relation to 
infection and, more specifically, M. tuberculosis infection, is very limited. What is 
clear, however, is that miRNAs play a central role in modulating inflammatory 
responses and that manipulating miRNA expression has the potential to allow fine-
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tuning of the inflammatory response to the advantage of the host and detriment of the 
pathogen. What is also clear is that each miRNA has numerous mRNA targets. In 
order to achieve directed manipulation of the inflammatory response an intricate 
understanding of miRNA networks, and how they work collectively, is required. 
 
It remains challenging to identify the specific targets of any single miRNA. From the 
literature there are many conflicting reports as to the behaviour of many miRNAs in 
disease states. Some of this may be due to external factors such as the varying 
platforms used to quantify miRNA expression presenting different miRNA 
expression results. Certainly our study showed significant variation between 
miRNAs measured from the same RNA through microarrays and qRT-PCR. It is also 
likely to be due to the complex interactions and numerous targets that each miRNA 
has. One of the most interesting aspects of miRNA biology is that one miRNA can 
target multiple genes and a single gene can be targeted by multiple miRNA. 
Furthermore, there appears to be a lot of overlap with different miRNAs seemingly 
to serve the same purpose. However, this is likely to be a reflection of our very basic 
knowledge of how miRNAs function and there is likely to be combinations of 
complex specificity depending upon the situation. One aspect of this is that is 
appears that many of the functions of miRNAs are cell- or tissue-type specific (van 
Rooij, 2011). 
 
The recent exponential growth in miRNA research has given rise to computational 
and experimental ways to functionally analyse miRNA targets. Identifying miRNA 
targets is key as it opens the possibility of directed miRNA-based therapeutic 
modalities, potentially targeting one of the receptors of a miRNA, without limiting 
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its other functional effects. The current methods to determine miRNA targets are 
discussed below. 
 
5.4.1.1! Computational assessment of miRNAs targets 
Computational framework for the functional assessment of miRNAS is one of the 
common methods used to determine target genes for miRNAs. Each miRNA is 
estimated to target approximately 100-200 genes (Friedman et al., 2009). There are 
several algorithms that have been developed that act to predict the mRNA targeted 
by each miRNA. Fundamentally, for each miRNA a list of potential target sites is 
determined on the 3’UTRs of human gene-coding transcripts based on a search for 
complementary binding sites for the sequence of the seven-nucleotide “seed” region. 
The miRNA “seed” is defined as positions two to eight from the 5’end of the mature 
miRNA. There may also be additional criteria for target prediction depending on 
which computer-generated algorithm is used. The major problem with computational 
prediction is the often high rate of false positives that are generated. Computational 
prediction of targets for both individual miRNAs or clusters of miRNAs can be 
performed using open-access platforms such as miRanda, TargetScan, Diana microT, 
PicTar and miRDB as listed in Table 5.6. 
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Table 5-6. Algorithms for computational miRNA target prediction 
Algorithm$ Website$
Last$
Update$ References$
miRanda$ www.microrna.org! NovB10! (Enright!et!al.,!2003;!John!et!al.,!2004)!
TargetScan$ www.targetscan.org! JunB12!
(Lewis! et! al.,! 2005;! Friedman! et! al.,!
2009;!Garcia!et!al.,!2011)!
DIANA8
microT8CDS$
www.microrna.gr/microTB
CDS! JulB12!
(Maragkakis! et! al.,! 2009;! Reczko! et! al.,!
2012;!Paraskevopoulou!et!al.,!2013)!
PicTar$ pictar.mdcBberlin.de! MarB07! (Lall!et!al.,!2006)!
miR8DB$ www.miRdb.org! AugB2014! (Wong!et!al.,!2015)!
 
5.4.1.2! Predicting miRNA targets through experimental means 
There are several tools available to selectively target miRNAs pathways. The most 
widely used approach is to regulate and study miRNA functions by using anti-miRs 
or miRNA mimics. Anti-miRs (or antagomiRs) are modified antisense 
oligonucleotides that can reduce the endogenous levels of miRNAs. The fundamental 
principle characterizing anti-miRs is that they need to bind with high affinity and be 
very specific for the miRNA of interest (Bartel, 2009). miRNA mimic technology, as 
the name suggests, mimics endogenous miRNAs thereby increasing the translational 
repression of the gene targets of the specific miRNAs (Z. Wang, 2011). By either 
blocking or enhancing miRNA expression and then studying the downstream effect, 
investigators can determine the specific miRNA targets and their functional effects. 
 
Another approach used has been the development of genetic knockout mice. 
Knockout mice that lack key miRNA processing factors such as Dicer and Drosha 
are embryonically lethal (C. Y. Park et al., 2010). This highlights the crucial role that 
miRNAs play in early embryonic development. miRNA-mRNA interactions can be 
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studied using this model with observations from knock-out mice models showing in 
some cases profound physiological effects. However, in other cases studies have 
shown some miRNA functions overlap, resulting in redundancy with several related 
miRNAs targeting similar related proteins to exert their biological functions (Bartel, 
2009). One example of this knock-out model is with the well-studied miR-155. miR-
155 knockout mice (miR-155 -/-) have been found to be defective in both B- and T-
cell immunity. More recently it was shown that dendritic cells from miR-155 -/- mice 
were less apoptotic than those from wild-type mice leading them to be more efficient 
at antigen presentation (Rodriguez et al., 2007; O'Connell et al., 2010; Changming 
Lu et al., 2011). More efficient antigen presentation would favour the host response 
to M. tuberculosis infection as antigen presentation plays an important role in 
activating the adaptive immune response against M. tuberculosis (Sia et al., 2015). 
 
The other loss-of-function method for validating targeted genes is a method known 
as “sponging”. The “sponge” mRNA contains multiple target sites that are 
complementary to the miRNA of interest. Binding of the sponge mRNA to miRNA 
acts to inhibit the activity of a family of miRNA sharing common gene targets (Ebert 
and Sharp, 2010a; 2010b; Tay et al., 2015). Although no publish work exists that has 
examined this technology in infection, miRNA sponge has been used to examine the 
functionality of oncogenic miRNAs. Ma and colleagues examined miR-9 and its 
ability to regulate metastatic properties of breast malignancy (L. Ma et al., 2010). 
Inhibiting miR-9 by using a miRNA sponge in malignant cells was found to inhibit 
metastasis formation (L. Ma et al., 2010). These findings are important as they have 
the possibility of improving clinical management by the addition of directly targeted 
therapies against malignant disease and in the future infectious diseases such as TB. 
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miRNAs have numerous mRNA targets. For this reason, it may be advantageous not 
to target the miRNA itself but one or more of its predicted mRNA targets. The 
benefit of this has recently been shown by Gamble et al. where the authors were able 
to block one target of miR-27b, a vascular endothelial-specific cadherin, and by 
doing so demonstrate an essential role for miR-27a in angiogenesis in the setting of 
ischaemia (Young et al., 2013). Such technology not only improves our 
understanding of miRNA function but can also translate into new clinical application 
through targeted therapeutics. 
 
Innate immunity employs a multi-layered response to control M. tuberculosis 
infection. In recent years the recognition of miRNAs and their regulatory role has 
uncovered another layer to the orchestrated response to infection and also other 
inflammatory conditions including malignancy. Alveolar macrophages are the first 
cell types to encounter M. tuberculosis and are critical in the initial innate response to 
this infection. This study has observed specific induction of miRNAs following M. 
tuberculosis infection of human macrophages. Concurrently, we observed 
modulation of known critical inflammatory cytokines and chemokines during 
infection. Depending on whether a miRNA functions in a pathogenic or 
compensatory manner, miRNA antagomiRs, or mimics, could be used as very 
targeted and specific therapies. In addition, a better understanding of disease 
processes can be achieved by defining in more detail molecular mechanisms of 
disease processes. Deciphering the complex network and interplay of miRNA 
activities and interactions, particularly with regards to cytokine and chemokine 
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expression, is of great significance and clearly warrants further studies especially 
given their potential clinical applications. 
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6! FINAL DISCUSSION 
Tuberculosis remains one the world’s deadliest communicable diseases. In 2013, an 
estimated nine million people developed TB that resulted in 1.5 million deaths. 
Given the estimated two billion people currently infected with latent M. tuberculosis, 
there is a large reservoir of potential TB disease. In recent years, due to the 
development of drug-resistance, TB control efforts have taken on an increased 
urgency. The current approaches to preventing, diagnosing and treating TB are 
inadequate. Developing new biomarkers that are able to predict reactivation in the 
latently infected individuals, assist in the diagnosis of TB, identifying non-
responders to therapy, and act as a surrogate endpoint in drug and vaccine 
development, will advance steps towards better TB control. The results presented in 
this thesis serve as a foundation for further developments in the area of miRNA 
biomarkers.  
 
miRNAs are small non-coding RNAs that are remarkably stable in cell-free form and 
measurable from samples that are easily obtainable such as plasma. This makes them 
an ideal biomarker, as their use is feasible in all settings including resource-poor 
areas, where the majority of TB is found. These data have revealed evidence for the 
potential role of specific miRNAs to discriminate TB disease from healthy 
individuals. In addition, there is a growing body of scientific evidence implicating 
the central role of miRNAs in modulating the molecular mechanism underlying the 
pathogenesis of TB. Therefore an intricate understanding of the functions and targets 
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of miRNAs is imperative as it opens the possibility of manipulating miRNA 
expression as a new directed treatment strategy. 
 
miRNAs were first discovered in 1993 by researches screening for genes 
instrumental in the development of C. elegans (R. C. Lee et al., 1993). It was not 
until 2002 when Calin et al. reported the association between miRNAs and chronic 
lymphocytic leukaemia, that it became clear that there was a direct link between 
miRNA expression and malignancy (Calin et al., 2002). Since this landmark 
discovery, many researchers have identified abnormal miRNA expression in the 
setting of other malignancies, and more recently, other pathologies including 
inflammatory lung conditions such as asthma and chronic obstructive pulmonary 
disease as well as infectious diseases like tuberculosis (Pottelberge et al., 2011; C. 
Wang et al., 2011; Graff et al., 2012; F. Liu et al., 2012; Solberg et al., 2012; Miotto 
et al., 2013). Earlier studies focussed on a small numbers of miRNAs, this was 
mainly due to limited technologies available to enable high throughput analysis 
and/or the vast cost of using such high throughput technology. The number of 
miRNAs identified in human species continues to grow along with technologies that 
allow simultaneous profiling of many thousands of miRNAs at a more realistic cost. 
These factors mean that the number of miRNAs implicated in human disease will 
continue to increase substantially in the coming years.  
 
While single prognostic biomarkers may be useful, it is likely that a combination of 
validated biomarkers will provide more reliable information and enable better 
stratification of patients. Combining several miRNAs, together with other 
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inflammatory mediators, such as cytokines, may serve this purpose. Identifying 
biomarker signatures in the setting of malignancy have already been shown in the 
literature to be a good diagnostic tool and predictor of treatment outcome and 
survival. The potential for miRNAs in current diagnostics began with a study 
comparing miRNA expression using miRNA microarray in 205 primary malignant 
tumours 131 metastatic tumours from 22 different tumour origins (Rosenfeld et al., 
2008). A binary decision tree algorithm was developed that would help distinguish 
cell of origin in cancers with poor differentiation. Poorly differentiated malignancies 
are notoriously hard to trace to the cell of origin using current diagnostics. From this 
study, it was found that by utilising 48 miRNAs, cell of origin was able to be 
determined in nearly 90% of cases. Based on this study, and later similar studies, 
there now is an available panel using 64 miRNAs (miRview-mets2) manufactured by 
Rosetta Genomics available for clinical use (Mueller et al., 2011; Varadhachary et 
al., 2011). In addition to this panel, Rosetta Genomics also commercially produces 
miRNA signature panels to help distinguish the different types of lung cancers using 
eight miRNAs and to separate renal cancers into its four primary types (benign 
oncocytoma, renal cell carcinoma, papillary renal carcinoma and chromophobe renal 
carcinoma). All panels rely on binary tree classification as in the original paper by 
Rosenfeld et al. (Rosenfeld et al., 2008).  
 
In our work presented here, we have been able to demonstrate that combining ten 
miRNAs and examining their expression profile in those with TB disease compared 
with healthy subjects delivered both excellent sensitivity, specificity and predictive 
values far greater than comparing a single miRNA in disease versus healthy state. 
The next step would be to combine this panel of miRNAs with other known TB 
 217 
inflammatory makers, to determine if this further improves the diagnostic accuracy. 
A number of serum proteins have been implicated as possible biomarkers for 
diagnosis of active TB or for predicting the response to therapy. Cytokine profiles 
have been associated with TB disease and treatment response (Azzurri et al., 2005; 
Djoba Siawaya et al., 2009; Kabeer et al., 2011; Hong et al., 2012). In particular a 
number of studies have demonstrated higher levels of IP-10 (CXCL-10) in newly 
diagnosed TB patients compared to healthy controls with levels declining with anti-
tuberculosis chemotherapy (Goletti et al., 2010; Wergeland et al., 2015). 
Interestingly only one study by Azzurri et al. found that patients who showed a 
sustained decrease in IP-10 after two months of therapy went on to have successful 
cure, while no changes in IP-10 levels were observed in patients who failed treatment 
(Azzurri et al., 2005). Along with protein profiles, transcriptional responses in 
monocytes and in peripheral blood have shown distinct gene expression profiles 
associated with active TB (Berry et al., 2010; Chanyi Lu et al., 2011; Lesho et al., 
2011). Again type-1 IFN-related genes, including IP-10 were up-regulated in active 
disease compared to latent M. tuberculosis infection or uninfected healthy controls. 
Indeed a study by Berry et al., (Berry et al., 2010) found that expression profiles 
correlated with the radiological extent of disease and were able to discriminate 
between TB and other infectious pathogens. Other studies have found that these 
profiles change rapidly following effective treatment, even within the first two weeks 
(Bloom et al., 2012). It would be interesting to determine how the protein and mRNA 
profiles compared with the miRNA profile during TB and to determine if it was 
possible to identify a combined profile that had sufficient sensitivity and specificity 
to distinguish active TB disease from other infections or from latent TB and to 
predict outcome to therapy. Predicting responses to therapy has been made more 
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difficult with the increase in drug-resistant TB. Drug-sensitivity testing to determine 
resistance patterns in TB patients has its limitations: it requires reliable and reputable 
laboratories together with well trained and skilled staff to perform testing that is 
complex with results that can be delayed for six-to-eight weeks. During this time the 
patient is receiving inadequate therapy with the real risk of further resistance 
amplification and the on-going transmission of drug-resistant TB. It is for these 
reasons that new ways to diagnose and predict treatment outcomes are imperative in 
order to combat TB. 
 
Currently there are numerous studies underway using serum, plasma, whole blood, 
PBMCs and other bodily fluids to identify biomarkers that better predict outcomes of 
M. tuberculosis infection, and enable faster evaluation of new therapeutics and 
vaccines (Jacobsen et al., 2007; Wallis et al., 2010; Chanyi Lu et al., 2011; Phillips et 
al., 2012; Hong et al., 2012). There are however a number of challenges with 
developing new biomarkers. Biomarkers of treatment response, cure and relapse 
have been reported in the literature. These studies however invariably involved 
relatively small cohorts in geographically restricted areas. The variability not only in 
sampling material and technique but heterogeneity between individuals that are both 
intrinsic and also related to extrinsic factors such as living standards and 
socioeconomic status mean that extrapolating these results to the wider community 
has so far proved difficult.  
 
The possible bias introduced by using small sample sizes was highlighted by our own 
study. The ten regulated miRNAs chosen from the test set of 19 TB patients and 14 
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healthy subjects, were all significantly regulated with fold changes greater than 1.5. 
However in the larger validation set only five of the miRNAs were significantly 
regulated prior to the commencement of therapy. Many of the published data relating 
to miRNAs have reported findings based on sample sizes similar to our test set. 
Before any conclusions can be drawn from such studies, larger cohorts will need to 
be examined.  
 
As miRNA research is only in its infancy, little is known about intrinsic or 
environmental factors that may or may not influence their expression. Sub-group 
analyses from both Chapter Three and Four suggested that miRNA expression was 
possibly influenced by ethnicity and/or geographical factors. Other factors, that were 
not examined here nor have been reported in the literature, may also influence 
miRNA expression such as the timing of sample collection (there may be a diurnal 
difference in miRNA expression similar to what is seen with hormones such as 
cortisol), smoking history or even dietary factors. As a single miRNA can target 
multiple mRNA coupled with an overlap in function, other comorbid conditions are 
likely to influence miRNA expression. When considering a diagnosis of TB, it is 
often hard to discriminate TB from other inflammatory lung conditions such as other 
bacterial pneumonias. Accurate diagnosis is important as treatment is vastly 
different. Other inflammatory lung conditions may have similarity in their regulation 
of miRNA expression. In order to identify a unique miRNA expression profile 
specific to TB it is imperative that future studies enrol patients not only with TB but 
with other respiratory pathologies.  
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Co-infection with HIV and TB is a major problem, particularly in the African 
continent and studies are required to understand how co-infection modifies the 
expression of miRNAs and potentially other biomarkers in these individuals to 
determine if the same biomarker panel can be utilised to aid diagnosis of TB in 
individuals with or without concurrent HIV co-infection. Miotto and colleagues 
examined miRNA expression from the sera of patients with active TB and compared 
it to those with active TB whom were co-infected with HIV and found differential 
miRNA expression across the two groups (Miotto et al., 2013). This suggests that 
specific miRNA bio-signatures will need to be utilised in those with co-infection. 
Few studies have examined those with HIV and TB as a cohort, and more work in 
the future will be needed in this area, as TB still remains the major cause of death in 
those with HIV (World Health Organization, 2014). A diagnostic miRNA panel for 
HIV-TB co-infection is imperative as historically TB in those with HIV infection has 
been difficult to diagnose due to their often atypical presentation and paucibacillary 
disease, making culture identification of M. tuberculosis more difficult 
(Sreeramareddy et al., 2009).   
 
Another major comorbidity that increases an individual’s risk of developing active 
TB disease is diabetes mellitus. Diabetes triples the risk of developing TB and 
adversely affects disease presentation and treatment outcomes (Lönnroth et al., 
2014). As the prevalence of diabetes increases, it is likely that it will surpass HIV as 
the most significant risk factor for developing active disease (L. S. Geiss et al., 
2014). How diabetes effects the expression of miRNA during TB infection is largely 
unknown but is another compounding factor that needs to be addressed in devising 
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new biomarkers. 
 
As shown in the study reported here the size of the cohort measured is clearly an 
issue in confirming the reliability of the results. Other potentially confounding 
factors include the type of sample measured, when it is collected, the control cohorts, 
and the clinical data and length of follow up necessary to determine relapse rates. 
One way to address these possible confounding factors is to develop large and 
centralised bio-banks that allow collection and storage of bio-specimens, such as 
cells, plasma and sputum, with associated clinical data from large cohorts of patients 
that have had adequate follow-up so as to determine clinical outcome (cure, relapse 
or recurrent disease). International collaborative studies with the development of bio-
banks will allow standardized scientific techniques to be applied to stored clinical 
samples with adequate clinical data to allow stratification of subjects. Historically, 
one of the main factors impeding such collaboration was inadequate funding, 
however of late, a large number of bodies have increased investment into biomarker 
studies. Already the Tuberculosis Trials Consortium in collaboration with AIDS 
Clinical Trials Group have established a biobank for the collection and storage of 
sputum, serum, urine, PBMCs, host mRNA and DNA from patients with TB which 
will be used to evaluate candidate biomarkers of TB treatment response. Similar bio-
banks could be established to examine miRNA as a diagnostic and prognostic 
biomarker.  
 
In order to work towards TB elimination and curtail the morbidity and mortality 
associated with the disease new therapeutics are urgently required. miRNA 
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manipulation has already shown promise as a new targeted therapeutic in 
malignancy. By overexpression of let-7 in lung cancer cell lines, it was shown that 
let-7 can repress resistance to radiation therapy both in vitro and in vivo (Weidhaas et 
al., 2007). Manipulation of miRNAs as a new therapeutic agent in TB has not yet 
been reported, but may be a new and exciting mechanism for treating M. tuberculosis 
infection. It may be possible to boost immunity to M. tuberculosis by delivering new 
therapeutics that target either specific miRNA or their binding sites and boost the 
hosts immune response. One benefit of these new therapies is that they could be used 
in conjunction with existing antibiotic therapies and may help to limit the duration of 
treatment, or lower the development of drug resistance. Critical to the development 
of miRNA-specific therapeutics is an understanding of the functions of miRNA and 
the relevant signalling pathways in M. tuberculosis infection and disease. An 
intricate understanding of miRNA function will enable the development of novel 
therapeutics that target directly pathologically essential miRNAs and/or their target 
genes. One of the first steps towards achieving this is in vitro studies of a largely 
purified population of cells as this facilitates a greater understanding of precise 
function though at the expense of analysing the system as a whole. It is for this 
reason that this body of work studied miRNA expression in macrophages, the key 
innate immune cell in M. tuberculosis infection. Results have provided an insight 
into host-mycobacteria interactions. To further this understanding, genetic 
manipulation of miRNA is the next step, as this will enable the study of phenotypic 
changes in culture or within the organism that occurs with gain or loss of function. 
By observing these changes a greater understanding of the functional relevance of 
miRNA can be achieved. An exquisite understanding of miRNA:mRNA is essential 
to allow manipulation as a mode of new and innovative targeted therapy. 
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This body of work has examined the role of miRNAs as a diagnostic tool with the 
aim of being able to diagnose TB quickly with a high degree of accuracy and as a 
predictor of treatment outcome. This is the first study to examine miRNA expression 
longitudinally and has improved current understanding of miRNA expression in the 
setting of TB disease both at the time of diagnosis and also over the course of 
therapy. Like many other published work, this study focussed on comparing miRNA 
expression in M. tuberculosis disease states to healthy controls/no infection. In 
clinical practice however, one of the major difficulties in diagnosing TB is to 
differentiate patients with TB disease from those with other respiratory pathologies. 
Future work, which examines miRNA expression across a myriad of lung 
pathologies, is critical to enable miRNAs to be a clinically relevant biomarker.  
 
The development of new biomarkers to diagnose and better manage TB is urgently 
required. This study has aimed to achieve this through the use of plasma miRNAs. 
The appeal of using miRNAs as a clinical biomarker is high, given their stability in 
the extracellular environment and their ease of measure in plasma and serum, which 
are readily obtainable, even in developing countries where TB is often endemic. The 
potential of manipulating miRNA expression as a targeted new therapy in TB is only 
beginning to be recognised. Further translational research that allows for a better 
understanding of miRNA as a diagnostic and prognostic tool as well as a targeted 
treatment approach has the potential to revolutionise the management of patients 
with this disease. 
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 Human Pathogen & 
Immunological Department 
Ningxia Medical University  
Yinchuan  
Email: 
yangyurong@hotmail.com 
Sydney Medical School 
 
Biomarkers in Tuberculosis 
Version 1, 25/07/2012 
 
Patient'Questionnaire'
 
 
Date of Interview    |__|__|__|__| / |__|__| / |__|__|   (yyyy/mm/dd) 
 
Location of clinic: 
 
Allocated Participant ID: 
 
Respondent for interview: |__|  
(1) Self;       (2) Parent;      (3) Child;      (4) Brother/sister;    (5) Spouse;   (6) Other 
      
 
GENERAL INFORMATION 
 
 
Sex |__|  M/F    
     
Age at date of interview: 
 
Ethnicity: 
 
Education |__|     (1) Illiterate  (2) Semi-literate (3) Primary school 
(4) Junior School (5) Senior School (6) College       
                              
Years of education: |__|__| 
 
Occupation: |__| (1) Farmer   (2) Businessman (3) Teacher 
                (4) Student   (5) Pre-School  (6) Other  
 
 
 
TUBERCULOSIS HISTORY 
 
1) Have you ever had been vaccinated for tuberculosis?           Y/N/D 
     If YES, do you have a BCG vaccination scar?      Y/N/D 
 
2) Have you ever been diagnosed with tuberculosis?                Y/N/D 
 270 
 271 
 272 
 273 
 274 
 
 275 
APPENDIX D: STANDARD OPERATING PROCEDURE FOR CHAPTER 
FOUR STUDY 
 276 
 1 
Standard Operating Procedures (SOP) 
For miRNAs in Tuberculosis 
 
 
Index of SOP 
  Title Page 
 Details of study 1 
 Foreword 1 
Overview Summary of Study 3 
Flowchart 1 Enrollment of TB patients 5 
Flowchart 2 Enrolment of healthy normals (controls) 7 
Flowchart 3 Laboratory processing protocol 9 
Flowchart 4 Department of Radiology protocol for subjects 11 
 Population included 13 
 Numbering for study 14 
 Withdrawal from study 15 
Appendix 1 List of Forms for the Study 16 
Appendix 2 Timetable for study 16 
Appendix 3 List of equipment needed 17 
Appendix 4 Sample Collection and Processing Procedure 18 
 
Details of study 
1. Title: MicroRNAs in Tuberculosis 
2. Duration: 9 months (from June 2013-February 2014) 
3. Management: Ningxia Infectious Diseases Hospital 
4. Co-operating organizations 
(a) In China 
Ningxia Infectious Diseased Hospital and Ningxia Medical University 
 
(b) In Australia 
University of Sydney, Australia 
The Centenary Institute, University of Sydney 
 
 
 
Foreword 
Tuberculosis (TB) remains a major health problem worldwide, with two million 
deaths from TB each year. The management of TB requires multi-drug chemotherapy 
for at least six months. Drug-resistant strains of TB are increasing. Currently, 
diagnosis of TB is dependent on culturing the organism (usually from sputum), which 
can take up to six to eight weeks. Treatment success is a sputum sample that is culture 
negative after two months of treatment. However, these culture results also take six to 
eight weeks, thus delaying the time taken to identify patients not responding to 
treatment. Identifying new biomarkers, through this research, may lead to an efficient 
way of monitoring response to treatment, and increase the early identification of non-
responders who may be harboring drug-resistant organisms. 
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MicroRNA (miRNA) are small non-coding RNA sequences that affect the translation 
of about 30% of human genes. This project aims to determine whether levels of 
specific miRNAs in patient blood can be used as a biomarker for the presence of 
active TB disease, and furthermore whether changes in miRNA levels can indicate 
early treatment failure. 
 
miRNA levels will be measured in the TB population, at the time of diagnosis, after 
one, two and six months of treatment month of treatment and compared to levels in 
age and sex matched healthy controls. miRNA levels will be measured at these four 
time points to determine what effect treatment has on miRNA expression.  
 
We hypothesise that the miRNA profiles of patients who are poor responders to 
treatment (often a surrogate marker of drug resistance) will differs from those who are 
responding well to treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 278 
 4 
SUMMARY of MIRNA STUDY 
 
Tuberculosis Patients enrolled into the study will have their 
blood collected at 4 time points 
 Prior to the commencement (or within 24 hours of 
commencing TB treatment) 
 After 1 month of treatment 
 After 2 month of treatment 
 After 6 months of treatment 
 
All patients will be paid 10 Yuan to cover their return trip to the 
clinic on visits 1,3,and 4 
 
Patients returning to visit 2 (unscheduled visit) will be given 10 
Yuan and an additional 50 Yuan to cover lost wages. In total for 
visit 2 they will receive 60 Yuan. 
 
Enrolled Controls will have their blood collected on ONE 
occastion only 
 
All controls will be given 10 Yuan to cover their return fare to 
the clinic. In addition 50 Yuan will be reimbursed for the time 
they had to spend away from their work (lost wages). 
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Flowchart 1 – For enrolling patients with pulmonary TB  
 
 
 
 
 
 
 
When a patient is newly diagnosed with tuberculosis in the hospital clinic, first 
confirm that they meet the inclusion criteria for the study. These inclusion criteria are 
given here: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R
outine case detection  
 
STEP 1: Does the patient meet the criteria for the study? 
Explain the study to the patient: we are testing for factors that are altered during TB infection  
o The study will only involve blood tests and brief questions.  
o The X-ray and blood tests are free of charge. 
o The patient will receive a reimbursement for participating in the study. 
o Give the patient the Information Form  
o Show the patient the Consent Form  
Ask the patient if they agr e to participate in e study. 
If the patient is at least 18 y ars old and agrees to participate in the study then they can join the study. 
 
STEP 2: Enroll in the study 
• The patient must sign the consent form  and agree to have the blood tests.  
• Allocate a Study Identification Number to the patient from the Study Workbook. This number 
must go on all forms written for this patient. 
• Enrol the patient on the Study Workbook  
• Complete specimen request forms: 
o On the study Blood test form complete name, number and date. 
o On the Microbiology request form: Write patient’s name, study identification number, 
date of test on the form. 
 
STEP 3: Obtain chest X-ray 
Each subject needs a good quality chest X-ray (to confirm whether there is pulmonary TB). 
Does the patient have a good CXR from the Department of Radiology? 
(a) If patient already has a chest X-ray from the current admission / review: Record the radiology 
number of the film on the Register Book.  
 
STEP 4: Collect blood for tests 
Take the patient to Pathology Department. The staff there will collect 10 mL EDTA tube for the 
miRNA test 
 
STEP 5: Complete enrolment 
• Check that all forms are complete 
• Complete the checklist on the Study Workbook. 
 
STEP 6: Give patient reimbursement 
After the patient has given their blood and completed their chest X-ray, give them a reimbursement. 
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Flowchart 2 – Enrolling healthy subjects (never had TB) 
  
 
STEP 1: Does the subject meet the criteria for the study? 
Explain the study to the subject: we are testing for risk factors for tuberculosis.  
o The study will only involve a blood test and brief questions.  
o The blood tests are free of charge. 
o The subject will receive a reimbursement for participating in the study. 
o Give the subject the Information Form  
o Show the subject the Consent Form 
Ask the patient if they agree to participate in the study. 
If the patient is at least 18 years old and agrees to participate in the study then they can join the study. 
 
STEP 2: Enroll in the study 
• Allocate the subject a study number form the Study Register Book  
• Complete the Registration Book with the subject. 
• Get the patient to complete the study questionnaire  
• Complete a Study Blood test request form: 
o Complete the subject’s name, study identification number and  date.  
 
 
STEP 4: Send subject to Pathology Department for blood test 
The subject will have a blood test at the Department of Pathology. 
• Give the subject the Blood test request form 
• Take the subject to the Department of Pathology for their blood test.  
• Notify the staff at the Department of Pathology that this test is for the miRNA research study. 
Staff will take blood in a 10 mL EDTA blood tube. 
 
STEP 5: Complete enrolment 
• Complete the check-list on the Study Register Book to make sure the subject has had all of 
their tests. Do this before giving the subject a gift. 
 
STEP 6: Give the reimbursement to the subject 
• After the patient has had their blood test and completed their questionnaire, give them the 
reimbursement 
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Flowchart 3 – Laboratory processing protocol at the 
Department of Microbiology
 
STEP 1: Record the results of culture: For TB patients only 
• When the results of cultures become available (or after 8 weeks if a negative culture) 
• write it in the STUDY LABORATORY BOOK  
 
Assistance with the study 
• For technical assistance with plasma extraction techniques email  
Dr Simone Barry at s.barry@centenary.org.au 
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Population included  
 
(a) Tuberculosis cases 
All new patients at the Outpatient Clinic with newly diagnosed tuberculosis should be 
considered for this study. There need to be a total of 100 patients recruited. The 
inclusion and exclusion criteria are written above. 
 
(b) Control cases 
Cases enrolled into the study will be asked to bring along a friend to their next visit 
and these people will act as controls. 
 
 
IV.  Guide to interviewing subjects 
 
Patients with tuberculosis should be recruited at the time the diagnosis is made (such 
as according to smear status). 
 
Interviews will take about 10 minutes. Follow the flow-charts above. 
 
 
Training for this study will emphasise the techniques to perform a good interview. 
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Numbering for tuberculosis patients 
An individual study code will be allocated to each index case, which includes a letter 
(T for a tuberculosis patient), followed by the patient number (3 digits, 001 to 500).  
For example for a patient with tuberculosis: 
 
 
 
 
T  1  2  2 A 
 
Numbering will begin at  0 0 1, and patients will have consecutive numbers according 
to their time and date of enrolment in the study.  
 
(b) Numbering for control subjects 
Control subjects will be numbered with a letter (C to indicate control), followed by a 
three-digit number (3 digits, 001 to 500). For example for a contact of the above 
patient may have the following number. 
 
 
 
 
C  1  0  2 
 
Numbering will begin at C 0 0 1, and controls will have consecutive numbers 
according to their time and date of enrolment in the study. There will be a list for new 
cases  and contacts. Staff enrolling patients in this study will use these forms to record 
details of all study subjects at the time of enrolment. 
 
1.2. Culture 
• Culture for TB will be performed on all specimens 
 
 
 
 
Indicates 
patient in 
Study Region 
Three digit patient 
number 
Indicates 
control  Three digit patient 
number 
Indicates collection 
timepoint. A= time 
point 1, B = time point 
2 and so on. 
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Withdrawal from study 
If a subject decides to withdraw from the study, then they can complete the 
Withdrawal of consent form. The study staff should place this form in the Study 
Folder, with other consent forms.  If the patient withdraws from the study then their 
specimens will not be analysed any further. 
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Appendices 
 
Appendix 1: Forms for MiRNA Study 
 
Description Details 
Patient information sheet (PIS) For consent of a patient with 
tuberculosis 
Control Information Sheet (CIS) For consent of normal controls (no 
TB) 
Consent form Consent form for patients and 
healthy normals to sign, if they 
agree to participate in the study 
 
Appendix 2: Timetable for study 
 
The timetable for the overall study will follow the following schedule. 
April 2013 June 2013-Feb 
2014 
Feb 2014 Jan-July 2014 
• Recruitment of 
Research staff 
• Translate study 
protocol into 
Chinese 
• Staff Training 
• Begin 
recruitment of 
cases and 
controls 
• Visit by Dr 
Saunders and Dr 
Barry 
• Analysis of 
Samples  
• Completion of 
Recruitment 
• Transfer of all 
remaining 
samples to 
Australia 
• Analysis of 
samples 
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Appendix 3: List of equipment needed  
 
(a) Equipment needed by staff performing enrolment 
- Subject information forms  
- Consent forms  
- Study register books  
- Request forms for sputum culture 
- Request forms for radiology 
- Study Folder (for placing completed forms) 
 
(b) Equipment needed in Department of Haematology 
- Blood collection tubes (10 mL EDTA) 
 
(c) Equipment needed in Department of Microbiology 
- Study FOLDER for placing completed request forms 
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)Ensure)tube)is)labeled)with)the)study)number,)date)and)collection)time))The)time)of)phlebotomy,)date)and)study)number)should)be)recorded)in)Study)Workbook)))
2.1 Plasma Preparation 
 
2.1.1 Equipment List 
  1 x EDTA for plasma (lavender lid) 
 Filter pipette tips 
 Transfer pipette 
 2ml eppendorf tubes 
 1.5 mL  screw top tubes 
 
2.1.2 Requirements 
 
The sample should be processed as soon as possible after blood taking (within 2 hours 
of the blood draw). 
 
The time elapsed between the taking of the blood and sample processing must be 
recorded for the sample in the Study Workbook 
 
2.1.3 Instructions for removal of BD Hemogard closure 
 
Grasp the blood tube with one hand, placing the thumb under the closure. With the 
other hand, twist the closure while simultaneously pushing up with the thumb of the 
other hand, only until the tube stopper is loosened. 
 
Move the thumb away before lifting the closure. Caution: Do not use the thumb to 
push closure off tubes. If the tube contains blood, an exposure hazard exists. 
 
Lift closure off tube.  
 
 
2.1.3 Procedure 
 
Keep  the sample at room temperature (18-220C) throughout processing 
 
The sample needs to be processed in sterile conditions using aseptic technique 
 
Upon arrival at the lab, centrifuge the blood in the EDTA  tube (lavender lid) at 1500 
g for 15 minutes at room temperature.  
 
This causes separation of the sample into 3 distinct phases: the upper layer of plasma 
(contains clotting factors), the narrow middle layer is the “buffy coat” (white blood 
cells), and the bottom layer is the red blood cells. 
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Appendix 4: Sample Collection and Processing 
Procedure 
 1.1 Sample)Collection)–)summary)Samples)to)be)obtained:)1)x)10)ml)EDTA)tube)for)miRNA)analysis)
 1.2 Materials)
Blood Collection Kit 
 1 x 21G butterfly needle 
 1 x Vacutainer needle holder 
 1 x gloves 
 1 x Torniquet 
 Alcohol Wipes 
 Cotton wool 
 Small Plasters 
 1 x Sharps bin for used needle  
 
Sample Tubes 
 1 x 10 ml EDTA tube (BD Vacutainer EDTA tube, lavender lid, Catalogue # 
367525) 
 1.3 Obtaining)Samples)1.3.1 Sample)tubes)should)be)labeled)with)study)number)1.3.2 Record)details)in)the)Study)Registry)Book:)*Study)number)*Date)and)time)that)the)samples)were)taken)
 
EQUIPMENT 
The equipment used throughout the study for sample collection and storage should be 
the same as outlined in this protocol. 
Any significant variation in equipment must be recorded in the Study Registry 
Book(G5/G6) 
 1.4 Protocol)for)taking)blood)1.4.1 Label)tubes)with)study)number,)date)and)collection)time)1.4.2 Aim)to)completely)fill)the)EDTA)tube.)EDTA)tubes)contain)a)certain)amount)of)anticoagulant)that)needs)to)be)mixed)in)an)exact)proportion)to)the)blood)
 1.5 Venipuncture)When)the)tube)is)full)and)blood)flow)ceases,)remove)it)from)the)holder.))Invert)the)EDTA)(lavender)lid))at)least)10)times)to)reach)a)proper)mix)of)additive)and)blood.)Do)not)shake))Safely)discard)the)used)needle)holder)and)syringe)into)the)sharps)bin.)
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!  
Figure 1. This is what the tube should look like after centrifugation. 
 
Review each sample for evidence of haemolysis 
  
 
Plasma samples > 100 mg/dL of haemoglobin should be discarded. 
 
Aliquot the plasma into 2 ml eppendorf tubes using filtered pipette. 
 
Spin the plasma for 3 minutes at maximum speed in the microcentrifuge (~14,000 g) 
to pellet platelets and residual red blood cells. 
 
Remove the top 80% and divide into 4- 1 ml screw capped tubes. Label each tube 
with date, study number and visit number (i.e visit 1, 2 or 3) 
 
 Sample Storage 
 
3.1 For immediate storage, samples need to be labeled with subject number, date of 
sample collection, visit number (i.e visit 1, 2 or 3) and assigned box numbers to aid 
location in the freezer. 
 
3.2 Protocol for sample storage 
 
3.2.1 Plasma 
!Plasma – upper layer 
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Frozen at -800C
